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Abstract 
Breast cancer (BC) patient management has been transformed over the last two decades due 
to the development and application of genome-wide technologies. The vast amounts of data 
generated by these assays, however, create new challenges for accurate and comprehensive 
analysis and interpretation. This thesis describes novel methods for fluorescence in-situ 
hybridization (FISH), array comparative genomic hybridization (aCGH), and next generation 
DNA- and RNA-sequencing, to improve upon current approaches used for these 
technologies. An ab initio algorithm was implemented to identify genomic intervals of single 
copy and highly divergent repetitive sequences that were applied to FISH and aCGH probe 
design. FISH probes with higher resolution than commercially available reagents were 
developed and validated on metaphase chromosomes. An aCGH microarray was developed 
that had improved reproducibility compared to the standard Agilent 44K array, which was 
achieved by placing oligonucleotide probes distant from conserved repetitive sequences.  
Splicing mutations are currently underrepresented in genome-wide sequencing analyses, and 
there are limited methods to validate genome-wide mutation predictions. This thesis 
describes Veridical, a program developed to statistically validate aberrant splicing caused by 
a predicted mutation. Splicing mutation analysis was performed on a large subset of BC 
patients previously analyzed by the Cancer Genome Atlas. This analysis revealed an elevated 
number of splicing mutations in genes involved in NCAM pathways in basal-like and HER2-
enriched lymph node positive tumours. Genome-wide technologies were leveraged further to 
develop chemosensitivity models that predict BC response to paclitaxel and gemcitabine. A 
type of machine learning, called support vector machines (SVM), was used to create 
predictive models from small sets of biologically-relevant genes to drug disposition or 
resistance. SVM models generated were able to predict sensitivity in two groups of 
independent patient data.  
High variability between individuals requires more accurate and higher resolution genomic 
data. However the data themselves are insufficient; also needed are more insightful analytical 
methods to fully exploit these data. This dissertation presents both improvements in data 
quality and accuracy as well as analytical procedures, with the aim of detecting and 
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interpreting critical genomic abnormalities that are hallmarks of BC subtypes, metastasis and 
therapy response. 
Keywords 
genomic technology, breast cancer, nucleic acid hybridization, fluorescence in-situ 
hybridization, microarray, copy number changes, next generation sequencing, splicing 
mutations, NCAM, mutation validation, chemosensitivity, support vector machines, machine 
learning, paclitaxel, gemcitabine, formalin fixed paraffin embedded tissue 
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Chapter 1  
1 Introduction 
1.1 Breast Cancer Overview 
Breast cancer is the most frequently diagnosed cancer worldwide (1). In Canada, 1 in 9 
women are expected develop breast cancer in their lifetime, with 24,000 new cases (26% 
of all cancer cases) in 2014 (2). Advancements in prevention, screening, and treatment 
strategies over the past 20 years have led to a steady decrease in mortality rates from 
breast cancer, yet it still accounts for 14% of cancer deaths in Canada (2). These rates are 
similar to those of the United States and other economically developed countries (1).  
After diagnosis, clinicians rely on multiple parameters to direct treatment strategies and 
predict prognosis, including clinical factors, such as patient age, lymph node status 
(positive or negative), tumour size, and histological grade, as well as the status of 
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 
receptor 2 (HER2) in the tumour.  
1.1.1 Gene Expression Subtypes of Breast Cancer 
Although all breast tumours are grouped under the umbrella of one disease, breast cancer 
is remarkably complex. The traditional markers used for tumour classification are not 
able to fully portray the biological variability observed among breast tumours (including 
genomic alterations, cellular composition, and response to treatment). With the 
advancement of microarray technology, gene expression profiling led to the sub 
classification of breast cancer into 5 categories: Luminal A, Luminal B, HER2-enriched, 
Basal-like, and Normal-like (3,4). More recently, an additional subtype was identified, 
Claudin-low (5), to make up the 5 intrinsic subtypes of breast cancer, and the additional 
Normal Breast-like group. These subtypes are now well-characterized, and have distinct 
gene expression patterns (3), require different treatment regimens (6) and vary in 
prognoses (7). 
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Luminal A tumours make up approximately 30% of breast cancer cases, and have the 
longest relapse-free and overall survival, whereas Luminal B tumours have lower relapse-
free survival, similar to the other subtypes (8). The large majority (at least >90%) of 
Luminal A and B tumours are ER+ and can be identified by their gene expression 
signatures characteristic of luminal epithelial cells. These genes include a group of 
transcription factors, including ER, which can be used to differentiate between Luminal 
A and B tumours, because this proliferation signature is expressed at higher levels in the 
Luminal B subtype (3,8). HER2-enriched tumours are characterized by the amplification 
of the HER2 gene and historically, they have had low relapse-free and overall survival 
(8). However, the development of Trastuzumab, a monoclonal antibody against HER2, 
improved response rate and reduced the risk of death for this subtype by 20% when used 
in conjunction with chemotherapy (9). Basal-like and Claudin-low subtypes are similar in 
that they have low expression in both the Luminal and HER2-enriched intrinsic 
expression signatures, but differ in at least two groups of genes. Unlike the Basal-like 
subtype, Claudin-low tumours show low expression in a gene cluster enriched with cell-
to-cell adhesion proteins, and high expression of a group of genes enriched with immune 
system response genes (8). Both Basal-like and Cluadin-low subtypes have poorer 
prognoses compared to Luminal A tumours, and similar to the outcomes of Luminal B 
tumours (8). Normal-like tumours are those that cluster with normal breast tissue in gene 
expression profiling. They have expression of genes that are characteristic of basal 
epithelial and adipose cells, and low expression of genes usually observed in Luminal 
cells. The intrinsic subtypes of breast cancer only consider tumour differences at the gene 
expression level and do not fully portray the molecular complexity of tumours at the 
genomic level. 
1.1.2 Genomic Analyses of Breast Cancer Tumours 
Genome instability is one of the major mechanisms that allows cells to develop into 
cancer (10). The cellular characteristics that enable malignant growth are known as the 
hallmarks of cancer, and include: the evasion of apoptosis, self-sufficiency in growth 
signals, insensitivity to anti-growth signals, sustained angiogenesis, limitless replicative 
potential, tissue invasion and metastasis, reprogramming of energy metabolism and 
 3 
 
evading immune destruction (10,11). Our understanding of tumour genomes, and the 
specific types of aberrations and mutations driving tumourigenesis, is increasing rapidly 
as next generation sequencing is becoming more advanced and affordable. 
At least five major genomic studies have begun to elucidate commonly mutated genes 
that may be causing or perpetuating tumour development in breast cancer (12-16). Two 
of these studies focused on tumours with specific pathological markers: one assessed 37 
Basal-like and 28 other triple negative breast cancer (ER, PR and HER2 are not 
expressed) (15), and the other study analyzed 77 ER positive (Luminal) tumours (13). 
The remaining three sequencing studies assessed either all intrinsic subtypes (12,14), or 
did not perform subtyping analysis (16). Between all five studies, whole genome or 
exome sequencing was performed on a total of 860 tumours, and reported a combined 
46,167 mutations (See Table 1.1 for a summary/breakdown of each study).  
These sequencing studies demonstrated that mutations in different tumour suppressor or 
oncogenes can lead to the same breast cancer phenotypes. A total of 55 genes were cited 
as frequently mutated, although many were mutated in less than 10% of tumours (see 
Table 1.2 for a list of all genes and their mutation frequencies). At least 33 genes were 
statistically significantly mutated in the breast cancer tumours assessed, and there was 
considerable overlap between the five studies (Figure 1.1). Not surprisingly, PIK3CA and 
TP53 were both identified to be significantly mutated in breast tumours across all five 
studies. TP53 was identified as a tumour suppressor gene more than two decades ago, and 
at that time, was observed to be the most commonly altered gene in tumours (17). 
Frequent mutations in PIK3CA in breast cancer were observed as early as 2004, where 
25% of the tumours assessed contained somatic mutations in the gene (18). Additional 
genes that were highlighted in at least two of the five studies included known breast 
cancer genes (GATA3, RB1, AKT1, CDH1, MAP3K1, MLL3, CDKN1B and PTEN) and 
newly identified ones (CBFB, RUNX1, TBX3 and SF3B1). 
These sequencing studies highlight the genomic diversity of mutations among breast 
cancer tumours. Of particular interest are the 40 (or more) genes that were identified as 
potential breast cancer genes in only one of five the studies. Discordance between the 
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Table 1.1 Summary of large-scale breast cancer sequencing studies. 
Paper No. Tum. Subtypes No. Mut.  
Ave No. 
Mut. / Tum. 
Significantly Mutated Genes 
Method to Identify Sig. 
Mutated Genes 
Banerji
12
 
(B)  
108 
Lum A = 38 
Lum B = 22  
HER2 = 21  
Basal = 13 
Norm = 5 
4985 46 
Known: PIK3CA, TP53, AKT1, GATA3, 
MAP3K1  
New: CBFB 
MutSig
19
 Algorithm - 
FDR <0.1 
Ellis
13
 (E) 77 
Lum A/B = 
77 
3208 42 
Known: PIK3CA, TP53, GATA3, CDH1, 
RB1, MLL3, MAP3K1, CDKN1B 
New: TBX3, RUNX1, LDLRAP1, STMN2, 
MYH9, AGTR2, SF3B1, CBFB, ATR 
MuSiC
20
 - Convolution 
Test FDR <0.26 
Shah
15
 (Sh) 65 Basal = 37 2414 37 
Known: TP53, PIK3CA, RB1, PTEN 
New: MYO3A, GH1 
Considered background 
mutation rates q < 0.1
21
 
Stephens
16
 
(St) 
100 N/A 7241 72 
Known*: PIK3CA, TP53, CDH1, GATA3, 
MLL3, AKT1  
New^: ARID1B, CASP8, MAP3K1, 
MAP3K13, NCOR1, SMARCD1, CDKN1B, 
AKT2, TBX3 
* cited as frequently 
mutated 
^ Searched for non-
random clustering of 
somatic mutations
22,23
 
TCGA
14
 (T) 510 
Lum A = 225 
Lum B = 126  
HER2 = 57 
Basal = 93 
28319 56 
Known: PIK3CA, PTEN, AKT1, TP53, 
GATA3, CDH1, RB1, MLL3, MAP3K1, 
CDKN1B  
New: TBX3, RUNX1, CBFB, AFF2, PIK3R1, 
PTPN22, PTPRD, NF1, SF3B1, CCND3 
MuSiC
20
 - Convolution 
and Likelihood Ratio 
Tests FDR <0.05 
N/A = subtyping analysis was not reported. 
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Table 1.2 Frequency of commonly mutated genes in breast cancer tumours (refer to Table 1.1 for study abbreviations and citations) 
 
Gene B E Sh St T 
 
Gene B E Sh St T 
1. PIK3CA 27% 58% 11% 30% 36% 29. SETD2 
  
2% 1% 
 2. TP53 27% 23% 54% 37% 37% 30. AFF2 
    
3% 
3. CDH1 
 
10% 3% 7% 7% 31. AGTR2 
 
3% 
   4. GATA3 4% 10% 
 
14% 11% 32. AKT2 
   
1% 
 5. MAP3K1 3% 17% 
 
6% 8% 33. APC 
   
1% 
 6. MLL3 
 
6% 3% 5% 7% 34. ARID1B 
   
3% 
 7. RB1 
 
5% 8% 2% 2% 35. ASXL1 
   
1% 
 8. AKT1 6% 
  
4% 2% 36. BRAF 
  
3% 
  9. CBFB 4% 3% 
  
2% 37. BRCA1 
   
1% 
 10. CDKN1B 
 
3% 
 
1% 1% 38. CCND3 
    
<1% 
11. NCOR1 
  
2% 3% 3% 39. COL6A3 
  
6% 
  12. PTEN 
  
8% 3% 3% 40. ERBB3 
  
3% 
  13. SF3B1 
 
4% 
 
4% 2% 41. GH1 
  
5% 
  14. TBX3 
 
5% 
 
3% 3% 42. KRAS 
   
1% 
 15. ARID1A 
  
2% 3% 
 
43. LDLRAP1 
 
3% 
   16. ARID2 
  
3% 1% 
 
44. MAP3K13 
   
2% 
 17. ATR 
 
8% 6% 
  
45. MYO3A 
  
9% 
  18. BAP1 
  
2% 1% 
 
46. NRAS 
  
3% 
  19. BRCA2 
  
5% 0% 
 
47. PTPN22 
    
1% 
20. CASP8 
  
3% 3% 
 
48. SMAD4 
   
1% 
 21. ERBB2 
  
3% 1% 
 
49. SMARCD1 
   
1% 
 22. MAP2K4 
   
4% 4% 50. STK11 
   
1% 
 23. MLL2 
  
2% 1% 
 
51. STMN2 
 
3% 
   24. MYH9 
 
5% 2% 
  
52. SYNE1 
  
6% 
  25. NF1 
   
2% 3% 53. SYNE2 
  
5% 
  26. PIK3R1 
  
3% 
 
3% 54. UBR5 
  
6% 
  27. PTPRD 
  
2% 
 
2% 55. USH2A 
  
9% 
  28. RUNX1 
 
5% 
  
4% 
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Figure 1.1 Significantly mutated genes in breast cancer tumours.  Genes identified as 
significantly or commonly mutated were extracted from five major sequencing studies (found 
within each circle and colour coded according to the legend on the top right): Banerji et al. (2012), 
Ellis et al. (2012), Shah et al. (2012), Stephens et al. (2012), and the Cancer Genome Atlas 
(2012). The number of studies the gene was identified in is indicated by the bottom legend on the 
right. 
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studies may be due to low mutation rates, ranging from 1-9%, or differences in the 
methods of variant calling, variant filtering, and identifying common/significantly 
mutated genes. Of the five papers, four unique methods were used to identify which 
genes were “commonly” or “significantly” mutated, which in some cases lead to 
discrepancies as to which genes were included as significant. For example, CASP8 was 
mutated in 3% of breast cancer tumours in two studies (Shah (15) and Stephens (16)), but 
only one study (Stephens) cited it as a potential new breast cancer gene. Shah et al., 
(2012), considered background mutation rates when identifying new breast cancer genes 
(q < 0.1) (21), whereas Stephens et al., (2012), searched for non-random clustering of 
somatic mutations (22,23). 
Regardless of the differences between the five studies, the long list of potential driver 
genes created from these studies provides a new gene set to be explored and analyzed by 
the breast cancer community. Mutations in newly recognized genes may have 
implications in prognosis, treatment response, or provide the opportunity to identify new 
pathways for therapeutic targeting. For example, Stephens et al., (2012), identified 9 new 
potential driver genes that have not been previously noted in either breast or other cancer 
types. These genes are involved in pathways regulating the JUN kinases MAP2K7 and 
MAP2K8. Mutations in the mitogen-activated protein kinase (MAPK) signaling pathway 
genes have been suggested to be associated with drug resistance (24), which could have 
implications for breast cancer treatment if tumours contain mutations in these genes. 
Copy number analyses identified commonly deleted or amplified genes, including well 
known tumour suppressor or oncogenes (TP53, PIK3CA, NRAS, EGFR, RB1, and ATM), 
as well as new genes of interest that were not identified through DNA sequence analysis 
(PRPS2, NRC31, and four PKC-related genes) (15). These results were similar to the 
Cancer Genome Atlas (TCGA) study that confirmed previously reported copy number 
variations, and highlighted many of the same genes affected by copy number changes 
(including PIK3CA, EGFR, FOXA1, and HER2 in amplified regions, as well as MLL3, 
PTEN, and RB1 in deleted regions) (14). The TCGA study also identified five copy 
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number clusters that correlated with the gene expression subtypes, which had been 
observed before (25).  
1.2 Genomic technologies used in breast cancer research 
and clinical management 
It is possible that in order to achieve the greatest overall success when treating patients, 
tumours will need to be characterized at the genomic and/or transcriptomic level to guide 
treatment.  This is the basis behind the NCI-Molecular Analysis for Therapy Choice 
(NCI-MATCH) trial that was recently announced in the United States, which aims to 
personalize drug selection based on analyzing patient’s tumours for specific genetic 
abnormalities for which a targeted drug exists. There are a number of cytogenetic and 
molecular techniques that can be used in both research and clinical settings to analyze 
tumours for different types of mutations, guide diagnosis, predict prognosis and select 
treatment. Among the most common include fluorescence in-situ hybridization, genomic 
or gene expression microarrays, and next generation sequencing. 
1.2.1 Fluorescence in-Situ Hybridization 
Fluorescent in situ hybridization (FISH) uses fluorescently labeled nucleic acid probes to 
detect targeted genomic or transcriptomic sequences. FISH can be used to localize 
specific DNA sequences on interphase or metaphase chromosomes, or RNA sequences in 
cells or tissue samples. FISH was first reported in 1980, by a group that used 3’ 
fluorescently labeled RNA to bind specific DNA sequences (26). Prior to the use of 
fluorophores, similar hybridization methods used radiolabelled probes, which was not 
optimal due to the instability of radiolabelled probes, low resolution, long exposure 
times, and the costs and risks associated with radioactive material (27). Before FISH was 
developed, conventional cytogenetic methods, such as karyotype analysis, were 
commonly used for disease research and diagnosis. Given its higher resolution, FISH can 
be used to detect structural rearrangements in chromosomes including translocations, 
inversions, insertions, and microdeletions, identify marker chromosomes, and delineate 
chromosomal breakpoints.  
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The first draft of the human genome provided the opportunity to develop thousands of 
DNA clones (primarily bacterial artificial chromosomes, or BACs) that contain genomic 
sequence tags, and have been mapped to specific chromosome bands (28). Libraries of 
BAC probes are commercially available, and can also be produced in the laboratory in 
high quantities using a polymerase with strand displacement activity (29). There have 
been numerous disease-specific FISH reagents and methods have been developed with 
proven clinical significance and higher resolution over conventional cytogenetic 
karyotyping (30,31). Although these BAC FISH probes are still commonly used, the 
majority of theses clones are greater than 100 kb, so their use is usually restricted to 
detecting larger rearrangements (Figure 1.2). For the majority of probe labeling and 
hybridization techniques, detecting small sequences (<10 kb) has been difficult, because 
smaller probes are often inconsistent and have low sensitivity (32). More recently, 
methods and techniques have been developed to improve the throughput, or resolution of 
FISH. For example, labeling probes using nick translation with an excess of DNA 
polymerase I has increased signal intensities of a 30 kb probe (32), using single copy 
DNA sequences has enabled FISH probe design where the exact DNA sequence and 
genomic location are known (33), and an automated analysis method using grid sampling 
was developed that reduced the time of analysis and evaluation of results down to 9 
minutes per sample (34). 
FISH is commonly used in clinical diagnosis for birth defects and developmental delay, 
prenatal testing, and acquired diseases. It is a main test for disorders caused by 
microdeletions (35) (such as Williams, Prader-Willi, Angelman, Miller-Dieker, 
DiGeorge, Wolf-Hirschhorn, Cri-du-chat, and Smith-Magenis Syndromes) or 
microduplications (35) (such as Charcot-Marie-tooth 1A and Pelizaeus-Merzbacher), and 
also has many different applications in oncology (36). For example, FISH is commonly 
used to detect specific gene fusions known to occur in certain types of cancers, such as 
the EML4-ALF fusion in non-small-cell lung cancer (37) and the BCR-ABL fusion (ie. 
the Philadelphia chromosome) in chronic myeloid leukemia (38). In breast cancer, the 
American Society of Clinical Oncology/College of American Pathologists has 
recommended that the HER2 status (amplified or not) should be tested for all invasive 
breast cancer (39). They consider tumours to be HER2-positive if there are more than 6 
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copies of HER2 per nucleus, or if the HER2 gene signal to chromosome 17 ratio is more 
than 2.2. FISH results are typically used to confirm, or are confirmed with 
immunohistochemical assays, which were 92% concordant when assessing hundreds of 
samples (40). Even so, as much as 20% of HER2 testing may be inaccurate (39), and 
probes with higher resolution to the HER2 gene may be useful in improving the precision 
of these tests. 
1.2.2 Array Comparative Genomic Hybridization  
Comparative genomic hybridization (CGH) was developed for use on solid tumours in 
1992, and was initially performed genome wide using metaphase chromosomes (41). The 
technique involves differentially labeling normal and tumour genomic DNA that are 
simultaneously hybridized to normal metaphase chromosomes in the presence of 
unlabeled Cot-1 DNA, which is used to block repetitive regions in the genome. Normal 
and tumour DNA are detected with red and green fluorophores, which allows 
quantification of the relative amount of normal versus tumour DNA using the ratio of 
green-to-red fluorescence. The resolution of CGH using metaphase chromosomes is low, 
detecting copy number changes greater than 20 megabases (Mb). However, at the time, it 
was still able to identify amplifications in tumours in regions containing oncogenes, 
including HER2 in breast cancer (41). The resolution of CGH was improved through it’s 
application to microarrays, where targeted P1 phage or BAC clones were spotted on glass 
slides, hybridized to the sample and reference genome, and then imaged to derive 
fluorescence ratios of each clone (42). The approach was validated, in part, through more 
accurately detecting HER2 amplification in a breast cancer cell line and four breast 
cancer tumours. The resolution and genomic coverage of chromosomal microarrays, 
including array comparative genomic hybridization (aCGH) was developed further, using 
cDNA as probes (43), as well as oligonucleotides, which continue to be the current 
design today (44).  
Chromosomal microarrays are now a first tier test to detect genomic aberrations 
associated with intellectual disability, autism, and many congenital disorders (45,46). 
aCGH can be used to determine major chromosomal aneuploidy as well as  
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Figure 1.2 Example of BAC end pairs and FISH clones overlapping ERBB2. A screen shot of 
the UCSC Genome Browser displays the length of BAC probes (black with arrows and green 
bars) relative to small genes, such as ERBB2 (highlighted in navy blue). The chromosome and 
scale along the top depict the genomic chromosomal and genomic location in the region 
displayed. 
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submicroscopic duplications and deletions that can not be elucidated using conventional 
karyotyping. More recently, single polymorphism nucleotide (SNP) arrays were 
developed, which can provide similar chromosomal information, but also can identify 
genomic regions with loss of heterozygosity or mosaicism. The number of 
oligonucleotides on one array now ranges from hundreds of thousands to millions, 
depending on the commercial platform, which allows for reliable detection of copy 
changes as small as 25 kb. Reliable detection of small chromosomal gains and losses are 
important in clinical diagnosis, as it is estimated that submicroscopic deletions and 
duplications may be the underlying cause of up to 15% of genetic diseases (47). 
Before the wide-spread adoption of next generation sequencing, aCGH in conjunction 
with gene expression data was used to segregate breast cancer tumours based on their 
copy number changes, and to identify likely “driver” or commonly dysregulated genes 
(48). Andre et al. (2009) found the number of copy number aberrations in any given 
tumour can range dramatically, from 1 to 318 copy number changes, and averaged 76. 
There were a total of 48 minimum common regions with frequent copy number changes 
(11 gains, 37 losses) that were found in >20% of samples. In addition, 20 genes were 
amplified in at least 10 cases, of which 15 genes were overexpressed at the mRNA level. 
Tumours were classified based their copy number profile, and there was partial overlap 
between the gene expression subtypes and aCGH-based classifications: basal-like 
tumours were more frequently class I (77%), 53% of Luminal A cancers were in class III, 
and 67% of HER2 tumours were class II (48).   
1.2.3 Gene Expression Microarrays 
Gene expression microarrays involve hybridizing fluorescently labelled complementary 
DNA (cDNA) to microarrays slides containing probes of mRNA sequences, and use 
similar principles as chromosomal microarrays. cDNA Microarrays used to analyze gene 
expression were first described by Schena and colleagues in 1995 (49). Forty-five cloned 
cDNA transcripts from Arabidopsis, a small flowering plant, were printed onto a glass 
slide for subsequent gene expression measurement using fluorescently labeled probes 
using reverse transcription of mRNA. Only one year later, microarrays containing 1,046 
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human cDNAs were described by the same group, representing one of the first parallel 
gene analyses that measured differential gene expression patterns under given 
experimental conditions (50). In this study, control treated (37°C) and heat-treated (43°C) 
human T (Jurkat) cells were fluorescently labeled with different fluorophores to identify 
gene expression changes in the heat shock response. The technique of measuring 
expression levels relative to a control sample is still widely used today. As with 
chromosomal microarrays, the resolution and capabilities of gene expression microarray 
have been significantly advanced with the application of oligonucleotide-spotted arrays 
that contain thousands of individual probes (51). Normalized gene expression values 
measured from signal intensities of the array are commonly clustered to visualize and 
quantitatively identify differences between two samples or states (52). Groups of genes 
that share biological function, chromosomal location or regulation within the differential 
gene sets can be determined, which helps infer the biological processes contributing to 
the two conditions measured (53). Gene expression microarrays have been particularly 
impactful in breast cancer, and have led to the identification of the intrinsic subtypes of 
breast cancer (3) (see section 1.1.1) and the development of gene expression signatures 
that are used for patient management and prognosis, and are described in detail in section 
1.4. 
1.2.4 Next Generation Sequencing 
DNA sequencing was first described by Sanger et al. in 1977, where chain-terminating 
dideoxynucleotides were incorporated into DNA strands by DNA polymerase during in 
vitro DNA replication (54). The first human genome was published over twenty years 
later in 2001, which was the result of a decade-long international collaboration of 20 
groups (55,56). The availability of this, and other, whole genome reference assemblies 
allow short DNA strands to be mapped, or aligned, to already known sequences in the 
genome. The possibility of short-read sequencing enabled the advancement of next-
generation DNA sequencing, which has been rapidly developed in recent years. Many 
sequencers now take less than a week to complete a reaction (57), and consequently, the 
cost per reaction has fallen dramatically, making it accessible for both research and 
clinical applications. 
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Next generation sequencing involves a multi-step process where the sample is prepared, 
sequenced, and then analyzed. Initially, DNA template preparation is required to ready 
the DNA sample for the specific sequencing platform being used. Briefly, this involves 
shearing the DNA to a smaller fragment size, ligating common primers (adapters) to both 
ends of the DNA fragments, and amplifying the template being sequenced (most 
commonly through emulsion PCR or solid-phase amplification) (58). DNA samples are 
also often enriched for a target sequence, such as all coding regions (whole exome 
sequencing) (59) or specific genomic loci of interest using customized capture methods 
(60). There are currently multiple next-generation platforms that can be used to perform 
sequencing, including ion semiconductor (Ion Torrent sequencing), Pyrosequencing (454 
Life Sciences), sequencing by synthesis (Illumina), and sequencing by ligation (SOLiD 
sequencing). Sequences are generated using the detection of individual nucleotides or 
oligonucleotides at sequential positions in the nucleic acid fragments being sequenced. 
For example, sequencing by synthesis employs nucleotides that are fluorescently 
modified with a reversible chain terminator, each nucleotide with a different colour (61), 
resulting in the addition of only a single nucleotide with DNA polymerase in a given 
cycle. The reaction is performed over millions of clusters, each containing many identical 
copies of a DNA fragment. Clusters are imaged during each cycle, and the colour the 
cluster emits indicates the nucleotide at that position. At the end of the cycle, the 
terminator is cleaved, allowing for the next nucleotide to be added. 
Once the sequencing portion is complete, the DNA sequences obtained (or “reads”) must 
be aligned to the human reference assembly to determine their specific genomic location. 
Reads can be single-end (one end of the DNA library is sequence), or paired-end (both 
ends of the DNA fragments are sequenced, meaning the sequences are in close 
chromosomal proximity to each other), and can range from 35-150 bp (ie. Illumina) to an 
average of 400 bp (ie. 454 Life Sciences). Mapping reads to the correct location of the 
approximately 3 billion nucleotides in the genome with high accuracy is an enormous 
task. For this reason, there have been over twenty sequence alignment software programs 
developed (62) (for example, Bowtie (63), Bowtie2 (64), SOAP2 (65), MAQ (66), BWA 
(67) and RMAP (68)). Many of these programs apply or improve upon the Burrows 
Wheeler Transformation, which is an algorithm that can be used to compress character 
  
15 
strings (or in this case the DNA sequence) using runs of similar characters (69). Each tool 
has strengths and caveats. Mapping quality, in many cases, is compromised for shorter 
runtimes through neglecting base quality scores, limiting the number of tolerated base 
mismatches, disabling gapped alignment or limiting gap length, and ignoring SNP 
information (62). A study comparing 6 common alignment programs found that most 
tools underestimate their mapping quality, and inaccurate alignments can be eliminated 
by removing reads with a mapping quality of less than 1 (70). 
After sequencing reads have been aligned to the genome, DNA variants, which are 
nucleotides or sets of nucleotides that differ from the reference genome, can be detected 
(most commonly SNPs, insertions, and deletions). Similar to the abundance of sequence 
alignments programs that are available, there are over thirty different programs that 
perform variant calling (71,72). The Genome Analysis Toolkit (GATK) (71), which was 
developed at the Broad Institute in Cambridge, Massachusetts, has become one of the 
most common and recommended programs used for variant calling (73,74). However, 
many other programs have strengths and are useful for certain types of experiments. For 
example, determining somatic mutations in cancer can be performed more effectively 
with programs specifically designed to compare tumour and matched normal sequences 
(75-78).  
One of the largest hurdles the genomics community will likely face over the next decade 
is the clinical interpretation of variants in genomes, exomes, and transcriptomes that 
result from next generation sequencing studies. Differentiating between non-pathogenic, 
natural variation and likely damaging mutations can be extremely difficult, and has 
significant implications for disease-related research. Once a variant list is compiled, 
which can contain thousands of variants per sample, there are a number of different 
software programs that can aid in variant interpretation. Usually, variants are assessed to 
determine whether they are common polymorphisms (79,80) (natural variation in the 
population), and whether they are likely to be pathogenic. Software programs have been 
designed for a number of different purposes, for example: to annotate whether the variant 
resides in an exon or within other genomic regions (promoters, splice sites, CpG islands) 
(81,82), to predict the effect of the variant on the protein product (83-85), and to assess 
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whether the variant is likely to cause defects in mRNA splicing (86,87). With the 
development of numerous software programs with overlapping functions, selecting which 
programs to use for sequencing analyses can be difficult. Between the numerous options 
for sequencing platforms, read alignment algorithms, and variant calling and 
interpretation software, there are hundreds of potential pipelines or combinations of 
analyses that can be performed (Table 1.3). For clinical laboratories, the American 
College of Medical Genetics does not recommend any specific software programs for 
next-generation sequencing analysis, rather, it is recommended to select programs based 
on what type of genomic variation you are expecting and the depth of sequencing 
coverage, and to explain any variant filtering criteria while clearly outlining limitations of 
the approach (89). 
1.3 DNA Variants 
Advancements in our technical ability to reliably detect mutations in thousands of genes 
in a given patient has greatly outpaced our ability to interpret and report on the data 
collected in a clinical setting (90). Single nucleotide variants (SNVs) or small 
insertions/deletions (indels) can be located in exons (protein coding regions), introns 
(between exons), or non-coding regions. A typical sequencing study usually does not 
analyze mutations in non-genic regions, given the low likelihood of pathogenicity and 
difficulty to predict its affect on cellular function. 
1.3.1 Protein Coding Mutations 
There are three possible amino acid consequences for a single nucleotide variant found in 
a coding region of a gene, and they can be classified as silent, missense, and nonsense 
(stop) mutations. Silent mutations arise when a single nucleotide is altered, but the 
mutated codon results in the incorporation of the wild-type amino acid into the protein. 
Conversely, missense mutations occur when the mutation leads to an alteration of the 
amino acid at the position of the variant. Nonsense mutations lead to a premature stop 
codon within the coding sequencing, which results in protein truncation. Small indels can 
  
17 
 
Table 1.3 DNA sequencing software 
Program  Citations* Reference** 
ALIGNMENT SOFTWARE 
Bowtie 4176 / 5854 Langmead B. Genome Biol. 2009;10:R25. 
BWA 3930 / 5715 Li H. Bioinformatics 2009;25:1754–1760. 
MAQ 1367 / 1975 Li H. Genome Res. 2008;18:1851–1858. 
Bowtie2 1173 / 1887 Langmead B. Nat. Methods 2012;9:357–359. 
SOAP2 997 / 1438 Li R. Bioinformatics 2009;25:1966–1967. 
BWA-SW 938 / 1412 Li H. Bioinformatics 2010;26:589–595. 
SSAHA2 563 / 828 Ning Z. Genome Res. 2001;11:1725–1729. 
BFAST 231 / 367 Homer N. PLoS ONE 2009;4:e7767. 
Stampy 227 / 333 Lunter G. Genome Res. 2011;21:936–939. 
ELAND NA / NA Cox AJ. Illumina. 2007 
Novoalign NA / NA Novoalign. http://novocraft.com. 
VARIANT CALLERS 
SAMtools  3953 / 5624 Li H. Bioinformatics 2009;25:2078–2079. 
GATK  1207 / 1756 DePristo MA. Nat. Genet. 2011;43:491–498. 
SOAP SNP  997 / 1438 Li R. Bioinformatics 2009;25:1966–1967. 
IMPUTE2  701 / 997 Howie BN. PLoS Genet. 2009;5:e1000529. 
VarScan 2 280 / 427 Koboldt DC. Genome Res. 2012;22:568–576. 
Dindel  174 / 237 Albers CA. Genome Res. 2011;21:961–973. 
CORTEX 83 / 143 Iqbal Z. Nat. Genet. 2012;44:226–232. 
SomaticSniper  84 / 117 Larson DE. Bioinformatics 2012;28:311–317. 
Beagle 73 / 105 Browning BL. Am. J. Hum. Genet. 2009;85:847–861. 
Strelka 55 / 89 Saunders CT. Bioinformatics 2012 28: 1811-7. 
CRISP  66 / 86 Bansal V. Bioinformatics 2010;26:i318–324. 
Atlas 2 58 / 82 Challis D. BMC Bioinformatics 2012;13:8. 
SliderII  24 / 43 Malhis N. Bioinformatics 2010;26:1029–1035. 
Bambino 21 / 31 Edmonson MN. Bioinformatics 2011;27:865–866. 
GSNP  2 / NA Lu M. Proc. Int. Conf. Parallel Processing. 2011; 6047227, 592-601 
MuTect  NA / NA https://confluence.broadinstitute.org/display/CGATools/MuTect. 
VARIANT INTERPRETATION 
PolyPhen  2312 / 3178 Adzhubei IA. Nat. Methods 2010;7:248–249. 
SIFT  1226 / 1682 Kumar P. Nat Protoc 2009;4:1073–1081 
ANNOVAR 910 / 1307 Wang K. Nucleic Acids Res. 2010;38:e164. 
ESEfinder  851 / 1137 Cartegni L. Nucleic Acids Res. 2003;31:3568–3571. 
PANTHER 845 / 1118 Thomas PD. Genome Res. 2003;13:2129–2141. 
ESRSearch 621 / 890 Fairbrother WG. Science 2002;297:1007–1013. 
HSF 439 / 581 Desmet F-O. Nucleic Acids Res. 2009;37:e67. 
VEP  263 / 390 McLaren W. Bioinformatics 2010;26:2069–2070 
SNAP  244 / 341 Bromberg Y. Nucleic Acids Res. 2007;35:3823–3835. 
MutationAssessor  182 / 272 Reva B. Nucleic Acids Res. 2011;39:e118. 
MutPred  173 / 251 Li B. Bioinformatics 2009;25:2744–2750. 
dbNSEP 144 / 219 Liu X. Hum. Mutat. 2011;32:894–899. 
ABSOLUTE  141 / 218 Carter SL. Nat. Biotechnol. 2012;30:413–421 
GSITIC 2.0 156 / 212 Mermel CH. Genome Biol. 2011;12:R41. 
CUPSAT  148 / 190 Parthiban V. Nucleic Acids Res. 2006;34:W239–242 
Align-GVGD  114 / 137 Mathe E. 2006;34:1317–1325 
SNPnexus  66 / 91 Chelala C. Bioinformatics 2009;25:655–661. 
*number of times the paper has been cited in Scopus / Google Scholar as of May, 2015 
** Many of the programs and references were extracted from Pabinger et al.88 
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also lead to missense or nonsense changes, insertions or deletions of one or a group of 
amino acids, or can result in a frameshift mutation, where the 3-nucleotide frame of the 
coding region is altered, leaving the portion of the protein after the mutation with an 
incorrect amino acid sequence.  
It is generally accepted that frameshift and nonsense mutations are the coding mutations 
most likely to be pathogenic or damaging to a protein. The clinical relevance or 
interpretation of these variants depends on the protein the mutation is found in, and 
whether that protein has a known cellular function or is cited to play a role in the 
phenotype being assessed. For example, a germ-line nonsense mutation in BRCA1 in an 
individual or family would be reported to the patient, as the mutation puts the individual 
at risk for developing breast or ovarian cancer (91). Correlating phenotype to genotype is 
much more difficult in the case of missense and silent mutations, as the effect on the 
protein’s function, if any, is hard to predict. However, clear and easy to interpret 
mutations account for a very low number of the overall mutational load that is detected in 
patients. In breast cancer, only 5-10% of families with a strong history of ovarian or 
breast cancer ever learn what the causal mutation is (92). For this reason, there have been 
many computational approaches, both sequence- and structure-based, that have attempted 
to assess the pathogenicity of missense mutations (93). Programs predicting splicing 
mutations or assessing their transcriptional effect, however, have been much more 
limited. 
1.3.2 Splicing Mutations 
Before proteins are translated, genes are transcribed and modified in a number of 
different ways: pre-mRNA splicing joins coding regions to be used during protein 
translation, and a 5’ cap and 3’ poly A tail are added to promote translation, and enable 
transcript transport and stability. Splicing involves over 100 factors (94), and is a multi-
step process that results in the removal of introns from RNA transcripts, adjoining 
neighbouring exons contained in the final mRNA. Splicing machinery, known as 
splicesomes, are made up of multiple proteins and recognize key sequences to delineate 
the intron/exon junctions. The 5’ and 3’ ends of the intron (known as 5’ donor or 3’ 
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acceptor sites) contain canonical dinucleotides “GT” and “AG” (95), respectively, which 
identify the intron boundaries (Figure 1.3). Within the intron there is a polypyrimidine 
tract, (Py)n, and an adenine (A), known as the “branch site” that is used for lariat 
formation. Briefly, splicing is carried out using two transesterification steps, whereby a 
2’-hydroxyl group of the adenine residue at the branch site attacks the phosphate at the 
donor site, leading to cleavage of the 5’ exon-intron boundary and lariat formation, and 
then subsequent attachment to the 3’ exon (as depicted in Figure 1.3) (96). The sequences 
spanning the intron/exon boundaries are conserved, but do have natural variation among 
different splice sites, which can be displayed as sequence logos (Figure 1.4 A). These 
sequences are 28 (acceptor) and 10 (donor) nucleotides in length, and dictate the overall 
strength of the splice site (or the likelihood of the splicing machinery recognizing the 
site) (98).  
Splicing is used in the cell as an additional level of protein diversity and regulation. 
Various protein isoforms can be produced from the same gene through the inclusion of 
different combinations of exons in the final mRNA transcript used for protein translation. 
Alternative splicing is suggested to be one of the most important components of the 
functional complexity of the human genome, and is estimated to affect 40-60% of all 
human genes (99). This natural alternative splicing is usually not pathogenic, as different 
transcripts of the same gene are often expressed in tissue specific patterns (100). 
Because splicing machinery relies on the pre-mRNA sequence to correctly remove an 
intron, mutations in these regions can lead to aberrant splicing that can damage or alter 
protein function. For example, if any of the highly conserved “GT” (or U in RNA) or 
“AG” nucleotides were altered, splicing would not properly occur at that intron (101). 
Although less common, mutations beyond these highly conserved dinucleotides in the 
splice site sequences (donor and acceptor) can lead to aberrant splicing and pathogenicity 
(97). The number of deleterious SNV splicing mutations described in the literature 
generally relates to the information content at each position of the sequence logo (Figure 
1.4 B).  
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Figure 1.3 Basic schematic of pre-mRNA splicing.  Diagram depicts an overview of mRNA 
splicing. Exons are indicated by the large blue-outlined boxes (as labeled), and introns are 
displayed as thin blue lines. Key nucleotides are labeled as “A”,”G”, and “U”, polypyrimidine tracts 
“(Py)n”. 
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Figure 1.4 Splicing 5’ donor and 3’ acceptor sequence logos and frequency of reported 
mutations.  A sequence logo for human acceptor (left) and donor (right) splice sites is displayed 
in A. The height of each nucleotide represents its frequency and the error bars indicate the 
standard deviation at that position. The distribution of deleterious single nucleotide variants 
reported in the literature to negatively affect splicing are displayed in B. This figure was adapted 
from Caminsky et al. (2014) (97) and Rogan et al. (2003) (98). 
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Splicing mutations can result in large changes to the final gene product, and hence, are 
commonly pathogenic. Up to 15% of all disease-causing mutations affect mRNA splicing 
(102), and this number is higher for certain genes, where splicing mutations can account 
for as many as 50% of the mutations reported (103). A number of different outcomes can 
arise from mutations that affect mRNA splicing. Mutations can inactivate a natural splice, 
which can result in the splicing machinery missing the corresponding donor or acceptor 
leading to intron retention (Figure 1.5 B), or the splicing machinery using a donor or 
acceptor from a neighbouring intron which would lead to exon skipping (Figure 1.5 C). 
An inactivating mutation at a natural splice site can also lead to the recognition of a 
weaker, so-called cryptic splice site in either the intron or exon, which would be 
recognized by the splicing machinery and result in the extension or truncation of the exon 
(termed cryptic splicing, Figure 1.5 D). A mutation may also activate a cryptic splice site, 
which would lead to a cryptic splicing phenotype (Figure 1.5 E). 
Numerous software programs have been developed to analyze mutations and their 
potential effect on mRNA splicing. Commonly, splicing software programs require a 
DNA sequence containing the mutation as the input (Table 1.4). The program then 
determines the presence of splice sites or splicing regulatory factor binding sites, such as 
exonic splicing enhancers. The effect of the mutation on splicing can be determined by 
comparing the mutated sequence versus the wild-type sequence. Because of the nature of 
these programs, genome-wide capabilities are limited, and analysis of thousands of 
mutations filtered from next generation sequencing studies would be extremely laborious. 
There are also programs that analyze mutations, or lists of mutations, to determine if any 
affect splicing. Many of the common variant annotation and interpretation software 
programs are limited to identifying mutations that are likely to alter splicing by their 
location at the conserved dinucleotides (for example, ANNOVAR (81)), or within a 
limited splicing region (for example, Variant Effect Predictor looks as far as 8 
nucleotides from the natural site (104)). The Automated Splice Site and Exon Definition 
Analyses (ASSEDA) (105), and the Shannon Human Splicing Pipeline (Shannon 
Pipeline) (86) software programs, however, employ information theory to extend the 
analysis to entire coding and non-coding regions of a gene. The application of 
information theory to DNA sequences was first proposed by Thomas D. Schneider in 
  
23 
 
Figure 1.5 Aberrant splicing patterns resulting from DNA variants. Wildtype (A) and 
aberrantly spliced (B-D) transcripts are displayed to portray examples of the potential affect a 
mutation can have on mRNA splicing. Exons are indicated by the blue boxes, white filled in exons 
represents regions not maintained in the final transcript, and the black lines correspond to the 
sequences joined after splicing has occurred. Red arrows represent splice site-inactivating 
mutations, and green arrows represent activating mutations. A mutation can decrease the 
strength of a splice site, which can lead to intron retention in the final transcript (B), the affected 
exon being skipped and not retained in the final transcript, or a now-stronger neighbouring cryptic 
splice site to be used (resulting in part of the middle exon included in the final transcript). 
Alternatively, Exonic (E-top) or intronic (E-bottom) cryptic splices can be activated, resulting in the 
extension or truncation of the exon. 
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Table 1.4 Splicing mutation and splice site analysis software. 
Program 
Genome wide 
capability? 
Analyzes 
mutations? 
Analyzes 
sequences? 
ANNOVAR81 yes yes no 
Variant Effect Predictor104 yes yes no 
ASSEDA105 no yes yes 
Shannon Pipeline86 yes yes no 
GeneSplicer107 yes no yes 
Human Splice Finder87 no yes yes (max 2500 nts) 
ESEfinder108 no no yes (max 5000 nts) 
MaxEntScan109 no no yes (9 nt sequences) 
Splice Site Prediction by Neural 
Network, NNSplice110 
no no yes 
NetGene2111,112 no no yes 
SpliceView113 no no yes (max 31000 nts) 
Splice Predictor114 no no yes 
GenScan115 no no yes 
Spliceman116 no no yes 
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1997 (106). The information theory-based approach is based on the formal relationship 
between information theory and the second law of thermodynamics. Each splice site is 
made up of information (measured in bits), which reflects the thermodynamic entropy 
and free energy of binding. The change in total information of the site is used to 
determine whether a mutation will strengthen or weaken the splice site. 
The limited genome-wide capabilities and regions analyzed by most splicing software 
programs has led to an underrepresentation of splicing mutations in genome-wide studies. 
In the 5 major breast cancer sequencing studies (12-16), splicing mutations accounted for 
only 1.78-2.18% of all of the mutations reported (Table 1.5). This is likely due to the 
rudimentary approaches used to identify splicing mutations, which were limited to 
mutations located at the canonical dinucleotides at donor or acceptor sites.  In addition, 
there are also currently limited efforts to attempt to validate the effect of splicing 
mutations on the mRNA transcript and protein product in large scale sequencing studies 
due to the large number of variants found, and efforts required for a single variant. 
1.4 Gene expression signatures in breast cancer 
The idea of personalized medicine is not new, however, clinical decision-making based 
on molecular profiling of individual tumours is still evolving. Early indications of 
personalized medicine date back to 1957, when 2 different papers suggested that genetic 
variation in enzymes may be linked to adverse drug response (117). Enzymes, such as 
cytochrome P450, can differ between individuals, which can determine how long and 
how much of the drug will remain active in the body. Characterizing an individual’s 
metabolizing enzymes can dictate the dose required for effective response, therefore 
tailoring the treatment strategy for each patient. Personalized medicine has now extended 
well beyond analyzing drug metabolizing enzymes. Breast cancer, even more so than 
most cancers, is a mixture of several diseases, so it is intuitive that it would be ideal to 
tailor treatment and therapy selection on an individualized basis. Although it has been 
proposed for many years, it is now becoming feasible to determine the molecular  
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Table 1.5 Splicing mutation analyses performed in previous sequencing studies. 
Paper No. Splicing 
Mutations  
(Percent of all 
mutations) 
Splicing mutation analysis  Validation approach to 
confirm affect on mRNA 
splicing. 
Banerji12  97  
(1.95%) 
Oncotator – Used gene 
annotations to identify 
mutations at splice sites. 
None 
Ellis13 69  
(2.15%) 
Used gene structure to 
annotate "splice site" 
mutations. 
None 
Shah15  43  
(1.78%) 
Mutations were called using 
RNA sequencing - de novo 
splice sites were 
determined with 
HMMSplicer. 
4 mutations were 
correlated to alternative 
splice junction usage in 
RNA sequencing data. 
Stephens16 158  
(2.18%) 
Mutations mapped to 
essential splice sites. 
None 
TCGA14 506  
(1.79%) 
Annotated at "splice site" 
with gene annotation file.  
None 
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 profile of each tumour, and personalize each clinical decision based on certain 
characteristics. Consequently, there have been many studies applying gene expression 
analyses to individualize breast cancer management, including predicting prognosis, the 
benefit of adjuvant chemotherapy, tumour response to treatment, and development of 
new therapies.  
1.4.1 Predicting prognosis and patient outcome 
Research groups have been successful identifying and analyzing gene expression 
signatures in breast cancer that outperform conventional clinicopathologic criteria in 
predicting prognosis. These tests are effective in aiding to predict which patients are most 
likely to benefit from chemotherapy. The most common tests used today include 
Oncotype DX, MammaPrint, and PAM50. Oncotype DX is made up of a 21-gene assay, 
and provides a quantitative likelihood of disease recurrence (118). It was developed and 
commercialized based off of a study from 2004 that assessed the probability of breast 
cancer recurrence at 10 years using 668 Tamoxifen-treated, lymph-node negative, and 
estrogen-receptor positive tumours. The assay employs reverse-transcriptase polymerase 
chain reaction (RT-PCR), and measures the expression of the 21 selected genes to 
calculate a recurrence score (either low, intermediate, or high). Similarly, MammaPrint 
uses a 70-gene assay to identify early-stage breast cancer patients that are at risk of 
distant recurrence or metastasis following surgery (7). The assay differs in that it was 
developed independent of ER status or any prior treatment, contrary to Oncotype DX. 
The 70-gene signature was developed using DNA microarray analysis on primary 
tumours of 117 young patients, and stratifies patients that have “poor prognosis” and 
would likely benefit from adjuvant therapy. PAM50 is a 50-gene test that has been 
optimized to stratify tumours based on the intrinsic subtypes of breast cancer, which are 
then used to develop a risk of recurrence score (119). It was developed using both 
microarray and RT-PCR using 189 protoype samples, and then tested with an additional 
761 patients to predict prognosis and 133 patients to predict complete pathological 
response to neoadjuvant chemotherapy. It is the only test of the three that directly 
leverages the intrinsic subtypes of breast cancer.  
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Gene expression signatures have an increased ability to recognize low-risk cases. This 
reduces the number of patients who receive adjuvant treatment, leads to a decrease in 
unnecessary toxicity, and lowers the cost of patient care (120). Regulatory bodies, such as 
the United States Food and Drug Administration (FDA), have recognized value and 
added benefit to patients by approving MammaPrint and PAM50 for clinical use, even 
though FDA approval is not required for laboratory-developed tests. Oncotype DX, 
which is currently the most commonly used test (121), is recommended by Cancer Care 
Ontario (122). The American Society of Clinical Oncology and the National 
Comprehensive Cancer Network also endorse these multigene assays to assist in 
treatment decisions for ER-positive cancer. Although these tests, and others, aid in 
deciding whether the patient would benefit from adjuvant therapy, clinicians still lack 
robust signatures that could indicate which specific treatments will be effective on a per 
patient basis (123,124).  
1.4.2 Selecting therapies and predicting treatment response 
Chemotherapy is currently recommended in cases where the benefit to the patient 
outweighs the risk of treatment. Conventional clinicopathological features indicating 
chemotherapy use for early breast cancer include histological grade 3 carcinomas, high 
Ki-67 levels, low hormone receptor status, HER2 amplification or triple negative status, 
and tumours that have spread to three or more lymph nodes (125). Chemotherapy can be 
used in breast cancer treatment either before (neoadjuvant) or after (adjuvant) surgery. 
Adjuvant chemotherapy using cyclophosphamide, methotrexate, and fluorouracil (CMF) 
for lymph node positive breast cancer was first cited as an effective treatment strategy in 
1976 (126), and was used until the substitution of methotrexate with epirubicin (CEF) 
(127) and then docetaxel (a taxane) (128) were later reported to be more successful 
combinations. Although clinical trials for many different adjuvant chemotherapy 
schedules have been conducted, there is ultimately still no consensus on which may be 
the most effective (129). Selection of the most effective adjuvant treatment is suggested 
to be individualized and should take into account clinical disease characteristics and 
patient-related factors (125,130,131). Treatment selection is already somewhat 
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personalized, profiling breast cancer tumours based on the intrinsic subtypes can direct 
recommendations in regard to endocrine, cytotoxic, and anti-HER2 therapies (Table 1.6).  
Numerous studies have attempted to leverage genomic profiling in order to characterize 
or predict tumour response or patient outcome when treating with specific therapies 
(Table 1.7). Gene expression is most commonly used for this type of analysis, and 
signatures or indicators have ranged from including only a few genes to many. The 
majority of the studies performed to date are completed with a limited number of samples 
and/or patients. The availability of both training and test sets can be limited for specific 
therapies, but is increasing with dataset depositories such as the Gene Expression 
Omnibus (GEO). For example, in 2003, a 92-gene expression signature was created using 
24 tumours, and was able to classify 10/11 sensitive tumours and 11/13 resistant tumours 
to neoadjuvant docetaxel in a leave-one-out analysis (132). No test set was used to 
validate the molecular profile, which was likely due to the limited availability of samples 
and/or the high costs for gene expression analyses at the time of the analysis. In contrast, 
a 20-gene signature was developed in 2014 to discriminate between chemoresistant and 
chemosensitive tumours to taxane-based therapies that used 160 tumours to develop the 
profile, and 659 datasets to test the method (133). Of the common prognostic gene 
signatures, the proliferation score from PAM50 is the only one that is able to identify 
patients that will benefit from a specific drug (low proliferation score predict weekly 
paclitaxel benefit) (134) or drug combinations (HER2-enriched tumours benefit from 
CEF over CMF) (135). Although our technological capabilities and access to data sets 
have greatly increased over the past decade, there is still no reliable genomic signature 
implemented in the clinic to select between chemotherapy agents on an individual basis. 
1.5 The Minimal Breast Cancer Genome and its Relevance 
to Chemotherapy 
Breast cancer studies to date have focused largely on genomic rearrangements, gene 
expression changes, and epigenetic alterations leading to the development and 
progression of the disease. Genomic regions in breast tumours that show high frequencies 
of abnormal rearrangements have been termed “saw-tooth” or “firestorm” regions (140),
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Table 1.6  Treatment recommendations according to tumour subtype and/or receptor 
status 
Subtype or receptor status Type of therapy 
Luminal A-like endocrine therapy is the most critical, often used alone 
Luminal B-like (HER2 -ve) endocrine therapy for all, cytotoxic therapy for most 
Luminal B-like (HER2 +ve) cytotoxic therapy + anti-HER2 + endocrine therapy 
HER2-positive cytotoxic therapy + anti-HER2  
Triple-negative cytotoxic therapy 
adopted from Schmidt et al. (2014) (129) 
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Table 1.7 Gene expression signatures developed to predict therapy response. 
Study Drug Tumour No. genes No. training 
samples  
No. test 
samples 
Indication 
Chang 
(2003)
132
 
Docetaxel (neoadjuvant)^ Locally 
advanced 
92 24 pre-operative 
core biopsies 
N/A Classifies tumours as sensitive 
or resistant (88% accuracy) 
Ma 
(2004)
136
 
Tamoxifen (adjuvant)* Hormone 
receptor 
positive 
2-gene ratio 60 N/A Predictive of disease-free 
survival 
Jansen 
(2005)
137
 
Tamoxifen (first line treatment)*  ER-positive, 
advanced 
44 46 66 Discriminate between patients 
with progressive disease and 
objective response 
Hallet 
(2012)
138
 
Chemotherapy regimens 
containing anthracycline and 
taxane drugs (neoadjuvant)^ 
N/A 2-gene 
index 
488 N/A Predicts complete pathological 
response 
He 
(2014)
133
 
Taxane-based therapies^ N/A 20 92 resistant / 68 
sensitive 
659 
datasets 
Discriminates between 
chemoresistant and 
chemosensitive individuals 
Schmitt 
(2015)
139
 
Trastuzumab and docetaxel 
(first line)*^ 
HER2-
positive 
8 79 frozen or FFPE 27 GEO 
datasets 
Predicted response to 
treatment (76% accuracy) 
* hormone therapy, ^ chemotherapy 
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and many genes have now been identified to be frequently mutated (14). However, 
studies that focus primarily on unaltered (“stable”) regions in breast cancer have been 
limited to date. 
Our laboratory has recently proposed that there is a minimal genome required for breast 
cancer cell survival (141). This minimal genome was derived by comparing independent 
data sets for regions of breast cancer genomes that are stable in copy number (140,142) 
with tumour gene expression levels that are similar to matched normal tissues (143,144). 
Genomic regions stable in copy number were obtained from two data sets that assessed a 
total of 243 (140) and 171 (142) primary breast tumours. The 812 derived “dually” stable 
regions (in both copy number and gene expression) contained a subset of 5,804 genes 
enriched for cellular metabolism, regulation of gene expression, DNA packaging, and 
regulation of apoptotic functions.  
A selection of the stable genes identified are targets of existing anti breast-cancer 
therapies, including paclitaxel, estradiol, and topotecan. Growth inhibition of the breast 
cancer cell lines MCF7, MDA-MB-231, HS578T, and T47D has been demonstrated using 
therapeutic agents that target gene products of the stable regions (145). There was not, 
however, consistent drug sensitivity across all cell lines. The average GI50 values (drug 
concentrations are –log10M units) for paclitaxel, gemcitabine, and topotecan were found 
to be 8.07, 6.65, and 6.92 respectively. Cell lines with GI50 values lower than 1 unit from 
these averages are considered outliers, as this relates to a 10-fold increase in the 
concentration of drug required for 50% growth inhibition.  
1.6 Thesis Scope and Objectives 
In order to improve patient care through tailoring therapies based on disease 
characteristics, the field will require advancements in our ability to effectively interpret 
and analyze large genomic data. We hypothesize that improvements in genome-wide 
analyses - diagnostic tools and reagents for better detection of genetic abnormalities, 
mutation interpretation, and genomic signatures for chemotherapy response - can result in 
a more accurate understanding of tumour biology. This thesis introduces improvements in 
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both the design and analysis of experiments, and then applies these techniques to breast 
cancer. We describe the generation of new data, as well as leveraging existing data sets, 
with the same overall goal of validating the proposed methods and interpreting the results 
obtained. 
Specifically, the main objectives of this thesis are to: 
1) Improve the design and analysis of nucleic acid hybridization studies (specifically 
FISH and aCGH). We sought to develop a novel method to identify single copy 
regions in the genome that contain highly divergent repetitive elements, which we 
predicted to act as single copy sequences in optimized experimental conditions. 
We aimed to generate small, single copy FISH probes that contained divergent 
repetitive elements, to confirm their predicted behavior in metaphase FISH. In 
addition, we proposed that oligonucleotide placement throughout the genome (ie. 
distance to highly conserved repetitive elements) within these single copy regions 
can affect the variation observed in microarray signal intensities. Accordingly, we 
sought to develop an aCGH microarray to test this theory and compare the 
platform’s reproducibility to a commonly used commercial platform. Both FISH 
and aCGH methods were validated on normal samples, as well as samples with 
known genomic alterations. 
2) The large number of predicted DNA variants arising from genome-wide studies 
creates new challenges to validate the effect of any given variant on the mRNA 
transcript and protein product. Splicing mutations represent a unique set of 
variants that can be validated using mRNA sequences. We aimed to develop a 
software tool that can conduct genome-wide, statistically robust validation of 
predicted splicing mutations using sample-matched RNA sequencing data.  
3) Splicing mutations are currently underpresented in large genomic studies, given 
that the majority of experiments only assess the canonical nucleotides at an 
intron/exon boundary. We aimed to carry out indepth splicing mutation analyses 
on a large set of breast cancer tumours using previously published data from the 
TCGA. We hoped to identify new underlying processes of tumour biology not 
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previously described by protein-coding dominated studies. Further, we planned to 
validate these mutations using the software described in objective 2.  
4) Current selection of the specific cytotoxic agents to be used for breast cancer 
patient care does not consider analyzing the tumour for genes involved in drug 
disposition. In addition to the classical pathological features, these genes may be 
informative in identifying which tumours are the most likely to respond to certain 
therapies. This thesis aimed to use machine learning to develop predictive models 
of breast cancer tumour sensitivity to paclitaxel and gemcitabine. Rather than 
completing a genome-wide study, we sought to start with a much smaller set of 
biologically-relevant genes based on what is known about paclitaxel and 
gemcitabine drug mechanisms of action. In addition, a set of FFPE tumour 
samples was obtained from patients that were treated with paclitaxel and 
gemcitabine, and whose response to these drugs is known. In addition to 
previously published data sets, we planned to validate the predictive gene 
signatures on these FFPE samples through nucleic acid extraction and analysis. In 
turn, we wanted to determine whether high quality data could be obtained from 
FFPE samples, and how suitable their use would be in studies involving 
chemosensitivity predictions. 
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Chapter 2  
2 Expanding probe repertoire and improving 
reproducibility in human genomic hybridization 
The work presented in this chapter is reproduced (with permission, Appendix S1) from: 
Dorman, S.N., Shirley, B.C., Knoll, J.H.M., Rogan, P.K. (2013) Expanding probe 
repertoire and improving reproducibility in human genomic hybridization. Nucleic Acids 
Research 41(7): e81. 
2.1 Introduction 
Genome-derived nucleic acid hybridization probes are routinely used diagnostically to 
identify, detect or quantify specific DNA sequences. It has long been recognized that 
repetitive sequences in these probes can interfere with the detection of chromosome 
abnormalities through cross hybridization to multiple regions of the genome. This is 
because repetitive sequences comprise at least 50% of the human genome and consist of a 
diverse set of distinct families (1) with variable degrees of divergence, many of which are 
conserved throughout mammalian evolution (2,3). Elimination of these sequences is a 
key consideration in genomic probe and experimental design. These sequences can be 
sequestered away from unique sequences in labelled probes (4,5), ‘blocked’ with 
unlabelled Cot-1 DNA (6–8), or eliminated from the probe sequence by masking all 
elements related to known repetitive sequence families (9). We present an approach to 
improve the genomic resolution and reproducibility of fluorescent in situ hybridization 
(FISH) and microarray comparative genomic hybridization (aCGH). Inclusion of 
evolutionarily highly divergent repetitive elements increases genomic coverage without 
compromising the specificity of FISH and aCGH to the extent that conserved repetitive 
sequences would. Contextual effects of proximate, conserved repetitive sequences on 
probe design are also investigated. 
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FISH is an essential diagnostic tool for detection of contextual chromosome 
rearrangements. However, the diversity of relevant chromosomal abnormalities seen in 
patients with cancer or congenital diseases far exceeds the catalogue of available 
recombinant probes. Commercial FISH probes often include multiple genes, which 
reduces their specificity for targeting abnormalities confined to individual genes. The 
Cancer Genome Project (10) has identified translocations in 317 cancer genes implicated 
in oncogenesis, 177 of which are <100 kb. Single copy FISH (scFISH) involves 
sequence-based genomic DNA probes that are 100–500-fold smaller than commercial 
FISH probes (11), thus providing the higher resolution necessary for specific detection of 
contextual changes within small genes. Nevertheless, repeat-masked probes contain 
exclusively unique genomic sequences, which limit access in genomic regions densely 
populated with repetitive elements for scFISH. 
aCGH determines copy number variation genome wide (12–14). It has been widely 
adopted in cancer research, disease gene discovery, prenatal diagnostics and has 
improved clinical diagnosis for patients with congenital and acquired diseases (15,16). 
aCGH has been recommended by the American and Canadian Colleges of Medical 
Genetics as a first-line test for individuals with development disabilities or congenital 
anomalies (17,18). Despite the ubiquity of this test, the accuracy and reproducibility of 
aCGH has recently been questioned (19–21). A study assessing 11 copy number variant 
(CNV) microarray platforms reported <50% similarity in CNV calls between software 
and analytical tools and <70% reproducibility in most replicate experiments (21). 
Multiple sources of data from different commercial platforms, analysed with the same 
software, call inconsistent copy number changes (CNC) (20), implicating the primary 
data as a significant contributor to this variability. 
In FISH and aCGH, non-specific cross-hybridization to other genomic locations is most 
commonly prevented by sequestering repetitive sequences with excess unlabelled Cot-1 
DNA (7,22). Addition of Cot-1 reduces consistency and increases variability in genomic 
hybridization to homologous targets, regardless of whether repetitive elements are 
present in the labelled DNA (23). Cot-1 DNA contains sc sequence impurities that 
increase variability in hybridizations. Probe sequences have also been designed to be 
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devoid of repetitive elements by synthesis of repeat-masked unique or sc intervals (9). 
However, the use of Cot-1 DNA in aCGH is unavoidable in order to prevent cross-
hybridization between non-allelic repetitive regions in the labelled sample. 
The proximity of repetitive elements to sc targets and the extent to which these sequences 
are conserved have not been considered in microarray probe design. We find that unique 
sequence microarray probes in close proximity to adjacent repetitive sequences, 
contribute to poor reproducibility of hybridization intensities, and the degree of repeat 
sequence divergence can affect the variability of hybridization intensities of these unique 
sequence probes. By mitigating these effects, it is possible to improve the genomic 
resolution and reproducibility of FISH and aCGH. 
2.2 Materials and methods 
2.2.1 scFISH probe design 
We deduced a complete set of effectively sc regions using an ab initio divide-and-
conquer search algorithm (24,25) directly from the reference human genome 
(GRCh37/hg19) (Appendix S2.1). This algorithm identified sc intervals without reliance 
on a catalogue of existing repetitive elements. The search constraints were tuned to 
include sequences containing highly divergent repetitive elements. Divergent copies of 
repetitive elements deviate sufficiently from conserved consensus sequences so as to 
preclude cross-hybridization to non-allelic genomic locations. A genome-wide set of ab 
initio sc intervals was derived and displayed as custom genome browser tracks. From 
these intervals, 15 scFISH probes >1.5 kb were designed to detect rearrangements within 
10 small cancer-related onco- and tumour-suppressor genes (<50 kb; CCND1, CDKN2A, 
CDKN2C, ERBB2, FGFR3, FLCN, KRAS, MYCN, NOTCH1, TP53) designated by the 
Sanger Institute Cancer Genome Project (10). Regions of at least 2.5 kb for scFISH were 
used for primer design for long polymerase chain reaction (PCR) as previously described 
(9). Appendix S2.2 indicates the eight probes that were produced, their genomic 
coordinates, length and primer sequences. 
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Divergent repetitive elements included in each probe were localized by genome-wide 
Basic Local Alignment Search Tool (BLAST) and analysed for degree and extent of 
divergence from consensus sequences of the same repeat family or subfamily. To 
estimate stability of probe sequences, nick translation products of 300 nucleotides (nt) 
were simulated by windowing along the length of a probe. Melting temperatures (Tm) for 
each imperfect duplex were estimated (26) and then plotted for higher and lower 
stringency, post-hybridization experimental wash conditions (2X SSC, 37°C, 50% 
formamide; and 2X SSC, 42°C, 50% formamide). With more stringent post-hybridization 
washing conditions, the divergent repetitive elements were not expected to cross-
hybridize to non-allelic genomic loci. Related, non-allelic sequences in the human 
genome were detected by BLAST analysis. All imperfect duplexes were estimated to 
exhibit predicted Tm at least 10°C lower than the homologous targets. 
The performance of eight probes containing divergent repetitive elements was validated 
by scFISH to human metaphase cells with a normal karyotype. Primers for a genome-
wide set of ab initio scFISH probes were designed using Primer 3 (27). Probe length and 
maximum Tm differences were optimized to produce the highest quality probes while 
maintaining genomic resolution. Primers were designed for intervals between 1.5–2 and 
3.5–4 kb, with maximum Tm differences set at 0.5°C, 1°C and 2°C. scFISH probes 
produced with maximum Tm differences did not significantly vary; therefore, 0.5°C was 
used to ensure the highest quality PCR amplification. Primer3 parameters used to 
generate the 1500–2000 bp products were PRIMER_OPT_SIZE = 27, 
PRIMER_MAX_SIZE = 28, PRIMER_MIN_SIZE = 26, PRIMER_ 
PRODUCT_SIZE_RANGE = 1500–2000, PRIMER_PAIR_MAX_DIFF_TM = 0.5, 
PRIMER_OPT_TM = 63, PRIMER_MAX_TM = 65, and PRIMER_MIN_TM = 61. To 
generate 3500–4000 bp products, the parameters used were PRIMER_OPT_SIZE = 33, 
PRIMER_MAX_SIZE = 35, PRIMER_MIN_SIZE = 30, PRIMER_PAIR_ 
MAX_DIFF_TM = 0.5, PRIMER_PRODUCT_SIZE_RANGE = 3500–4000, 
PRIMER_OPT_TM = 64, PRIMER_MAX_TM = 66, PRIMER_MIN_TM = 62. 
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2.2.2 scFISH probe development and hybridization 
Ab initio sc products were optimized by gradient thermal cycling, then amplified using 
long PCR with Platinum Pfx DNA Polymerase (Invitrogen™, CA). Amplicons were gel 
purified, extracted (QIAquick kit, Qiagen CA) and labelled by nick translation with 
digoxigenin-11-dUTP (Roche Diagnostics, ON, Can). Probes were hybridized on normal 
human lymphocyte metaphase chromosomes, detected with Cy3-conjugated anti-digoxin 
antibody (Cedarlane, CA), then washed and stained with 4',6-diamidino-2-phenylindole 
(DAPI) (28). At least 20 metaphases from cytogenetic preparations of control individuals 
were examined for each probe to confirm the chromosome location and hybridization 
efficiency. A probe from CDKN2A, which is abnormal in the preponderance of 
melanomas, was also hybridized to metaphase chromosomes of the melanoma cell line 
A-375 (29). 
2.2.3 Genome-wide aCGH 
A pool of suitable oligonucleotide probes from ab initio intervals was designed with 
PICKY (30), which matches melting temperatures to avoid complementarity between 
probes and stable hairpin formation. Default parameters were modified as follows: left 
selection boundary 200, right selection boundary 200, maximum oligonucleotide size 60, 
maximum match length 20, minimum match length 17 and probes per gene 5. PICKY-
suggested 2 057 653 coordinate-defined probes from 513 689 ab initio sc intervals. 
A subset of these probe sequences was selected to populate a custom genome-wide 
4x44K array. To minimize cross-hybridization of ab initio probes to repetitive sequences 
within the labelled genomic sample, oligonucleotides were chosen complimentary to 
genomic targets whose distance to an adjacent conserved repetitive element exceeded the 
length of the labelled extension products. Products were <300 nt. Oligonucleotide targets 
and adjacent repeat elements were separated by at least 300 nt, for repetitive sequences 
with <30% divergence (higher divergence sequences were tolerated). For purposes of 
comparison, ab initio oligonucleotide targets were paired with Agilent Technologies 
Human Catalog CGH 4 × 44K microarray (Agilent 44K) genomic probe sequences in 
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closest genomic proximity to ensure similar distributions. Where possible, gene coverage 
was maximized. The Galaxy metaserver (https://main.g2.bx.psu.edu) was used to ‘fetch’ 
the closest non-overlapping feature for every interval, ‘subtract’ intervals present in the 
ab initio and Agilent 44K oligonucleotide sets and determine the base ‘coverage’ of all 
intervals. We first determined the distance in nt of the closest repeat masked repetitive 
element to each probe. Oligonucleotides within 300 nt of a repeat were subtracted from 
the set. The closest ab initio probe to a corresponding sequence on the Agilent 44K array 
was fetched. The distance between ab initio probes and adjacent repeat elements was then 
maximized on the custom designed microarray by selecting oligonucleotides central to 
each ab initio interval. Gene coverage, which was determined from the proximity of 
probes to known NCBI RefSeq gene sequences, demonstrated that the paired set of ab 
initio probes did not cover all known genes (31). Gene coverage in the custom microarray 
was improved by adding 1510 probes within or adjacent to the missing genes. 
Ab initio normalization and replicate probes were also selected in close proximity of the 
corresponding Agilent probes. Both the custom designed ab initio 44K and commercial 
Agilent 44K microarrays were manufactured by Agilent. We hybridized them with 
genomic DNA from HapMap family trios (YRI: GM19143/GM19144/GM19415, and 
CEU: GM07019/GM07056/GM07022). DNA from the offspring (GM19145/GM07019) 
was used as the reference sample and co-hybridized with either the maternal 
(GM19143/GM07056) or paternal (GM19144/GM07022) sample on two replicate sectors 
of each array. To produce extension products <300 nt, DNA was subjected to heat 
fragmentation (98°C for 10′) before labelling and sized by electrophoresis. Pairs of 
genomic DNA samples (0.5 µg each) were individually enzymatically labelled using 5′-
terminally labelled, fluorescent random nonamers (either Cy3 or Cy5 from IDT) with 
5′→3′-exo- Klenow DNA polymerase (New England Biolabs), then mixed and co-
hybridized according to the Agilent Oligonucleotide Array-Based CGH for Genomic 
DNA Analysis Protocol (v6.2). Microarrays were scanned and quantified with Agilent 
Feature Extraction software (v10.5.1.1). Hybridization intensities of Agilent’s non-human 
control sequences were used to correct for background fluorescence. The coefficients of 
variation [CV = |(Log2 ratio or signal intensity) standard deviation|/mean] were 
calculated from replicate spot intensities of each autosomal probe sequence on the same 
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microarray platform. Identical probe sequences were replicated within the same and on 
different sectors on the array, enabling comparisons of both inter- and intra-array 
reproducibility on each platform. 
2.2.4 Locus-specific aCGH 
Reusable 12K oligonucleotide microarrays were produced using a microarray DNA 
synthesizer in our laboratory (CustomArray, Bothell, WA). Duplicate arrays containing 
either ab initio sc probes or the published Agilent 44K array probe sequences were 
manufactured. These arrays were designed to contain a higher concentration of probes 
mapping within chromosome 15q11.2q13 to fully assess CNCs present in patient samples 
with chromosome abnormalities in this region. In all, 125 ab initio sc probes and 84 
published Agilent 44K probes were replicated multiple times on each respective array. 
The remaining array content had genome-wide distribution which maximized gene 
coverage and minimized the distance between the pairs of Agilent and ab initio derived 
probe sequences. 
Genomic DNA from WJK35, an Angelman syndrome (AS) patient cell line with a 
previously mapped chromosome 15 deletion (32) was used to assess reproducibility for 
calling copy number differences. DNA was labelled with random Cy5 nonamers as 
indicated earlier in the text. Each array was hybridized, washed and scanned, then 
stripped and re-hybridized with the same labelled DNA product. One of the microarrays 
could not be re-hybridized to a labelled DNA after the initial hybridization study because 
it failed a quality control test for intra-array reproducibility. For all of the other arrays, 
labelled genomic DNA was removed from the microarrays after the initial hybridization 
(Stripping Kit, CustomArray) and then re-imaged. Array performance was assessed for 
quality control by re-hybridizing a Cy5-labelled, random nonamer, which verifies probe 
integrity and consistency of signal intensity before subsequent re-hybridization. Custom 
microarrays were imaged with an Axon GenePix 4000 B microarray scanner (Molecular 
Devices US). CNV was analysed with Nexus 6.0 (Biodiscovery US) software. 
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2.3 Results 
2.3.1 Genome-wide coverage of ab initio sc intervals 
The density and coverage of unique sequences for hybridization studies in any genomic 
region is finite, and in some instances, underrepresented in regions associated with 
disease or relevant to gene regulation and expression. For example, more than one-fifth 
of RefSeq genes are covered >50% in gene lengths by repetitive elements (31). We 
implemented an ab initio algorithm, which does not require a catalogue of repetitive 
elements to locate all genomic intervals devoid of multicopy sequences (Appendix S2.1). 
The density and lengths of contiguous DNA sequences used for probe design were 
increased by tuning sequence alignment stringency to include divergent repetitive 
elements with hybridization kinetics similar to sc sequences, at the same time avoiding 
segmentally duplicated and self-chained alignments of close paralogues. Before selecting 
scFISH and microarray probes, the distribution of ab initio intervals was characterized 
among previously annotated genomic features. Overlapping, adjacent intervals were 
merged to generate contiguous sequences of maximal length, then compared with the 
complement of the collective set of annotated repetitive features with an exclusive 
disjunction (OR) operation (1,33–36). The coverage or sensitivity for the ab initio set of 
intervals comprised 87% of the complementing sequences. The specificity was 83%, 
indicating 17% contained multicopy sequences. However, alignments to human self-
chained, paralogous sequence families comprised >90% of these false positive intervals, 
necessitating an additional filtering step to eliminate these potential probes. 
The ab initio probe intervals were densely distributed along chromosomes, with >50% of 
intervals exceeding 1 kb. Less than 0.2% of all ab initio intervals were separated by >32 
kb, with the majority (98%) occurring <8 kb apart. Gaps in the reference sequence 
assembly accounted for many of the widely separated ab initio regions. Gene coverage 
was assessed for ab initio intervals ≥50 nt to define potential targets for probe design of 
oligonucleotides for both aCGH and FISH. Genes with ≥50% coverage by ab initio 
intervals ranged from 5% of those on the Y chromosome to 84% of those on chromosome 
18. On average, <8% of genes were completely missed by the ab initio algorithm (from 
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3% on chromosome 3 to 87% on the Y chromosome). Genes ≤20 kb comprised 90% of 
the genes without coverage. Ab initio intervals overlapped other genomic annotations (at 
genome.ucsc.edu), including 85% of CpG islands, 99% of Vista enhancers, 98% of 
transcribed, ultraconserved intergenic sequences and 97% of intragenic sequences. Ab 
initio sequence intervals covered the majority of disease-associated genes in the 
Catalogue of Somatic Mutations in Cancer (COSMIC) (84%), Gene Reviews (93%) and 
Pathogenic International Standards for Cytogenomic Arrays (ISCA) gene (95%) 
databases. 
We then designed genome-wide sets of ab initio scFISH probes. PCR primer pairs were 
selected for 957 304 scFISH probes >1.5 kb from 194 795 unique genomic intervals 
(Supplementary Table 2.1, for all Supplementary Tables see the “Additional Files” 
electronic document). Of these, 455 978 of the scFISH probes overlap with known genes. 
Gene coverage varied from 48 to 58% for scFISH probes designed to be 1.5–2 kb and 
3.5–4 kb, respectively. These two subsets of FISH probes together cover 71% of NCBI 
RefSeq genes. The median distance between adjacent scFISH probes is 6140 nt, with 
89.5% of scFISH probes occurring within 25 kb of each other. 
A set of oligonucleotides was designed for production of genome-wide and regionally 
targeted aCGH platforms. A total of 2 057 649 oligonucleotide sequences were derived, 
756 235 of which were separated by at least 300 nt from the nearest conserved repetitive 
sequence (Supplementary Table 2.2). Oligonucleotide hybridization to these target 
sequences should reduce variability in signal intensities by minimizing cross-
hybridization of labelled DNA to repetitive regions in non-target or Cot-1 DNA (23) and 
prevent sequestration of labelled sc sequences linked to cross-hybridizing adjacent 
repetitive sequences (37). The full oligonucleotide set covers 84.7% of known genes, 
whereas the reduced subset of well-separated sc targets covers 81.5%. The reduced subset 
of adjacent sc probes is separated from each other by ≤25 kb, with a median distance of 
1.094 kb. Exceptionally long inter-probe intervals (>250 kb; n = 176) either occurred in 
centromeric regions, were enriched in multicopy sequences (i.e. paralogous self-chained 
alignments or segmental duplications), or were unsequenced. 
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2.3.2 Ab initio scFISH probes 
Cytogenetic rearrangements involving small cancer genes (<50 kb) have been 
documented; however, large commercial FISH probes may not provide adequate 
specificity to resolve intragenic CNCs or delineate intragenic juxtaposition of sequences. 
Ab initio scFISH probe sequences containing divergent repetitive elements were used to 
detect small cancer genes (9,11) for CCND1, CDKN2A, ERBB2, NOTCH1 and TP53. All 
scFISH probes hybridized to the correct chromosomal locations with high efficiency and 
specificity—17q21.1 (ERBB2), 9p21 (CDKN2A), 17p13.1 (TP53), 11q13 (CCND1) and 
9q34.3 (NOTCH1). Representative hybridizations are shown in Figure 2.1. Inclusion of 
divergent repetitive elements in these probes did not produce any observed cross-
hybridization with high stringency washing conditions. In addition, we hybridized 
CDKN2A Probe 1 to metaphase cells from a melanoma cell line (A-375). An aberrant 
hybridization pattern was observed on one chromosome 9p, with its hybridization signal 
telomeric relative to the normal chromosomal position (see Figure 2.1D). Inclusion of 
highly divergent repetitive elements significantly expands access to portions of the 
genome that were previously avoided by repeat masking sc sequences. A total of 95.6% 
(915 279) of these FISH probes overlap at least one divergent repetitive element. Ab 
initio scFISH probes consisting exclusively of sc sequences now comprise a minority of 
(3.7%; 35 658) of the genomic intervals. 
2.3.3 Ab initio aCGH 
Inclusion of divergent repetitive elements in genomic probes expands the regions 
accessible for probe development and the potential genomic resolution of aCGH. We 
have previously suggested that probe placement and, in particular, oligonucleotide targets 
in close proximity to conserved repetitive sequences may increase the variability in signal 
intensities observed in microarray hybridization (23). To test this idea, we selected 
oligonucleotide probes located greater than 300 nt away (the target size of the random 
primed DNA sample) from a conserved repetitive element. Hybridization results from our 
custom array design were directly compared with those obtained from the Agilent 44K  
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Figure 2.1: FISH validated sc probes.  Normal metaphase chromosomes from three cells 
hybridized with probes targeting TP53 on chromosome 17p13.1 (A), ERBB2 on 17q21.1 (B) and 
CDKN2A Probe1 on 9p21.3 (C) are shown. Hybridized chromosomes of each cell are enlarged 
and presented to the left of their respective metaphases. In panel (D), chromosome 9s from three 
different cells from melanoma A-375 cell line, hybridized to CDKN2A Probe 1, are presented. A 
complete metaphase is shown on the left and an ideogram of chromosome 9 on the right. One 
chromosome 9 in each cell shows hybridization as expected at 9p21.3 (white arrows), whereas 
the other homologue shows hybridization at the end of the chromosome (9p24.3-pter, red arrow). 
The aberrant location of the hybridization is likely due to a paracentric inversion between 9p21.3 
and 9p24.3. Chromosomes are counterstained with DAPI. Note: The aberrant hybridization 
pattern is consistently seen on the chromosome 9 with the pale staining heterochromatin 
polymorphism in the q arm. 
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platform using the same labeled HapMap trio samples (i.e. healthy individuals). 
Reproducibilities of the ab initio and Agilent microarrays were compared from the CV of 
hybridization intensities of replicate oligonucleotide probes. The custom oligonucleotide 
array of genomic targets with this content exhibited lower variability in hybridization 
kinetics and increased consistency of signal intensities in aCGH. The median CVs of all 
probes in both replicates were lower in the ab initio custom array for both log2 ratio 
(17.8%) and proband (green) signal intensities (24.1%; Table 2.1; Mann–Whitney rank 
sum test; P < 0.001). Red signal intensities were excluded because they represented two 
different individuals (two sectors of each mother/father), which was insufficient to 
reliably compute CVs. The subset of probes contributing to higher variability in signal 
intensities in the Agilent platform exhibited lower reproducibility as a function of 
genomic location. CVs of different subsets of Agilent probes (all probes, probes within 
300 nt of a repeat, and probes greater than 300 nt of the closest repeat) were compared 
with CVs for the closest ab initio probes. The mean CVs of the intensity log2 ratios of the 
ab initio probes were on average 48.3% below that of the corresponding Agilent genomic 
targets, when the corresponding Agilent probe was located within 300 nt of a conserved 
repetitive element (paired Student’s t-test; P < 0.05; Table 2.2). The mean CVs after 
background correction for all probes, regardless of genomic context were 34% lower for 
one HapMap family (P < 0.001); however, the difference was not significant for the other 
family. For paired sets of ab initio and Agilent probes, CVs were not significantly 
different for Agilent probes separated from adjacent repetitive sequences by >300 nt. In 
probe pairs where the Agilent oligonucleotide was within 300 nt of a repeat, the CVs of 
the ab initio proband signal were lower in all instances, consistent with our previous 
analyses (23). We interpret these findings as follows: probes within 300 nt of a repetitive 
element have the potential to hybridize to a random-primed DNA extension product that 
contains both a sc target sequence as well as adjacent repetitive elements. Conserved 
repetitive elements present in hybridized DNA sample are susceptible to cross-
hybridization with repeats in non-target labelled and Cot-1 DNA. Figure 2.2A illustrates 
an example of this for a pair of probe sequences in TP53. Labelled random-primed (or 
nick translated) extension products containing a Tigger5 conserved repeat element
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Table 2.1: Comparison of CV of replicate probes by platform: Mann–Whitney rank sum 
test 
CVs tested Log2 Ratio Proband 
Platform
a
 AG AI AG AI 
YRI DNA Samples     
Median CV 49.37 37.34 4.25 2.26 
Interquartile range 85.62 66.51 3.18 1.65 
P-value <0.001 <0.001 
CEU DNA samples     
Median CV 88.69 78.70 3.51 3.46 
Interquartile range 155.89 140.67 2.97 2.72 
P-value <0.001 <0.001 
Median CVs of the log2 ratio and proband signal intensities (‘Proband’) were compared for both 
HapMap family DNA samples (YRI/CEU). Bolded values indicate CVs that were significantly 
lower in the ab initio platform compared with the corresponding Agilent data. Interquartile range 
demonstrates the larger range of CVs in the Agilent platform. 
a
AG = Agilent; number of probes = 42 492; AI = Ab initio; number of probes = 41 898; YRI = 
Yoruban HapMap trio; CEU = Caucasian HapMap trio. 
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Table 2.2: Comparison of CV of replicate probes by platform: Paired t-tests 
CVs tested Log2 Ratio  
Platform
a
 AG AI P-value* 
YRI DNA Samples    
All probes 328 216 0.0019 
AG probes <300 nt 366 218 0.0046 
AG probes >300 nt 260 213 0.0855 
CEU DNA samples    
All probes 869 901 0.4655 
AG probes <300 nt 1025 449 0.0348 
AG probes >300 nt 594 1695 0.0975 
Paired t-tests were performed for log2 ratio CVs for all probe pairs, probe pairs where the Agilent 
oligonucleotide was within 300 nt of a repetitive element (AG probes <300 nt), and for probe pairs 
where the Agilent oligonucleotide probe was at least 300 nt from an adjacent repetitive element 
(AG probes >300 nt). 
a
AG = Agilent; number of probes = 42 492; AI = Ab Initio; number of probes = 41 898; YRI = 
Yoruban HapMap trio; CEU = Caucasian HapMap trio. 
*Bolded values indicate P < 0.05. 
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Figure 2.2: The effect of genomic context on hybridization signal intensity variability. (A) 
This panel demonstrates how the subtle differences in genomic location of ab initio and Agilent 
probes (dark grey; light grey vertical bars show target on extension products) may explain the 
higher CV in the Agilent platform. Simulated 5′ labelled, random-primed DNA extension products 
(of 300 nt) are windowed along the TP53 gene with the locations of a pair of Agilent and ab initio 
sc oligonucleotide probes. Increasing the distance between microarray probe sequences (in grey) 
and repetitive elements (in red) reduces the likelihood of hybridization to a labelled DNA product 
containing both the unique target (in black) and repetitive sequence. Extension products 
containing an adjacent Tigger5 repetitive element would be expected to hybridize to the Agilent 
probe located 179 nt away, but not to the ab initio sc probe situated 462 nt from the repeat, even 
though both are sc (black) probes. The average CV of this Agilent probe was 146, compared with 
the ab initio probe, which had a CV of 32. (B) Accurate hybridization signal intensity is achieved 
with sc target labelled DNA (black), exclusively hybridizing to probe sequence. Panels C and E 
depict how the presence of repetitive sequences in labelled target DNA can lead to higher than 
expected signal intensities. (C) Signals can be amplified by repeats (red) in close proximity to sc 
sequences (black), leading to non-allelic cross-hybridizations between repetitive elements 
adjacent to the labelled target DNA and other regions of the genome. (D) Unlabelled Cot-1 DNA is 
known to be contaminated with sc sequences (blue), which can serve as microarray probe 
targets. These contaminants in Cot-1 can suppress hybridization to desired target sequences by 
blocking the target labelled DNA from hybridizing to the probe sequences, reducing the overall 
fluorescent signal. (E) The major repetitive fraction in Cot-1 DNA will hybridize to labelled, 
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random-primed DNA containing repetitive sequence (e.g. Tigger5 in this instance). This can result 
in an undesirable increase in signal intensity through bridging hybridization of labelled DNA target 
to other non-allelic repetitive sequences. This can be mediated by cross-hybridization to repetitive 
sequences in Cot-1 DNA, which is usually added in stochiometric excess of the labelled sequence 
in microarray studies.   
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(11.5% divergent from the TcMar-Tigger consensus) cross-hybridized to the published 
Agilent probe sequence 179 nt away (CV = 146), but did not hybridize to the ab initio 
probe situated 462 nt from this repeat element (CV = 32). Calibration of the lengths of 
the labelled genomic DNA used in aCGH has been demonstrated to significantly improve 
microarray performance (38). Indeed, the observed CVs of these specific probes confirm 
the expected results. 
2.3.4 Probe parameters affecting CVs 
As the increased variability in microarray signal intensities can be attributed to proximate 
repetitive elements, we performed analysis of variance (ANOVA) and principal 
component analyses (PCA) to examine the characteristics of the oligonucleotide 
sequences that contribute to this source of noise. Genomic features (GC content, probe 
length, distance of nearest neighbouring repeat element and divergence) were determined 
for each set of paired probes and assessed by ANOVA for association with signal 
intensities and CVs. Repeat distance was associated with the log2 ratio CVs in both 
Agilent arrays (P < 0.05 and P < 0.001). In the second Agilent hybridization, repeat 
divergence (P < 0.05) was also associated with CVs. However, the CVs of log2 ratios 
were associated with neither repeat distance nor repeat divergence in either ab initio array 
(P > 0.05). PCA of data from both microarray platforms were consistent among replicate 
hybridizations for each platform; however, differences between Agilent and ab initio 
arrays were evident for two PCA eigenvectors (Table 2.3). The third component of the ab 
initio data was comprised of CV alone, with no significant interaction with the other 
factors, as expected from ANOVA. Differences in the Agilent data show that both the 
distance between probe and adjacent repetitive sequences, specifically within 300 nt, and 
the degree to which the repeat sequence is conserved, are not independent of the CVs of 
the probe signal intensities.  
We then analysed the CVs of signal intensities from both the Agilent and Affymetrix 
(Santa Clara, US) microarrays for the same HapMap samples analysed previously. The 
CVs of four data sets (two Agilent, two Affymetrix) were compared within the same 
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Table 2.3: Principal components analysis of genomic and probe parameters with CV in 
HapMap pedigrees 
Platform characteristics YRI trio CEU trio 
Eigenvectors 1 2 3 1 2 3 
AB INITIO       
CV intensity −0.0087 0.0734 0.9970 0.0038 −0.0723 0.9959 
GC content 0.4895 −0.4466 0.0201 0.4894 −0.4441 −0.0742 
Probe length −0.2562 0.6979 −0.0689 −0.2562 0.7002 0.0195 
Repeat distance 0.6546 0.2000 −0.0061 0.6547 0.1987 0.0268 
Repeat divergence −0.5159 −0.5178 0.0288 −0.5159 −0.5174 −0.0388 
% Variance explained 26.9705 21.6464 19.9922 26.9700 21.6461 20.0012 
 
AGILENT       
CV intensity −0.0397 −0.5311 0.8035 0.0065 0.5145 0.8554 
GC content −0.6950 0.0436 0.0250 −0.6957 0.0444 −0.0118 
Probe length 0.6976 −0.0016 −0.0149 0.6979 −0.0088 −0.0066 
Repeat distance −0.1643 −0.2629 −0.4577 −0.1647 −0.3947 0.1772 
Repeat divergence −0.0409 0.8043 0.3796 −0.0412 0.7599 −0.4865 
% Variance explained 36.8101 20.1829 19.9547 36.7845 20.1786 19.9373 
Principal component analysis was carried out to assess the relationship between probe CVs, GC 
content, probe length, distance of the closest repeat and its divergence from the consensus 
family sequence. In the ab initio probe set, the CV eigenvalues showed little or no interaction with 
other probe properties (compare eigenvectors 1 or 2 versus 3). In contrast, the corresponding 
eigenvalues were related to distance from and divergence of adjacent repetitive sequences in 
data from the Agilent platform. Bolded numbers indicate the parameter has a positive or negative 
effect of at least 15% overall. 
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hybridization. This eliminated the possibility that the observed results were derived from 
subtle differences in experimental conditions or labelling of genomic DNA. Probe CVs 
were calculated for the Agilent 44K array and the publically available Affymetrix 
Genome-Wide Human SNP Array 6.0 Sample Data Set 
(http://www.affymetrix.com/support/technical/sample_data/genomewide_snp6_data.affx)
. The median CVs were compared using a Mann–Whitney Ranked Sum Test. Probes 
were categorized based on the repeat proximity (either within or beyond 300 nt) and level 
of divergence (±20% relative to the consensus repeat) of the repetitive element adjacent  
to a probe (Table 2.4). For both commercial data sources, probes within 300 nt of a 
repetitive element exhibit significantly higher CVs (P < 0.001), though the Affymetrix 
probes had lower CVs overall than those on the Agilent array. In the Affymetrix data, the 
level of repeat divergence contributes to probe signal intensity variability to a greater 
extent than the probe proximity to adjacent repetitive elements. In particular, the 
combination of low divergence and close proximity produces the highest probe CVs in 
both commercial microarray platforms. As expected, repeat divergence did not contribute 
to probe signal intensity CVs for probes at least 300 nt away from adjacent repetitive 
elements. 
2.3.5 Targeted chromosome 15q11.2q13 aCGH detects AS deletion 
Lower variability in signal intensities is desirable in aCGH to achieve more consistent 
calling of CNCs and accurate determination of copy number using fewer probes. To 
assess the reliability of ab initio probes in CNC detection, we performed aCGH on a 
sample with a documented chromosome deletion using custom-synthesized, targeted 
microarrays. A set of 12K oligonucleotide microarrays were produced with probes 
concentrated in the chromosome 15q11.2q13 region and genome-wide representation at 
other chromosomal locations. The arrays were simultaneously hybridized to random-
primed DNA from a lymphoblastoid cell line derived from a patient with AS carrying a 
defined deletion of 5.01 Mb (32). 
The same labelled sample was used in eight hybridizations: four containing identical  
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Table 2.4: Analysis of variation of CVs in Agilent and Affymetrix aCGH probe subsets 
Repeat 
distance 
Repeat 
divergence 
No. 
probes Median P-value
a
 
Repeat 
distance 
Repeat 
divergence 
No. 
probes Median P-value
a
 
A. Affymetrix-GM07019 B. Affymetrix-GM19145 
<300 <20 576 831 0.0246 <0.001 <300 <20 576 363 0.0236 <0.001 
>300 >20 276 461 0.0235 
 
>300 >20 276 705 0.0223 
 All <20 840 370 0.0244 <0.001 All <20 840 369 0.0235 <0.001 
 
>20 880 374 0.0237 
  
>20 880 375 0.0224 
 <300 All 1 180 744 0.0242 <0.001 <300 All 1 180 033 0.023 <0.001 
>300 
 
540 000 0.0238 
 
>300 
 
540 711 0.0227 
 <300 <20 576 831 0.0246 <0.001 <300 <20 576 363 0.0236 <0.001 
 
>20 603 913 0.0238 
  
>20 603 670 0.0224 
 >300 <20 263 539 0.024 <0.001 >300 <20 264 006 0.0232 <0.001 
 
>20 276 461 0.0235 
  
>20 276 705 0.0223 
 C. Agilent-GM07019 D. Agilent-GM19145 
<300 <20 14 052 0.921 <0.001 <300 <20 14 052 0.503 <0.001 
>300 >20 6 940 0.861 
 
>300 >20 6 940 0.433 
 All <20 21 866 0.897 0.011 All <20 21 866 0.484 <0.001 
 
>20 18 644 0.875 
  
>20 18 644 0.449 
 <300 All 25 756 0.901 <0.001 <300 All 25 756 0.482 <0.001 
>300 
 
14 754 0.862 
 
>300 
 
14 754 0.443 
 <300 <20 14 052 0.921 0.007 <300 <20 14 052 0.503 <0.001 
 
>20 11 704 0.884 
  
>20 11 704 0.457 
 >300 <20 7 814 0.863 0.555 >300 <20 7 814 0.452 0.301 
 
>20 6 940 0.861 
  
>20 6 940 0.433 
 
Comparison of probe CVs of Agilent and Affymetrix platforms based on proximity to and divergence level of neighbouring repetitive elements. 
Probe CVs were calculated for Affymetrix (panels A and B) and Agilent (panels C and D) data from hybridizations with the HapMap proband 
samples (panels A and C: GM07019, panels B and D: GM19145) used in this study. Median CVs of different groups of probes within each platform 
were compared using the Mann–Whitney rank sum test. Probe subsets were selected based on the distance to the closest repetitive element in nt 
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(either less or greater than 300 nt) and the divergence of the repetitive element from a consensus family sequence (less than or greater than 
20%). 
a
Mann–Whitney rank sum test. 
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probe content from the ab initio custom array and four containing published probe 
sequences from the Agilent 44K array. One of the arrays containing the Agilent probe 
design failed quality control owing to uneven oligonucleotide synthesis and was excluded 
from further analyses. The ab initio platform contained 125 probes and the Agilent 
platform contained 84 within the common AS deletion-breakpoint interval. Each probe 
was replicated on the array three times. The ab initio probes were distributed on average 
52.54 kb apart throughout the CNC region, with a median distance between 
oligonucleotides of 18.01 kb. The Agilent probes were slightly more dispersed, with an 
average distance between oligonucleotides of 77.83 kb and a median distance of 52.11 
kb. CNC detection was done by Rank Segmentation (39,40) and required at least five 
probes in a segment to assign a CNC. 
Results from five of seven genomic microarrays called the AS deletion accurately: all 
four replicates of the ab initio probe set and one replicate containing Agilent probe 
sequences. Figure 2.3 indicates representative examples of primary signal intensities for 
the oligonucleotide probes spanning the deletion interval and flanking sequences for the 
ab initio and Agilent-based microarrays. The primary signal intensities of the ab initio 
probes displayed lower overall variability in the distributions of intensities in this 
genomic region. Ab initio probes within the deletion interval were then matched, based 
solely on genomic proximity, to the 76 Agilent probe sequences (excluding the 
breakpoint regions). Considering the matched probes alone, all four data sets from the ab 
initio platform were able to call the CNC, which was detectable on only a single array 
with Agilent probe content. 
We tested the limits of sensitivity of the ab initio and Agilent microarrays to call CNCs 
by reducing the probe densities in this region by selecting one of two alternating probes 
(n = 37). All four replicates of the ab initio array still detected the AS deletion. 
Interestingly, one of the Agilent replicate arrays called the deletion, but it was a different 
microarray from the one indicated in the previous analysis that involved twice as many 
probes. The resolution and consistency of both array platforms of calling deletions was 
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Figure 2.3: Primary hybridization signal intensity data from ab initio and Agilent probe 
sequences covering Angelman syndrome (AS) chromosome deletion region (chromosome 
15q11.2q13.1). Primary signal intensity data are displayed from Nexus Biodiscovery software for 
one replicate each of the (A) ab initio and (B) Agilent probe sequences. Red and blue bars 
indicate copy number loss or gain, respectively. Details on the CNCs displayed were outputted as 
follows: (A) Deletion genome coordinate range called the following: 21 937 154–30 319 444, 
length: 8 362 290 nt, probe count: 123, probe signal intensity mean: 53.84, probe signal intensity 
median: −13.00. (B) Miscalled duplication coordinate range: 22 866 888–30 322 138, length: 7 
455 250 nt, probe count: 73, probe signal intensity mean: 140.16, probe signal intensity median: 
13.7. This figure demonstrates the greater variation in Agilent probe sequence signal intensities 
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compared with those from the ab initio array. The average standard deviation of the probe signal 
intensities between replicates in the ab initio CNC region (chr15: 21 937 154–30 319 444) is 
138.08, whereas it is 238.04 (72% higher) for the Agilent probe sequences in the CNC region 
(chr15: 22 866 888–30 322 138). 
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unreliable when only 12 probes were scored (every third probe from the set of 37). A 
defined region within the deletion (ab initio—chr15:22 815 291–24 061 148 (hg19); 
Agilent—chr15:22 784 523–23 930 870) that spans the Angelman breakpoint 2 (BP2) 
(32) was called as a gain in one ab initio data set and all three Agilent data sets. By 
contrast, the region of the deletion distal to BP2 (ab initio—chr15:25 207 252–30 319 
444; Agilent—chr15:25 143 144–30 322 138) is inferred as a copy number loss in all 
seven data sets. The mean CVs of all probes within BP2 that inconsistently called CNCs 
in both platforms were 34.87% (ab initio) and 17.75% (Agilent) higher than the other 
probes in the deletion interval. This is likely due to higher noise in the observed signal 
intensities. This may be related to interference of segmental duplicons in the 
hybridization, which are known to distort aCGH results (32). Segmental duplicons span 
47% (ab initio) and 53% (Agilent) of the BP2 region. This is considerably higher 
compared with the genomic interval that was consistently called as a deletion and 
contains a smaller proportion of segmentally duplicated sequences (14%).  
2.4 Discussion 
Sequences of synthetic DNA probes used in genomic hybridization have been 
traditionally derived from unique sequences, or include repetitive elements that are 
sequestered during hybridization (4–9). The contextual effects of the genomic proximity 
of these sequences to repetitive elements have generally not been accounted for in 
assessing probe performance. Judicious selection of probes distant from adjacent 
conserved repetitive sequences can improve reproducibility of human genomic 
hybridization. Furthermore, probes incorporating divergent repetitive sequences do not 
adversely affect sc probe specificity. Under more stringent hybridization conditions, 
cross-hybridization catalysed by repetitive sequences is preventable. The inclusion of 
divergent repetitive elements expands genome-wide probe coverage, the outcome of 
which are increased lengths of scFISH probes in those regions and higher resolution in 
delineating novel genomic rearrangements by hybridization-based methods (such as 
genomic microarrays, multiplex ligation-dependent probe amplification (MLPA), PCR 
and others). 
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There are other established methods for producing short FISH probes. Software has been 
used to design smaller (10–100 kb) FISH probes (41), similar to our own scFISH 
products (9,11). Pools of labelled oligonucleotides have been used to visualize regions as 
small as 6.7 kb (42); however, the efficiency of detection with these pools is currently 
insufficient to be recommended for clinical use. Furthermore, both of these methods still 
require repeat-free regions for probe design. The ab initio scFISH probes presented here 
can reliably target small genes that are known to be commonly rearranged in cancer. By 
contrast, conventional, recombinant FISH probes extend well beyond the boundaries of 
these genes and often include neighbouring genes. Repeat-masked probes that lack 
divergent repetitive elements (9) within these genes are often too short to perform 
scFISH. 
The coverage and level of specificity achieved by ab initio scFISH can confirm 
intragenic rearrangements or define small chromosomal aberrations detected by aCGH. 
Abnormalities that can be detected by these probes include small deletions (genes or 
exons), gene amplification, translocations and inversions involving the probe’s genomic 
location. For example, CCND1 at 11q13.3 is only 13.37 kb. A common translocation 
t(11;14)(q13,q32), which over-expresses this gene has been found in 20% of multiple 
myeloma cases (43,44) and 94% of mantle cell lymphoma patients (45). We have created 
two probes (<4 kb) targeting exons 3 (probe 1) and 5 (probe 2) of CCND1. In patients 
carrying this translocation, these probes will hybridize to the derivative chromosome 14. 
Commercial and cloned probes in this genomic region are considerably longer and would 
not detect rearrangements confined to this gene. 
Despite the widespread application of aCGH for genome-wide copy number 
determination (46,47), the inter- and intra-platform reproducibility of both expression and 
copy number microarray data may be less than satisfactory (19–21,23,37,48–51). These 
previous studies have generally assumed that discrepancies resulted from stochastic noise 
in signal intensity measurements and have been attributed to algorithms used to call CNC 
analyses. Higher CVs of signal intensities have also been linked to probe length and 
composition, cross-, self- and perfect match hybridization free energies, melting 
temperatures, position within a target sequence, sequence complexity, potential 
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secondary structure and sequence information content (52). Nonetheless, these 
parameters have been described as insufficient for optimizing probe performance (53). 
Our results suggest that the variability in aCGH studies does not originate solely from 
stochastic effects, but rather a systematic error introduced during probe design. We 
demonstrated that the genomic location of the probe relative to neighbouring conserved 
repetitive elements and the level of sequence divergence of the nearest repeat can account 
for 40% of the variance observed in the Agilent genomic microarray data. We were 
however not able to explain all of the variance in the signal intensity data. It has been 
recognized that self–self hybridization in solution may be responsible for variability by 
sequestering some of the labelled hybridizable sequences (37). We propose that 
formation of these duplexes is frequently catalysed by repeats in labelled DNA 
containing the sc target sequence. Repetitive sequences throughout the genome are of 
sufficiently high concentration for such events to be commonplace during hybridization. 
Other factors such as variation in the quantity of probe on the array and hybridization 
kinetics, could also account for the unexplained variance. 
When expanding the oligonucleotide set with additional probes, it is important to 
consider the probe characteristics that are the most crucial to minimizing CVs. Probes 
within 300 nt of adjacent repetitive elements with <20% divergence from eponymic 
repeat family members have the poorest performance, with CVs on average 8.41% higher 
than those with greater separation from these elements. The variation of signal intensities 
is likely due to cross-hybridization to repetitive sequences present in the labelled target 
DNA as well as Cot-1 DNA contaminated with the sc sequences detected by the probe 
(Figure 2.2). Figure 2.2B illustrates the expected hybridization pattern, when labelled sc 
target DNA hybridizes to the probe resulting in an accurate signal intensity. Figure 2.2C 
demonstrates the cross-hybridization that can occur when the microarray probe is located 
within 300 nt of a conserved repeat element (e.g. Agilent probe in panel 2A), resulting in 
an unexpected, higher signal intensity. In Figure 2.2D, reduced signal intensity can result 
from cross-hybridization of unlabelled sc sequences present in Cot-1 DNA, which could 
block the labelled target sequences from hybridizing to the array. The signal can also be 
amplified when labelled DNA is bridged through non-allelic elements in unlabelled Cot-1 
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DNA (Figure 2.2E). Increasing the genomic distance between sc target sequences used as 
probes on the microarray and conserved repetitive elements in the genome diminishes the 
likelihood of cross-hybridization to labelled target DNA products containing non-allelic 
repetitive sequences. We demonstrated that signal intensity CVs can be reduced by 
avoiding probe placement within 300 nt of a repeat element. 
The reliability of calling CNCs is improved with probes that exhibit lower variation in 
primary signal intensities. Such probe sequences are of sufficient density in the genome 
that the same rearrangements analysed with commercial microarrays can be detected with 
greater reliability. The Agilent 44K array did not have sufficient probe density or low 
enough CVs to reliably detect a common chromosome 15q11.2q13 deletion, whereas a 
CNC based on 36 ab initio-designed probes was consistently called. Lowering CVs in 
microarray hybridization studies actually decreases the number of probes required for 
accurate CNC detection without significant loss in genomic resolution while still 
detecting small chromosome rearrangements. An implication of reliable detection of 
chromosome rearrangements with fewer probes is that it would facilitate increased 
multiplexing, with additional sectors on the same microarray allowing analysis of larger 
numbers of patient samples per array. 
To overcome limitations in sensitivity, manufacturers have increased probe densities to 
perform copy number analysis by averaging CNC calling using the results of multiple 
probes. These probe densities partially compensate for loss of dynamic range that results 
from normalization (which statistically reduces noise). We have taken a different 
approach by populating the array with probes that have inherently lower susceptibility to 
noise. Future studies will determine the minimum number of ab initio probes required to 
call well-characterized CNCs for various clinically relevant genomic imbalances. 
Optimizing CNV calling algorithms will nevertheless continue to be a crucial factor in 
aCGH microarray experiments. Reliable detection of genomic abnormalities is crucial in 
diagnostic microarray studies, especially in situations where each patient sample is 
analysed with a single hybridization array. 
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Chapter 3  
3 Validation of predicted mRNA splicing mutations using 
high-throughput transcriptome data   
The work presented in this chapter is reproduced (with permission, Appendix S1) from: 
Viner, C., Dorman, S.N., Shirley, B.C., and Rogan, P.K. (2014) Validation of predicted 
mRNA splicing mutations using high-throughput transcriptome data. [v2; ref status: 
Indexed, http://f1000r.es/378] F1000Research 3:8. DOI:10.12688/f1000research.3-8.v2 
3.1 Introduction 
DNA variant analysis of complete genome or exome data has typically relied on filtering 
of alleles according to population frequency and alterations in coding of amino acids. 
Numerous variants of unknown significance (VUS) in both coding and non-coding gene 
regions cannot be categorized with these approaches. To address these limitations, in 
silico methods that predict biological impact of individual sequence variants on protein 
coding and gene expression have been developed, which exhibit varying degrees of 
sensitivity and specificity (1). These approaches have generally not been capable of 
objective, efficient variant analysis on a genome-scale. 
Splicing variants, in particular, are known to be a significant cause of human disease (2-
5) and indeed have even been hypothesized to be the most frequent cause of hereditary 
disease
 
(6). Computational identification of mRNA splicing mutations within DNA 
sequencing (DNA-Seq) data has been implemented to varying degrees of sensitivity, with 
most software only evaluating conservation solely at the intronic dinucleotides adjacent 
to the junction (i.e.
 
(7)). Other approaches are capable of detecting significant mutations 
at other positions with constitutive, and in certain instances, cryptic, splice sites (5,8,9) 
which can result in aberrations in mRNA splicing. Presently, only information theory-
based mRNA splicing mutation analysis has been implemented on a genome scale (10). 
Splicing mutations can abrogate recognition of natural, constitutive splice sites 
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(inactivating mutation), weaken their binding affinity (leaky mutation), or alter splicing 
regulatory protein binding sites that participate in exon definition. The abnormal 
molecular phenotypes of these mutations comprise: (a) complete exon skipping, (b) 
reduced efficiency of splicing, (c) failure to remove introns (also termed intron retention 
or intron inclusion), or (d) cryptic splice site activation, which may define abnormal exon 
boundaries in transcripts using non-constitutive, proximate sequences, extending or 
truncating the exon. Some mutations may result in combinations of these molecular 
phenotypes. Nevertheless, novel or strengthened cryptic sites can be activated 
independently of any direct effect on the corresponding natural splice site. The 
prevalence of these splicing events has been determined by ourselves and others (5,11-
13). The diversity of possible molecular phenotypes makes such aberrant splicing 
challenging to corroborate at the scale required for complete genome (or exome) 
analyses. This has motivated the development of statistically robust algorithms and 
software to comprehensively validate the predicted outcomes of splicing mutation 
analysis. 
Putative splicing variants require empirical confirmation based on expression studies 
from appropriate tissues carrying the mutation, compared with control samples lacking 
the mutation. In mutations identified from complete genome or exome sequences, 
corresponding transcriptome analysis based on RNA sequencing (RNA-Seq) is 
performed to corroborate variants predicted to alter splicing. Manually inspecting a large 
set of splicing variants of interest with reference to the experimental samples’ RNA-Seq 
data in a program like the Integrative Genomics Viewer (IGV) (14), or simply performing 
database searches to find existing evidence would be time-consuming for large-scale 
analyses. Checking control samples would be required to ensure that the variant is not a 
result of alternative splicing, but is actually causally linked to the variant of interest. 
Manual inspection of the number of control samples required for statistical power to 
verify that each displays normal splicing would be laborious and does not easily lend 
itself to statistical analyses. This may lead to either missing contradictory evidence or to 
discarding a variant due to the perceived observation of statistically insignificant altered 
splicing within control samples. In addition, a list of putative splicing variants returned 
by variant prediction software can often be extremely large. The validation of such a 
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significant quantity of variants may not be feasible, for example, in certain types of 
cancer, in instances where the genomic mutational load is high and only manual 
annotation is performed. We have therefore developed Veridical, a software program that 
automatically searches all given experimental and control RNA-Seq data to validate 
DNA-derived splicing variants. When adequate expression data are available at the locus 
carrying the mutation, this approach reveals a comprehensive set of genes exhibiting 
mRNA splicing defects in complete genomes and exomes. Veridical and its associated 
software programs are available at: https://mutationforecaster.com. 
3.2 Methods 
The program Veridical was developed to allow high-throughput validation of predicted 
splicing mutations using RNA sequencing data. Veridical requires at least three files to 
operate: a DNA variant file containing putative mRNA splicing mutations, a file listing of 
corresponding transcriptome (RNA-Seq) BAM files, and a file annotating exome 
structure (Appendix S3.1-S3.3). A separate file listing RNA-Seq BAM files for control 
samples (i.e. normal tissue) can also be provided. Here, we demonstrate the capabilities 
of the software for mutations predicted in a set of breast tumours. Veridical compares 
RNA-Seq data from the same tumours with RNA-Seq data from control samples lacking 
the predicted mutation. However, in principle, potential splicing mutations for any 
disease state with available RNA-Seq data can be investigated. In each tumour, every 
variant is analyzed by checking the informative sequencing reads from the corresponding 
RNA-Seq experiment for non-constitutive splice isoforms, and comparing these results 
with the same type of data from all other tumour and normal samples that do not carry the 
variant in their exomes. 
Veridical concomitantly evaluates control samples, providing for an unbiased assessment 
of splicing variants of potentially diverse phenotypic consequences. Note that control 
samples include all non-variant containing files (i.e. RNA-Seq files for those tumours 
without the variant of interest), as well any normal samples provided. Increasing the 
number of the set of control samples, while computationally more expensive, increases 
the statistical robustness of the results obtained. 
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For each variant, Veridical directly analyzes sequence reads aligned to the exons and 
introns that are predicted to be affected by the genomic variant. We elected to avoid 
indirect measures of exon skipping, such as loss of heterozygosity in the transcript, 
because of the possibility of confusion with other molecular etiologies (i.e. deletion or 
gene conversion), unrelated to the splicing mutations. The nearest natural site is found 
using the exome annotation file provided, based upon the directionality of the variant, as 
defined within Table 3.1. The genomic coordinates of the neighboring exon boundaries 
are then found and the program proceeds, iterating over all known transcript variants for 
the given gene. A diagram of this procedure is provided in Figure 3.1. The variant 
location, C, is specifically referring to the variant itself. JC refers to the variant-induced 
location of the predicted mRNA splice site, which is often proximate to, but distinct from 
the coordinate of the actual genomic mutation itself. 
The program uses the BamTools API (15) to iterate over all of the reads within a given 
genomic region across experimental and control samples. Individual reads are then 
assessed for their corroborating value towards the analysis of the variant being processed, 
as outlined in the flowchart in Figure 3.2. Validating reads are based on whether they 
alter either the location of the splice junction (i.e. junction-spanning) or the abundance of 
the transcript, particularly in intronic regions (i.e. read-abundance). Junction-spanning 
reads contain DNA sequences from two adjacent exons or are reads that extend into the 
intron (Equation 1(e)). These reads directly show whether the intronic sequence is 
removed or retained by the spliceosome, respectively. Read-abundance validated reads 
are based upon sequences predicted to be found in the mutated transcript in comparison 
with sequences that are expected to be excised from the mature transcript in the absence 
of a mutation (Equation 1(f)). Both types of reads can be used to validate cryptic splicing, 
exon skipping, or intron inclusion. A read is said to corroborate cryptic splicing if and 
only if the variant under consideration is expected to activate cryptic splicing. Junction-
spanning, cryptic splicing reads are those in which a read is exactly split from the cryptic 
splice site to the adjacent exon junction (Equation 1(a)). For read-abundance cryptic 
splicing, we define the concept of a read fraction, which is the ratio of the number of 
reads corroborating the cryptically spliced isoform and the number of reads that do not 
support the use of the cryptic splice site (i.e. non-cryptic corroborating) in the same  
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Table 3.1 Definitions used within Veridical to determine in which reads are checked. A 
and B represent natural site positions, defined in Figure 3.1(B). 
α
 – 5’ splice site β – 3’ splice site 
Pertinent Splice Site 
A B Strand Direction 
Exonic Donor
α
 +   
Exonic Donor
α
 -  
Intronic Acceptor
β
 +  
Intronic Acceptor
β
 -  
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A) 
 
B) 
 
Figure 3.1 Diagram portraying the definitions used within Veridical to specify genic variant 
position and read coordinates.  We employ the same conventions as IGV (14). Blue lines 
denote genes, wherein thick lines represent exons and thin lines represent introns. A) All reads 
overlapping or between D or E are extracted from the BAM files. We assume, for clarity of 
illustration, that the genome coordinate D < E. The variant, C, is contained somewhere within the 
middle exon or within one of its adjacent introns. B) Veridical searches for validating reads 
between A and B, the orientation of which is direction dependent. As indicated, the variant, C, is 
contained somewhere within the middle exon or within one of its adjacent introns. Depending 
upon the location of the variant, and the directionality (as described within Table 3.1), the interval 
boundaries may be delimited by either the blue or red set of labels. 
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Figure 3.2 The algorithm employed by Veridical to validate variants.   Refer to Table 3.1 for 
definitions concerning direction and Figure 3.1 for variable depictions. B is defined as follows: B 
(B site left (←) of A ⇒ B := D. B site right (→) of A ⇒ B := E.  
  
96 
genomic region of a sample. Cryptic corroborating reads are those which occur within the 
expected region where cryptic splicing occurs (i.e. spliced-in regions). This region is 
bounded by the variant splice site location and the adjacent (direction dependent) splice 
junction (Equation 1(a)). Non-cryptic corroborating reads, which we also termed “anti-
cryptic” reads, are those that do not lie within this region, but would still be retained 
within the portion that would be excised, had cryptic splicing occurred (Equation 1(b)). 
To identify instances of exon skipping, Veridical only employs junction-spanning reads. 
A read is considered to corroborate exon skipping if the connecting read segments are 
split such that it connects two exon boundaries, skipping an exon in between (Equation 
1(c)). A read is considered to corroborate intron inclusion when the read is continuous 
and either overlaps with the intron-exon boundary (and is then said to be junction-
spanning) or if the read is within an intron (and is then said to be based upon read-
abundance). We only consider an intron inclusion read to be junction spanning if it spans 
the relevant splice junction, A. Equation 1(d) formalizes this concept. We occasionally 
use the term “total intron inclusion” to denote that any such count of intron inclusion 
reads includes both those containing and not containing the mutation itself. Graphical 
examples of some of these validation events, with a defined variant location, are provided 
in Figure 3.3.  
We proceed to formalize the above descriptions as follows. A given read is denoted by r, 
with start and end coordinates (rs, re), if the read is continuous, or otherwise, with start 
and end coordinate pairs, (rs1, re1) and (rs2, re2) as diagrammed within Figure 3.3. Let ℓ be 
the length of the read. The set ζ denotes the totality of validating reads. The criterion for r 
∈ ζ is detailed below. It is important to note that validating reads are necessary but not 
sufficient to validate a variant. Sufficiency is achieved only if the number of validating 
reads is statistically significant relative to those present in control samples. ζ itself is 
partitioned into three sets: ζc, ζe, and ζi for evidence of cryptic splicing, exon skipping, 
and intron inclusion, respectively. We allow partitions to be empty. Let JC denote the 
adjacent splice junction, and let B denote the downstream natural site, as defined by 
Figure 3.3 and Table 3.1. Without loss of generality, we consider only the red (i.e.  
 
  
97 
A) 
 
B) 
  
C) 
 
Figure 3.3 Illustrative examples of aberrant splicing detection. Grey lines denote reads, 
wherein thick lines denote a read mapping to genomic sequence and thin lines represent 
connecting segments of reads split across spliced-in regions (i.e. exons or included introns). 
Dotted blue rectangles denote portions of genes which are spliced out in a mutant transcript, but 
are otherwise present in a normal transcript. Mutant reads are purple if they are junction-spanning 
and green if they are read-abundance based. Start and end coordinates of reads with two 
portions are denoted by (rs1, re1) and (rs2, re2), while coordinates of those with only a single 
portion are denoted by (rs, re). Refer to the caption of Figure 3.1 for additional graphical element 
descriptions. A) An example of a normally spliced transcript, assuming Veridical is validating a 
specific variant, C, shown in yellow. The adjacent intron-exon boundary, in this case, corresponds 
to both the adjacent splice junction, JC, and the relevant natural site A. B is the downstream 
natural site. Veridical would not identify any aberrant splicing. B) An example of the variant 
causing the activation of a cryptic splice site. Additionally, there is intron inclusion present within 
the analysis region. Veridical would identify and report read counts for reads pertaining to the 
(junction-spanning, purple) cryptic splicing event and those pertaining to the observed (junction-
spanning and read-abundance, green) intron inclusion. Since this pertains to a cryptic variant, the 
adjacent splice junction, JC, is distinct from the relevant natural site A. C) An example of the 
variant causing the containing exon to be skipped. Veridical would report read counts for reads 
pertaining to the junction-spanning exon skipping event. These discontinuous reads are those, 
that like the one shown, span the variant containing exon. 
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direction is right) set of labels within Figure 3.1(B), as further typified by Figure 3.3. 
Then the (splice consequence) partitions of ζ are given by: 
𝑟 ∈ 𝜁𝑐 ⇔ 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 𝑖𝑠 𝑐𝑟𝑦𝑝𝑡𝑖𝑐 ∧ (𝑟𝑆2 − 𝑟𝑒1 = 𝐵 − 𝐽𝐶 ∨ (𝑟𝑆 > 𝐽𝐶  ∧ 𝑟𝑒 < 𝐴)) (1a) 
𝑟 ∉ 𝜁𝑐 ∧ 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 𝑖𝑠 𝑐𝑟𝑦𝑝𝑡𝑖𝑐 ∧ ¬(𝑟𝑆2 − 𝑟𝑒1 = 𝐵 − 𝐽𝐶) ⇒ 𝑟 ∈ 𝑎𝑛𝑡𝑖 − 𝑐𝑟𝑦𝑝𝑡𝑖𝑐 (1b) 
𝑟 ∈ 𝜁𝑒 ⇔ (𝑟𝑒1 = 𝐷 ∧ 𝑟𝑆2 = 𝐸) (1c) 
𝑟 ∈ 𝜁𝑖 ⇔ (𝐴 ∈ [𝑟𝑆, 𝑟𝑒]) ∨ ((𝐴 ∉ [𝑟𝑆, 𝑟𝑒]) ∧ 𝑟𝑆 > 𝐴 − ℓ ∧ 𝑟𝑒 < 𝐵 ∧ ¬(𝐴 ∈ [𝑟𝑆, 𝑟𝑒])) (1d) 
We separately partition ζ by its evidence type, the set of junction-spanning reads, δ and 
read-abundance reads, α: 
𝑟 ∈ 𝛿 ⇔ (𝐴 ∈ [𝑟𝑆, 𝑟𝑒]) ∨ (𝑟 ∈ 𝜁𝐶 ∧ 𝑟𝑆2 − 𝑟𝑒1 = 𝐵 − 𝐽𝐶)  (1e) 
𝑟 ∈ ∝ ⇔ 𝑟 ∉  𝛿 (1f) 
Once all validating reads are tallied for both the experimental and control samples, a p-v  
alue is computed. This is determined by computing a z-score upon Yeo-Johnson (YJ) 
(16) transformed data. This transformation, shown in Equation 2, ensures that the data is 
sufficiently normally distributed to be amenable to parametric testing. 
Ψ(𝓍, 𝜆) =
{
 
 
 
 
(𝓍+1)𝜆
𝜆
 𝑖𝑓 𝓍 ≥ 0 ∧ 𝜆 ≠ 0
𝑙𝑜𝑔(𝓍 + 1) 𝑖𝑓 𝓍 ≥ 0 ∧ 𝜆 = 0
−
(−𝓍+1)2−𝜆−1
2−𝜆
 𝑖𝑓 𝓍 < 0 ∧ 𝜆 ≠ 2
− log(−𝓍 + 1) 𝑖𝑓 𝓍 < 0 ∧ 𝜆 = 2
 (2) 
The transform is similar to the Box-Cox power transformation, but obviates the 
requirement of inputting strictly positive values and has more desirable statistical 
properties. Furthermore, this transformation allowed us to avoid the use of non-
parametric testing, which has its own pitfalls regarding assumptions of the underlying 
data distribution (17). We selected λ = 12, because Veridical’s untransformed output is 
skewed left, due to their being, in general, less validating reads in control samples and the 
fact that there are, by design, vastly more control samples than experimental samples. We 
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found that this value for λ generally made the distribution much more normal. A 
comparison of the distributions of untransformed and transformed data is provided in 
Appendix S3.4. We were not concerned about small departures from normality as a z-test 
with a large number of samples is robust to such deviations (18). 
Thus, we can compute the p-value of the pairwise unions of the two sets of partitions of ζ, 
except the irrelevant ζe ∪ α = Ø. We only provide p-values for these pairwise unions and 
do not attempt to provide p-values for the partitions for the different consequences of the 
mutations on splicing. While such values would be useful, we do not currently have a 
robust means to compute them. Our previous work provides guidance on interpretation of 
splicing mutation outcomes (3-5,10). Thus for ζx ∈ {ζc, ζe, ζi}, let ΦZ (z) represent the 
cumulative distribution function of the one-sided (right-tailed — i.e. P[X > x]) standard 
normal distribution. Let N represent the total number of samples and let V represent the 
set of all ζx validations, across all samples. Then: 
𝜇 =
∑ 𝑉𝑗
𝑁
𝑗=1
𝑁
        𝜎 = √
1
𝑁
∑ (𝑉𝑗 − ?̅?)2
𝑁
𝑗=1     𝑧 =
|𝜁𝑥|−𝜇
𝜎
     𝑝 = Φ(Ψ(𝓏,
1
2
)) 
The program outputs two tables, along with summaries thereof. The first table lists all 
validated read counts across all categories for experimental samples, while the second 
table does the same for the control samples. P-values are shown in parentheses within the 
experimental table, which refer to the column-dependent (i.e. the read type is given in the 
column header) p-value for that read type with respect to that same read type in control 
samples. The program produces three files: a log file containing all details regarding 
validated variants, an output file with the programs progress reports and summaries, and 
a filtered validated variant file. The filtered file contains all validated variants of 
statistical significance (set as p < 0.05, by default), defined as variants with one or more 
validating reads achieving statistical significance in a strongly corroborating read type. 
These categories are limited to all junction-spanning based splicing consequences and 
read-abundance total intron inclusion. For example, a cryptic variant for which p = 0.04 
in the junction-spanning cryptic column would meet this criteria, assuming the default 
significance threshold. 
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The p-values given by Veridical are more robust when the program is provided with a 
large number of samples. The minimum sample size is dependent upon the desired 
power, α value, and the effect size (ES). The minimum samples size could be computed 
as follows: 𝑁 = ⌈
𝜎2𝓏2
𝐸𝑆2
⌉. For α = 0.05 and β = 0.2 (for a power of 0.8): z = 2.4865 for the 
one-tailed test. Then, 𝑁 = ⌈
𝜎22.48652
𝐸𝑆2
⌉. Ideally, Veridical could be run with a trial number 
of samples. 
Then, one would compute effect sizes from Veridical’s output. The standard deviation in 
the above formula could also be estimated from one’s data, although it should be 
transformed using Yeo-Johnson (such as via an appropriate R package) before computing 
this estimation. 
We elected to use RefSeq (19) genes for the exome annotation, as opposed to, the more 
permissive exome annotation sets, UCSC Known Genes (20) or Ensembl (21). The large 
number of transcript variants within Ensembl, in particular, caused many spurious intron 
inclusion validation events. This occurred because reads were found to be intronic in 
many cases, when in actuality they were exonic with respect to the more common 
transcript variant. In addition, the inclusion of the large number of rare transcripts in 
Ensembl significantly increased program run-time and made validation events much 
more challenging to interpret unequivocally. The use of RefSeq, which is a conservative 
annotation of the human exome, resolves these issues. It is possible that some subset of 
unknown or Ensemble annotated intronic transcripts could be sufficiently prevalent to 
merit inclusion in our analysis. We do not attempt to perform the difficult task of 
deciding which of these transcripts would be worth using. Indeed, the task of confirming 
and annotating of such transcripts is already done by the more conservative annotation 
we employ. 
We also provide an R program (22) which produces publication quality histograms 
displaying embedded Q-Q plots and p-values, to evaluate for normality of the read 
distribution and statistical significance, respectively. The R program performs the YJ 
transformation as implemented in the car package (23). The histograms generated by the 
program use the Freedman-Draconis (24) rule for break determination, and the Q-Q plots 
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use algorithm Type 8 for their quantile function, as recommended by Hyndman and Fan 
(25). This program is embedded within a Perl script, for better integration into our 
workflow. Lastly, a Perl program was implemented to automatically retrieve and 
correctly format an exome annotation file from the UCSC database (20) for use in 
Veridical. All data use hg19/GRCh37, however when new versions of the genome 
become available, this program can be used to update the annotation file. 
3.3 Results 
Veridical validates predicted mRNA splicing mutations using high-throughput RNA 
sequencing data. We demonstrate how Veridical and its associated R program are used to 
validate predicted splicing mutations in somatic breast cancer. Each example depicts a 
particular variant-induced splicing consequence, analyzed by Veridical, with its 
corresponding significance level. The relevant primary RNA-Seq data are displayed in 
IGV, along with histograms and Q-Q plots showing the read distributions for each 
example. The source data are obtained from controlled-access breast carcinoma data from 
The Cancer Genome Atlas (TCGA) (26). Tumour-normal matched DNA sequencing data 
from the TCGA consortium was used to predict a set of splicing mutations, and a subset 
of corresponding RNA sequencing data was analyzed to confirm these predictions with 
Veridical. Overall, 442 tumour samples and 106 normal samples were analyzed. Briefly, 
all variants used as examples in this manuscript came from running the matched TCGA 
exome files (to which the RNA-Seq data corresponds) through SomaticSniper (27) and 
Strelka (28) to call somatic mutations, followed by the Shannon Human Splicing Pipeline 
(10) to find splicing mutations, which served as the input to Veridical. Details of the 
RNA-Seq data can be found within the supplementary methods of the TCGA paper (26). 
Accordingly, the following examples demonstrate the utility of Veridical to identify 
potentially pathogenic mutations from a much larger subset of predicted variants.  
3.3.1 Leaky Mutations 
Mutations that reduce, but not abolish, the spliceosome’s ability to recognize the 
intron/exon boundary are termed leaky (3). This can lead to the mis-splicing (intron 
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inclusion and/or exon skipping) of many but not all transcripts. An example, provided in 
Figure 3.4, displays a predicted leaky mutation (chr5:162905690G>T) in the HMMR 
gene in which both junction-spanning exon skipping (p < 0.01) and read-abundance-
based intron inclusion (p = 0.04) are observed. We predict this mutation to be leaky 
because its final Ri exceeds 1.6 bits — the minimal individual information required to 
recognize a splice site and produce correctly spliced mRNA (4). Indeed, the natural site, 
while weakened by 2.16 bits, remains strong — 10.67 bits. This prediction is validated by 
the variant-containing sample’s RNA-Seq data (Figure 3.4), in which both exon skipping 
(5 reads) and intron inclusion (14 reads, 12 of which are shown, versus an average of 
4.051 such reads per control sample) are observed, along with 70 reads portraying wild-
type splicing. Only a single normally spliced read contains the G→T mutation. These 
results are consistent with an imbalance of expression of the two alleles, as expected for a 
leaky variant. Figure 3.5 shows that for the distribution of read-abundance-based intron 
inclusion is marginally statistically significant (p = 0.04). 
3.3.2 Inactivating Mutations 
Variants that inactivate splice sites have negative final Ri values (3) with only rare 
exceptions (4), indicating that splice site recognition is essentially abolished in these 
cases. We present the analysis of two inactivating mutations within the PTEN and 
TMTC2 genes from different tumour exomes, namely: chr10:89711873A>G and 
chr12:83359523G>A, respectively. The PTEN variant displays junction-spanning exon 
skipping events (p < 0.01), while the TMTC2 gene portrays both junction-spanning and 
read-abundance-based intron inclusion (both splicing consequences with p < 0.01). In 
addition, all intron inclusion reads in the experimental sample contain the mutation itself, 
while only one such read exists across all control samples analyzed (p < 0.01). The PTEN 
variant contains numerous exon skipping reads (32 versus an average of 2.466 such reads 
per control sample). The TMTC2 variant contains many junction-spanning intron 
inclusion reads with the G→A mutation (all of its junction-spanning intron inclusion 
reads: 22 versus an average of 0.002 such reads per control sample). IGV screenshots for 
these variants are provided within Figure 3.6. This figure also shows an example of 
junction-spanning cryptic splice site activated by the mutation (chr1:985377C>T) within 
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A) 
  
B) 
 
Figure 3.4 IGV images depicting a predicted leaky mutation  (chr5:162905690G>T) within the 
natural acceptor site of exon 12 (162905689–162905806) of HMMR. This gene has four transcript 
variants and the given exon number pertains to isoforms a and b (reference sequences 
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NM_001142556 and NM_012484). RNA-Seq reads are shown in the centre panel. The bottom 
blue track depicts RefSeq genes, wherein each blue rectangle denotes an exon and blue 
connecting lines denote introns. In the middle panel, each rectangle (grey by default) denotes an 
aligned read, while thin lines are segments of reads split across exons. Red and blue coloured 
rectangles in the middle panel denote aligned reads of inserts that are larger or smaller than 
expected, respectively. Reads are highlighted by their splicing consequence, as follows: cryptic 
splicing (green), exon skipping (purple), junction-spanning intron inclusion (dark green), and read-
abundance intron inclusion (cyan). (A) depicts a genomic region of chromosome 5: 162902054–
162909787. The variant occurs in the middle exon. Intron inclusion can be seen in this image, 
represented by the reads between the first and middle exon (since the direction is left, as 
described within Table 1). These 14 reads are read-abundance-based, since they do not span the 
intron-exon junction. (B) depicts a closer view of the region shown in (A) — 162905660–
162905719. The dotted vertical black lines are centred upon the first base of the variant-
containing exon. The thin lines in the middle panel that span the entire exon fragment are 
evidence of exon skipping. These 5 reads are split across the exon before and after the variant-
containing exon, as seen in (A). 
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Figure 3.5 Histogram of read-abundance-based intron inclusion with embedded Q-Q plots 
of the predicted leaky mutation (chr5:162905690G>T) within HMMR, as shown in Figure 4. 
The arrowhead denotes the number of reads (14 in this case) in the variant-containing file, which 
is more than observed in the control samples (p = 0.04).  
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 A) 
 
B) 
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C) 
  
D) 
 
Figure 3.6 Examples of validated mutations.  (A) depicts an inactivating mutation 
(chr10:89711873A>G) within the natural acceptor site of exon 6 (89711874–89712016) of PTEN. 
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The dotted vertical black line denotes the location of the relevant splice site. The region displayed 
is 89711004–89712744 on chromosome 10. Many of the 32 exon skipping reads are evident, 
typified by the thin lines in the middle panel that span the entire exon. There is also a substantial 
amount of read-abundance-based intron inclusion, shown by the reads to the left of the dotted 
vertical line. Exon skipping was statistically significant (p < 0.01), while read-abundance-based 
intron inclusion was not (p = 0.53). Panels (B) and (C) depict an inactivating mutation 
(chr12:83359523G>A) within the natural donor site of exon 6 (83359338–83359523) of TMTC2. 
(B) depicts a closer view (83359501–83359544) of the region shown in (C) and only shows exon 
6. Some of the 22 junction-spanning intron inclusion reads can be seen. In this case, all of these 
reads contain the mutation, shown by the green adenine base in each read, between the two 
vertical dotted lines. (C) depicts a genomic region of chromosome 12: 83359221–83360885, 
TMTC2 exons 6–7. The variant occurs in the left exon. 65 read-abundance-based intron inclusion 
can be seen in this image, represented by the reads between the two exons. Panel (D) depicts a 
mutation (chr1:985377C>T) causing a cryptic donor to be activated within exon 27 (the second 
from left, 985282–985417) of AGRN. The region displayed is 984876–985876 on chromosome 1 
(exons 26–29 are visible). Some of the 34 cryptic (junction-spanning) reads are portrayed. The 
dotted black vertical line denotes the cryptic splice site, at which cryptic reads end. The read-
abundance-based intron inclusion, of which two reads are visible, was not statistically significant 
(p = 0.68). Refer to the caption of Figure 4 for IGV graphical element descriptions.  
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the AGRN gene. The concordance between the splicing outcomes generated by these 
mutations and the Veridical results indicates that the proposed method detects both 
mutations that inactivate splice sites and cryptic splice site activation. 
3.3.3 Cryptic Mutations 
Recurrent genetic mutations in some oncogenes have been reported among tumours 
within the same, or different, tissues of origin. Common recurrent mutations present in 
multiple abnormal samples are recognized by Veridical. This avoids including a variant-
containing sample among the control group, and outputs the results of all of the variant-
containing samples. A relevant example is shown in Figure 3.7. The mutation 
(chr1:46726876G>T) causes activation of a cryptic splice site within RAD54L in 
multiple tumours. Upon computation of the p-values for each of the variant-containing 
tumours, relative to all non-variant containing tumours and normal controls, not all 
variant-containing tumours displayed splicing abnormalities at statistically significant 
levels. Of the six variant-containing tumours, two had significant levels of junction-
spanning intron inclusion, and one showed statistically significant read-abundance-based 
intron inclusion. Details for all of the aforementioned variants, including a summary of 
read counts pertaining to each relevant splicing consequence, for experimental versus 
control samples, are provided in Table 3.2. 
3.3.4 Performance 
The performance of the software is affected by the number of predicted splicing 
mutations, the number of abnormal samples containing mutations and control samples 
and the corresponding RNA-Seq data for each type of sample. Veridical has the ability to 
analyze approximately 3000 variants in approximately 4 hours, assuming an input of 100 
BAM files of RNA-Seq data. The relationship between time and numbers of BAM files 
and variants are plotted in Figure 3.8 for a 2.27 GHz processor. Veridical uses memory in 
linear proportion to the number and size of the input BAM files. In our tests, using RNA-
Seq BAM files with an average size of approximately 6 GB, Veridical used 
approximately 0.7 GB for ten files to 1 GB for 100 files. 
  
110 
A) 
 
B) 
 
  
111 
C) 
  
D) 
 
  
112 
Figure 3.7 IGV images and their corresponding histograms with embedded Q-Q plots 
depicting all six variant-containing files with a mutation  (chr1:46726876G>T) which, in some 
cases, causes a cryptic donor to be activated within the intron between exons 7 and 8 of 
RAD54L. This results in the extension of the downstream natural donor (the 5′ end of exon 8). 
This gene has two transcript variants and the given exon numbers pertain to isoform a (reference 
sequence NM_003579). Only samples IV and V have statistically significant intron inclusion 
relative to controls. read-abundance-based intron inclusion can be seen in (A), between the two 
exons. The region displayed is on chromosome 1: 46726639–46726976. (B) depicts the 
corresponding histogram for the 15 read-abundance-based intron inclusion reads (p = 0.05) that 
are present in sample IV. The intron-exon boundary on the right is the downstream natural donor. 
(C) typifies some of the 13 junction-spanning intron inclusion reads that are a direct result of the 
intronic cryptic site’s activation. In these instances, reads extending past the intron-exon 
boundary are being spliced at the cryptic site, instead of the natural donor. In particular, samples 
IV and V both have a statistically significant numbers of such reads, 7 (p = 0.01) and 5 (p = 0.04), 
respectively. This is further typified by the corresponding histogram in (D). (C) focuses upon exon 
8 from (A) and displays the genomic positions 46726908–46726957. Refer to the caption of 
Figure 4 for IGV graphical element descriptions. In the histograms, arrowheads denote numbers 
of reads in the variant-containing files. The bottom of the plots provide p-values for each 
respective arrowhead. Statistically significant p-values and their corresponding arrowheads are 
denoted in red.  
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Table 3.2 Examples of variants validated by Veridical and their selected read types.  
Gene Chr Cv Cs Variant Type Initial 
Ri 
Final 
Ri 
ΔRi # SC ET p-
value 
RE RT RN Rμ Figure 
HMMR chr5 162905690 162905689 G/T Leaky 12.83 10.67 -2.16  ES JS <0.01 5 11 0 0.02 3.4,3.5 
          ES RA 0.04 14 2133 103 4.051  
PTEN chr10 89711873 89711874 A/G Inactivating 12.09 -2.62 -14.71  ES JS <0.01 32 975 386 2.466 6(A) 
TMTC2 chr12 83359523 83359524 G/A Inactivating 1.74 -1.27 -3.01  ES JS <0.01 22 2241 383 4.754 6(B) 
          ES JSwM <0.01 22 0 1 0.002  
          ES RA <0.01 65 7293 1395 15.739 6(C) 
AGRN chr1 985377 985376 C/T Cryptic -2.24 4.79 7.03  CS JS <0.01 34 97 23 0.217 6(D) 
RAD54L chr1 46726876 46726895 G/T Cryptic 13.4 14.84 1.44 I CS JS NA 0 645 58 1.274 7 
          CS RA 0.54 3 2171 290 4.458  
         II CS JS 0.51 1 645 58 1.274  
          CS RA 0.33 6 2171 290 4.458  
         III CS JS NA 0 645 58 1.274  
          CS RA 0.33 6 2171 290 4.458  
         IV CS JS 0.01 7 645 58 1.274  
          CS RA 0.05 15 2171 290 4.458  
         V CS JS 0.04 5 645 58 1.274  
          CS RA NA 0 2171 290 4.458  
         VI CS JS NA 0 645 58 1.274  
          CS RA NA 0 2171 290 4.458  
Header abbreviations Chr, Cv, Cs, #, SC, and ET, denote chromosome, variant coordinate, splice site coordinate, sample number (where 
applicable), splicing consequence, and evidence type, respectively. Headers containing R with some subscript denote numbers of validated reads 
for the specified variant’s splicing consequence(s) and evidence type(s). RE denotes reads within variant-containing tumour samples. RT and RN 
denote control samples, for tumours and normal cells, respectively. Rμ is the per sample mean of RT and RN. Splicing consequences: CS denotes 
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cryptic splicing, ES denotes exon skipping, and II denotes intron inclusion. Evidence types: JS denotes junction-spanning and RA denotes read-
abundance. 
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Figure 3.8 Profiling data for Veridical runtime.  Tests were conducted upon an Intel Xeon @ 
2.27 GHz. Visualizations were generated with R (22) using Lattice and Effects. A surface plot of 
time vs. numbers of BAM files and variants is provided in (A). Effect plots are given in (B) and 
demonstrate the effects of the numbers of BAM files and variants upon runtime. The effect plots 
were generated using a linear regression model (R
2
 = 0.7525).  
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3.4 Discussion 
We have implemented Veridical, a software program that automates confirmation of 
mRNA splicing mutations by comparing sequence read-mapped expression data from 
samples containing variants that are predicted to cause defective splicing with control 
samples lacking these mutations. The program objectively evaluates each mutation with 
statistical tests that determine the likelihood of and exclude normal splicing. To our 
knowledge, no other software currently validates splicing mutations with RNA-Seq data 
on a genome-wide scale, although many applications can accurately detect conventional 
alternative splice isoforms (i.e. (29)). Veridical is intended for use with large data sets 
derived from many samples, each containing several hundred variants that have been 
previously prioritized as likely splicing mutations, regardless of how the candidate 
mutations are selected. It is not practical to analyze all variants present in an exome or 
genome, rather only a filtered subset, due to the extensive computations required for 
statistical validation. As such, Veridical is a key component of an end-to-end, hypothesis-
based, splicing mutation analysis framework that also includes the Shannon splicing 
mutation pipeline (10) and the Automated Splice Site Analysis and Exon Definition 
server (5). There is a trade-off between lengthy run-times and statistical robustness of 
Veridical, especially when there are either a large number of variants or a large number 
of RNA-Seq files. As with most statistical methods, those employed here are not 
amenable to small sample sets, but become quite powerful when a large number of 
controls are employed. In order to ensure that mutations can be validated, we recommend 
an excess of control transcriptome data relative to those from samples containing 
mutations (> 5 : 1), guided by the power analysis described in Methods. We do not 
recommend the use of a single nor a few control samples to corroborate a putative 
mutation. Not surprisingly, we have found that junction-spanning reads have the greatest 
value for corroborating cryptic splicing and exon skipping. Even a single such read is 
almost always sufficient to merit the validation of a variant, provided that sufficient 
control samples are used. For intron inclusion, both junction-spanning and read-
abundance-based reads are useful and a variant can readily be validated with either, 
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provided that the variant-containing experimental sample(s) show a statistically 
significant increase in the presence of either form of intron inclusion corroborating reads. 
Veridical is able to automatically process variants from multiple different experimental 
samples, and can group the variant information if any given mutation is present in more 
than one sample. The use of a large sample size allows for robust statistical analyses to be 
performed, which aid significantly in the interpretation of results. The main utility of 
Veridical is to filter through large data sets of predicted splicing mutations to prioritize 
the variants. This helps to predict which variants will have a deleterious effect upon the 
protein product. Veridical is able to avoid reporting splicing changes that are naturally 
occurring through checking all variant-containing and non-containing control samples for 
the predicted splicing consequence. In addition, running multiple tumour samples at once 
allows for manual inspection to discover samples that contained the alternative splicing 
pattern, and consequently, permits the identification of DNA mutations in the same 
location which went undetected during genome sequencing. 
The statistical power of Veridical is dependent upon the quality of the RNA-Seq data 
used to validate putative variants. In particular, a lack of sufficient coverage at a 
particular locus will cause Veridical to be unable to report any significant results. A 
coverage of at least 20 reads should be sufficient. This estimate is based upon alternative 
splicing analyses in which this threshold was found to imply concordance with 
microarray and RT-PCR measurements (30-33). There are many potential legitimate 
reasons why a mutation may not be validated: (a) A lack of gene expression in the variant 
containing tumour sample, (b) nonsense-mediated decay may result in a loss of 
expression of the entire transcript, (c) the gene itself may have multiple paralogs and 
reads may not be unambiguously mapped, (d) other non-splicing mutations could account 
for a loss of expression, and (e) confounding natural alternative splicing isoforms may 
result in a loss of statistical significance during read mapping of the control samples. The 
prevalence of loci with insufficient data is dependent upon the coverage of the 
sequencing technology used. As sequencing technologies improve, the proportion of 
validated mutations is expected to increase. Such an increase would mirror that observed 
for the prevalence of alternative splicing events (34). In addition, mutated splicing factors 
  
118 
can disrupt splicing fidelity and exon definition (35). This effect could decrease 
Veridical’s ability to validate splicing mutations affected by a disruption of the definition 
of the pertinent exon. Veridical does not currently form any equivalence between distinct 
variants affecting the same splice site. Such variants will be analyzed independently. 
Veridical is intended to be used with RNA-Seq data that not only corresponds to matched 
DNA-Seq data, but also only for sets of samples with comparable sequencing protocols, 
since the non-normalized comparisons performed rely upon the evening out of batch 
effects, due to a substantial number of control samples. It is important to note that 
acceptance of the null hypothesis, due to an absence of evidence required to disprove it, 
does not imply that the underlying prediction of a mutation at a particular locus is 
incorrect, but merely that the current empirical methods employed were insufficient to 
corroborate it. 
“Validate,” in the present context, refers to the condition where sufficient statistical 
evidence has been marshaled in support of a variant. However, the threshold for 
significance can vary so these analyses can also be thought of as strongly corroborating 
variants. Recent studies in Bayesian statistics have suggested that a p-value threshold of 
0.05 does not correspond to strong support of the alternative hypothesis. Accordingly, 
Johnson (36) recommends the use of tests at the 0.005 or 0.001 level of significance. 
We consider alternative splicing to be a different problem. Veridical does not aim to 
identify putatively pathogenic variants, but rather, to confirm existing in silico 
predictions thereof. We do infer exon skipping events (i.e. alternative splicing) de novo, 
but only to catalog dysregulated splicing “phenotypes” due to genomic sequence variants. 
This is not the first study to use a large control dataset. Indeed the Variant Annotation, 
Analysis & Search Tool (VAAST) (37) does this to search for disease-causing (non-
splicing) variants and the Multivariate Analysis of Transcript Splicing (MATS) (29) tool 
(among others) can be used for the discovery of alternative splicing events. However, in 
our case, in most instances the distribution of reads in a single sample is compared to the 
distributions of reads in the control set, as opposed to a likelihood framework-based 
approach. We are suggesting that our approach be coupled to existing approaches to act 
as an a posteriori, hypothesis-driven, check on the veridicality of specific variants. 
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While there is considerable prior evidence for splicing mutations that alter natural and 
cryptic splice site recognition, we were somewhat surprised at the apparent high 
frequency of statistically significant intron inclusion revealed by Veridical. In fact, 
evidence indicates that a significant portion of the genome is transcribed (34), and it is 
estimated that 95% of known genes are alternatively spliced (30). Defective mRNA 
splicing can lead to multiple alternative transcripts including those with retained introns, 
cassette exons, alternate promoters/terminators, extended or truncated exons, and reduced 
exons (38). In breast cancer, exon skipping and intron retention were observed to be the 
most common form of alternative splicing in triple negative, non-triple negative, and 
HER2 positive breast cancer (39). In normal tissue, intron retention and exon skipping 
has been predicted to affect 2572 exons in 2127 genes and 50 633 exons in 12 797 genes, 
respectively (40). In addition, previous studies suggest that the order of intron removal 
can influence the final mRNA transcript composition of exons and introns (41). Intron 
inclusion observed in normal tissue may result from those introns that are removed from 
the transcript at the end of mRNA splicing. Given that these splicing events are relatively 
common in normal tissues, it becomes all the more important to distinguish expression 
patterns that are clearly due to the effects of splicing mutations — one of the guiding 
principles of the Veridical method. 
Veridical is an important analytical resource for unsupervised, thorough validation of 
splicing mutations through the use of companion RNA-Seq data from the same samples. 
The approach will be broadly applicable for many types of genetic abnormalities, and 
should reveal numerous, previously unrecognized, mRNA splicing mutations in exome 
and complete genome sequences. 
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Chapter 4  
4 Splicing mutation analysis reveals previously 
unrecognized pathways in lymph node-invasive breast 
cancer 
The work presented in this chapter is reproduced (with permission, Appendix S1) from: 
Dorman, S.N., Viner, C., Rogan, P.K. (2014) Splicing mutation analysis reveals 
previously unrecognized pathways in lymph node-invasive breast cancer. Scientific 
Reports 4:7063. DOI: 10.1038/srep07063 
4.1 Introduction 
Large-scale DNA sequencing studies have attempted to elucidate the genomic landscapes 
of breast cancer tumours to identify mutated genes and genomic variation that contribute 
to tumour development and progression (1-5). Typically, somatic mutations within gene 
coding regions are identified and then filtered for rare or novel variants predicted to affect 
protein structure or function (6-9). Frequently mutated genes are cataloged, with the goal 
of inferring defective genes that are more likely to contribute to tumour phenotypes. 
However, there does not appear to be a consistent set of somatic driver mutations in most 
breast cancer cases. For instance, in 100 cases, 73 different combinations of abnormal 
gene sequences were reported (4). 
Some established cancer genes are enriched for mutations (i.e. TP53, PIK3CA, PTEN, 
MAP3K1, AKT1, CDH1, GATA3, MLL3 and RB1), in addition to genes that were not 
previously associated with breast cancer (including CBFB, RUNX1, TBX3, NF1 and 
SF3B1) (1-5). At least 49 genes (including known breast cancer genes) have been found 
to be significantly mutated, 16 of these reproducibly across multiple studies, and the 
majority were mutated in <10% of tumours. 
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Inconsistencies in mutation composition among different tumours present significant 
challenges to understanding the underlying etiology of tumour phenotypes. As a result of 
epistasis, mutations in genes with linked biochemical functions would be expected to 
reveal dysfunctional pathways in tumours (10). Focusing analyses to one molecular 
subtype of breast cancer can also be useful in delineating dysregulated pathways that 
define the basis of tumour phenotypes (3). Significant insight into tumour biology has 
come from selecting tumours with specific clinical identifiers, for example, by limiting 
mutation catalogs in metastatic tumours (10,11). 
Somatic mutation analyses of tumour exomes have focused on alteration of amino acid 
sequences, or highly conserved dinucleotides adjacent to exons, which usually impact 
mRNA splicing. Since these variants most likely comprise only a fraction of the total 
mutational load, the pathways inferred to be dysregulated in these tumours may be 
incomplete. For example, in familial breast cancer, variants of unknown significance 
have been explained by both experimental validation and in silico predictions of defects 
in BRCA 1/2 mRNA splicing (12,13). Typically, genomic studies have used tools that 
predict splicing mutations based on the highly conserved dinucleotide sequences at 
mRNA 5′ donor and 3′ acceptor sites (8,14). There are other well established methods 
that can identify splicing mutations beyond those directly at natural sites (15-17), but 
these approaches have not been applied to genome-scale cancer studies, until recently 
(18). Published studies have revealed only a small fraction of reported somatic mutations 
in cancer to be splicing mutations, accounting for only 2% of those reported (1-5). The 
present study considers the possibility that many somatic splicing mutations may be 
overlooked or are undetected by the conservative approaches currently used in analyses 
of tumour genomes. 
Splicing mutations frequently lead to changes in the sequence and structure of the 
encoded protein, which are usually distinguishable from those generated by normal 
alternative splice isoforms. Constitutive splicing mutations are frequently deleterious and 
are a major cause of inherited and acquired diseases (19). In cancer, aberrant splicing 
(including alternative isoforms that are not a result of cis mutation) is known to cause or 
promote tumour propagation (20), and has been described as an additional hallmark of 
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the disease (21). RNA analyses can detect the effect of many splicing mutations directly 
(22,23). In this paper, we comprehensively analyze predicted splicing mutations in breast 
cancer tumours using DNA sequencing data from The Cancer Genome Atlas (TCGA) 
(5). We then use tumour-matched RNA sequencing data to statistically validate aberrant 
splicing patterns of expressed genes in these tumours that result from these mutations 
(24). We extended our splicing mutation analyses beyond molecular breast cancer 
subtypes and identified other clinical parameters associated with specific mutation 
pathways. We suggest that DNA sequencing analyses that incorporate in-depth splicing 
mutation studies reveal additional mutant genes and biochemical pathways, which may 
contribute to breast cancer etiology. 
4.2 Methods 
This study involved a reanalysis of controlled-access data from The Cancer Genome 
Atlas Project (NCBI dbGaP Project #988: Predicting common genetic variants that alter 
the splicing of human gene transcripts, PI: PK Rogan). DNA and RNA breast cancer 
sequencing data were obtained for 445 tumours from 442 patients (Supplementary Table 
4.1; July, 2012 DNA-Seq download; July, 2013 RNA-Seq Download) (5). The tumour-
normal pairs used mirrored those published by the TCGA in the Level 2 mutation data. 
Duplicate mutations in the same patient from two different tumour-normal pairs are 
reported, but were treated as one tumour for the mutation summaries reported by tumour. 
Somatic mutations were predicted from the same DNA sequencing data using two 
different algorithms: Strelka (v1.0.10) (6) and SomaticSniper (v1.0.2) (44) (See 
Appendix S4.1). Realignment was not necessary before running Strelka because of the 
program's internal realignment capabilities, so Strelka was run on the raw BAM files 
downloaded from TCGA. Default parameters were used with the provided Burrows-
Wheeler Aligner (BWA) configuration file, since BWA was used in the initial exome 
alignments. Additionally, the isSkipDepthFilters configuration option was changed to 
true, since such depth filters are designed for use on whole-genome data and would 
erroneously filter out most data when used with exome sequencing data. Strelka's BWA 
quality control script was run to remove variants considered low quality. Variants that 
were found to be common SNPs, defined by those that were annotated with dbSNP135 in 
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over 1% of the population, were filtered out from the variant set before any subsequent 
analyses. 
Somatic mutations, including single-nucleotide variants (SNVs) and insertion/deletions 
(indels) were used to predict the coding and non-coding genic effects of the variants. 
Annovar (August 23, 2013 release) (8) was used with default parameters to predict which 
variants are likely to affect amino acid sequence and splicing at the natural splice sites. 
The Shannon Human Splicing Pipeline Version 2.0 (Shannon Pipeline) (18) was used to 
complete a more in-depth analysis of splicing mutations, which predicts variants that will 
alter the binding affinity of the natural site or cause cryptic splicing (i.e. extension or 
truncation of an exon). The Shannon Pipeline results were subsequently filtered to 
prioritize which variants are most likely to have the greatest effect on mRNA splicing, 
using the filtering criteria outlined in Appendix S4.2. 
Multiple factor analyses used the R package FactoMineR (version 1.25) (45). Clinical 
parameters were obtained from the TCGA including AJCC tumour staging (metastasis 
stage code, neoplasm disease lymph node stage, and neoplasm disease stage), receptor 
statuses (estrogen, progesterone, and HER2/neu immunohistochemistry receptor statuses) 
as well as patient status (neoplasm cancer status and vital status). These clinical 
parameters were input into FactoMineR as qualitative groups, as listed above, along with 
the number of NCAM1 pathway mutations. Within the program, options were set to 
perform clustering after MFA, and to automatically determine the choice of the number 
of clusters. A second MFA was performed based on the number of NCAM1 pathway 
mutations per tumour in genes present only in the NCAM1 related pathways that were 
also not present in the collagen or extracellular matrix pathways. 
Word Clouds were generated to portray the overrepresentation analysis of mutated 
pathway results generated with Reactome (29,30) and, in particular, the differences 
between lymph node-positive and -negative tumour samples. The primary input data for 
these graphics was the overrepresented pathways from Reactome, partitioned according 
to subtype and lymph status. Additional sets were composed of all subtypes and all 
subtypes with only pathways not found within both lymph status partitions. However, this 
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direct data was not suitable for plotting, as many pathways were vastly too specific and 
varied to portray any broader trends. Pathway abstraction was undertaken to mitigate 
these difficulties and allow for visual perception of trends in the data. The full Reactome 
human pathway hierarchy was downloaded, using the provided RESTful API (46). A 
query to abstract pathways was performed using the BaseX XML database engine (47). 
The abstraction was designed to generalize the pathways, while still maintaining 
sufficient specificity to confer biological meaning in this context. To accomplish this, 
corresponding pathways of specific depths were retrieved and abstracted by taking 
instead higher-order pathways in the hierarchy. Reactions or black box events that were 
four or five levels deep, as well as pathways that were four levels deep, were abstracted 
by taking the corresponding element of depth three (i.e. their parent or grandparent). 
Pathways one level higher in the hierarchy (i.e. the parent pathway) of all other pathways, 
reactions, or black box events (i.e. those not at the aforementioned depths) were 
retrieved. The resulting abstracted pathways were then used as input for the word clouds. 
They were generated using R (v3.0.2) with the RColorBrewer (v1.0.5 tm, and wordcloud 
packages (v2.4) (48). Parameters used to generate the word clouds were as follows: scale 
= c(wordFit,0.3), min.freq = 2, random.order = F, colors = brewer.pal(6, “Dark2”)[−1])), 
vfont = c(“serif”,“plain”). 
The Mutational Significance in Cancer (v0.4) (MuSiC) (25) suite of tools was employed 
to identify genes significantly mutated in the breast cancer samples analyzed with the 
variant set derived in this study. Three tools from genome MuSiC were used with all 
default parameters: bmr calc-bmr, bmr calc-covg, and smg. NCBI Reference Sequence 
Genes release 62 (RefSeq) (49) were used as the regions of interest (ROI) file with the 
Human Feb. 2009 (GRCh37/hg19) assembly reference sequence for bmr calc-bmr and 
bmr calc-covg. All FDRs that we report pertaining to the MuSiC analysis used the 
Fisher's combined P-value (FCPT), convolution (CT) and likelihood ratio (LRT) 
statistical tests. 
The software program Veridical (24) was used for in silico validation of all predicted 
splicing mutations using its default settings. At the time the program was run, Veridical 
rounded p-values to 2 decimal places. Validated results reported were filtered for cryptic 
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variants using reads demonstrating junction-spanning cryptic sites, junction-spanning 
exon skipping, or read-abundance intron inclusion, whereas reads for predicted natural 
splice site variants were filtered for all of the above evidence types, except for cryptic 
splice site-activating, junction-spanning reads. Variants were considered validated if at 
least one of the above categories for the indicated variant type were excluded from 
normal controls, but present in the transcriptome containing the predicted mutation (p ≤ 
0.05, after transformation of both sample and control read counts to a normal distribution 
and use of a parametric Z test). Validation was not always possible in instances where 
predicted mutations occurred in genes or exons with minimal cDNA coverage, resulting 
from either low expression in the breast tumours carrying the mutation (50), tissue-
specificity of gene expression, or transcript instability from nonsense-mediated decay. 
Although Veridical provided experimental validation of predicted splicing mutations, the 
impact of these and protein coding mutations on tumour progression and biology could 
not be determined from the present analyses. Further laboratory studies with the original 
tumour tissues (which were not available), cell line or model organism studies would be 
required to prove biological significance. 
RSeQC's (v2.3.7) ReadDist (51) script was used to generate the genome-wide intron 
inclusion data with the RefSeq gene annotation file to determine intronic genomic 
sequences. We ran BedTools multicov (v2.17.0) (52) upon the RefSeq (49) exome 
annotation BED file retrieved from the UCSC table browser (53) with a minimum map 
quality of 1. The returned coverage values were multiplied by the read length, and 
divided by the number of exonic bases. In cases of genes with more than one transcript, 
the shortest transcript was used such that the coverage values per exonic base were 
maximized, which is the most conservative assumption to adopt when excluding variants 
due to low coverage. The heat map, provided in Appendix S4.3, was generated by breast 
cancer subtype for this data using the R packages Hmisc (v3.14.3) and gplots (v2.12.1). 
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4.3 Results 
4.3.1 Derivation of mutations 
Somatic mutations in 472 breast cancer tumours from 445 breast cancer patients were 
called using matched tumour-normal DNA exome sequencing data from TCGA (5) 
(Supplementary Table 4.1). There were 149,959 single-nucleotide variants (SNVs) and 
10,000 insertion/deletions (indels) detected using the variant caller, Strelka
 
(6) (see 
Appendix S4.1 for results from an alternative variant caller and reasons for our selection 
of Strelka). Protein coding mutations were annotated by ANNOVAR (8) and splicing 
mutations with the Shannon Human Splicing Pipeline (18) (Table 4.1, see Supplementary 
Tables 4.2–4.4 for a list of all mutations). The Shannon Pipeline predicted significantly 
more splicing mutations than reported by TCGA, because the information-theoretic 
method employed enables analyses of variants beyond exon boundaries that alter mRNA 
splicing. 948 variants were found to affect both protein coding and splicing in 747 genes, 
among 319 tumours. DYNC2H1, TP53 and PASD were the most commonly mutated of 
this group, containing 21, 11, and 9 exonic variants, respectively. Alteration of mRNA 
splicing was predicted as a result of 213 substitutions at synonymous codons among 139 
tumours. Reanalysis of coding changes confirmed high concordance with the validated 
TCGA SNVs, however indels were less reproducible (Appendix S4.4). Overall, 82.1% (n 
= 21,041) of protein coding mutations, and 86.5% (n = 371) of splicing mutations 
reported by TCGA were confirmed. A small subset of protein coding TCGA substitutions 
that were missed occurred within genes commonly mutated in breast cancer (35 TP53, 13 
MLL3, 22 GATA3, 25 MAP3K1, 11 CDH1 and 10 PIK3CA; see Appendix S4.5), however 
all splicing-associated SNVs found by TCGA in cancer-related genes were detected. 
4.3.2 Significantly mutated genes 
Significantly mutated genes were identified with the Mutational Significance in Cancer 
(MuSiC) software suite (25). There were 225 genes with false discovery rates (FDR) of  
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Table 4.1: Single nucleotide variant summaries by mutation type 
Type Mutation Count 
Protein Coding  
Synonymous 14,717 
Nonsynonymous 40,649 
Stop gain or loss 2,587 
Total protein coding variants 57,953 
Splicing  
Cryptic 1,130 
Inactivating 1,355 
Leaky 2,721 
Total splicing variants 5,206 
Protein coding mutations also predicted to affect splicing  
Synonymous 213 
Nonsynonymous 664 
Stop gain or loss 71 
Total 948 
Synonymous also splicing 1.4473% 
Nonsynonymous also splicing 1.6335% 
Stop gain or loss also splicing 2.7445% 
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<0.05, based on the Fisher's combined P-value (FCPT), convolution (CT) and likelihood 
ratio (LRT) tests. These results were compared with the 49 genes previously identified as 
significantly mutated (1-5) (Appendix S4.6). Among the previous genes reported by 
TCGA, TP53, CDH1, MAP3K1, and MLL3 were significantly mutated in this study by all 
tests, and AFF2, SF3B1, and CBFB were significant for the CT and LRT tests only. We 
additionally identified ARID1A as significantly mutated, concordant with an independent, 
large-scale, breast cancer genomics study (4). 
4.3.3 Validating predicted splicing mutations 
Changes in mRNA splicing from the predicted mutations were validated with Veridical 
(24), which corroborates predicted, aberrant splice isoforms by assessing mutation-
derived sequence reads in tumour RNA relative to their abundance in controls lacking the 
mutation. Controls comprised tumours lacking a particular mutation (usually, n = 414) 
plus additional normal samples (n = 106). Of all variants analyzed from the 415 tumours 
with RNA-Seq data (n = 4,952), 988 variants (~20%) in 819 genes caused one or more 
splicing aberrations at significantly higher levels than in controls (p ≤ 0.05; i.e. intron 
inclusion, exon skipping, or cryptic splicing). Predicted natural splice site mutations (822 
of 3,863, or 21.3%), were validated by abnormal mRNA isoforms more often than cryptic 
splice site mutations (166 of 1,089 or 15.2% variants). A total of 309 mutations were 
found to cause exon skipping, of which 163 (53%) led to expected frameshift mutations. 
Sufficient expression levels for each gene, based on RNA-Seq coverage, were required 
for validation of mutations. An expression heat map, clustered by BC subtype, is shown 
in Appendix S4.3. Variants occurring within significantly expressed genes (defined as an 
average of ≥20 reads per base) were statistically validated for 862 (27%) of 3,156 
variants (p ≤ 0.05). Of 263 variants reported by TCGA in genes with at least this level of 
expression, 156 (59%) were validated by exon skipping (26 variants), by intron inclusion 
(80 variants), and by the combination of both types of evidence (50 variants, p ≤ 0.05). 
Predicted cryptic splicing mutations were confirmed based on the presence of unique 
junction-spanning reads corresponding the ectopically spliced isoforms in GATA3, 
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PALB2, CBFB, ABL1, C2CD2L, ENSA, NASP, NOP9, and TFE3 (Appendix S4.7.1). 
Four of these genes have been linked to tumourigenesis: ABL1, an oncogene, GATA3 and 
PALB2, which are associated with familial breast cancer (26,27), and CBFB has been 
recently implicated in breast cancer by TCGA (5) and others (1,2). These cryptic splicing 
mutations lead to short exonic deletions that alter the reading frame, and likely affect the 
activity of the gene products (Figure 4.1). The GATA3 cryptic isoform is the only 
detectable transcript in the majority of controls, although it is substantially more 
abundant in the tumour sample (Appendix S4.7.2). 
The most commonly mutated genes with splicing mutations were also found by MuSiC to 
be significantly mutated in these tumours (n = 13, FDR < 0.05), and at least one third of 
the mutations were validated with RNA-Seq data (Table 4.2). In TP53, which exhibited 
the highest density of splicing mutations (Figure 4.2), 18 of 23 (78%) predicted variants 
were validated to cause aberrant splicing (p ≤ 0.05). All of the validated mutations 
exhibited statistically significant intron inclusion above normal controls, which was not 
observed genome wide (Appendix S4.8). In three instances, the variants also resulted in 
exon skipping. 
4.3.4 Copy number analysis of mutated genes 
The validated mutations are organized and segregated by tumour subtype on a Circos plot 
(28) (Figure 4.3). Copy number changes portray the genomic locations of deletions or 
amplifications that coincide with these variants. Validated splicing mutations exhibit a 
relatively uniform genomic distribution, except for significantly mutated genes, such as 
TP53 on chromosome 17 and HMCN1 on chromosome 1. We investigated variants in 
regions showing copy number losses, which may constitute the “second hit” in 
oncogenesis. Of the 49 genes found to be significantly mutated in breast cancer (1-5), 
five contained splicing mutations (BRCA1 (2 tumours), PTEN (2 tumours), MAP2K4 (4 
tumours), MAP3K1 (4 tumours) and KMT2C (7 tumours; also known as MLL3)) and also 
recurred within commonly deleted intervals. Of all genes with validated mutations in 
 
  
134 
 
Figure 4.1 mRNA of ABL1, CBFB, GATA3 and PALB2, which each have validated cryptic 
splicing mutations confirmed using tumour-matched RNA-Seq data.  Full gene lengths are 
displayed with vertical black bars outlining exon boundaries. The location of the cryptic variant is 
denoted by the red V, and the variant consequence is highlighted by white (wild type), dark grey 
(exonic deletion), and red (frameshift mutation). Conserved domains and protein interactions are 
labeled by the yellow and blue horizontal bars, respectively. In ABL1, the catalytic and C-terminal 
F-actin binding domains are disrupted. In PALB2, the region that interacts with BRCA2 is 
truncated. In the GATA3 aberrant transcript, the second zinc finger domain and a conserved motif 
crucial for DNA binding and protein function are affected by the altered reading frame. 
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Table 4.2: Genes most commonly mutated with splicing mutations 
Gene Symbol* 
# Splicing 
Mutations 
# Validated % Validated 
TP53 24 18 75 
HMCN1 19 9 47 
KMT2C (MLL3) 19 7 37 
FHAD1 12 4 33 
RAB3GAP1 11 4 36 
BCLAF1 11 3 27 
ANKEF1 10 6 60 
RRM1 8 4 50 
RPRD1A 7 2 29 
SCAMP5 7 2 29 
CDH1 6 4 67 
ACTR3 6 2 33 
*FDR < 0.05 for all genes from MuSiC (Fisher's combined P-value, convolution and likelihood 
ratio tests). 
  
136 
 
  
137 
Figure 4.2: Splicing mutations in TP53, KMT2C and CDH1. TP53, KMT2C and CDH1 gene lengths are displayed with both exons (thick 
lines/boxes) and introns (thin horizontal lines), along with the location of all splicing mutations. Diamond markers denote cryptic mutations, natural 
splice site mutations are indicated by a circle and the colour of the marker corresponds with breast cancer tumour subtype. Mutations validated by 
Veridical are found above the gene, and those mutations not assessed or not validated are below. 
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Figure 4.3: Circos plot of validated splicing mutations by tumour subtype. From the 
outermost ring in, chromosomes are labeled clockwise with copy number data inside them that 
displays deletions in red and amplifications in blue, mutations validated by Veridical (indicated by 
black ticks) are then plotted by subtype with basal-like in the outer white ring, HER2-enriched in 
the outer grey ring, then luminal A (inner white) and luminal B (inner grey). 
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deleted regions, 9 harbored more than 2 variants: 1 had three, 4 had four, and only 
KMT2C possessed more than 4 variants. 
4.3.5 Analysis of pathways enriched in mutant genes 
Mutated genes were clustered by pathway overrepresentation analysis (29) for protein 
coding (Supplementary Table 4.5, n = 202) and splicing mutations (Supplementary Table 
4.6, n = 452). There were 100 pathways common to both mutation sets (Appendix 
S4.9.1). Pathways associated with all types of mRNA splicing mutations include those 
that affect collagen structural genes and enzymes that modify or metabolize collagen (n = 
14, Appendix S4.9.2 #1–14), and several that involve the extracellular matrix (ECM, n = 
4, Appendix S4.9.2 #15–18). Many of these pathways (n = 17, Appendix S4.9.2 #1–
13,15–18) are also overrepresented by pathway analysis of protein coding mutations. 
4.3.6 Relationship of mutation spectra to clinical findings 
Segregating splicing mutations by patient lymph node status revealed significant 
differences in mutated pathways between the two groups. Biochemical pathways with 
overrepresented mutant genes in lymph node-negative (LN−) vs. lymph node-positive 
(LN+) tumours are indicated in Supplementary Tables 4.7 and 4.8, and compared in 
Supplementary Table 4.9. There are 94 pathways overrepresented in both LN+ and LN− 
(Supplementary Table 4.9 #421–514), including 17 collagen (Supplementary Table 4.9 
#421–437), and 3 ECM (Supplementary Table 4.9 #438–440) pathways. Ontologically-
related pathways (29,30) were grouped (Appendix S4.9.3) and visualized as Word Clouds 
(Figure 4.4). Pathway groups overrepresented (p < 0.05) in both tumour subsets included 
17 pathways involving collagen-ECM protein phosphorylation pathways, metabolism, 
cell cycle, DNA repair, and cellular response to stress. However, 13 pathways involving 
collagen (Supplementary Table 4.9 #1–13), and 9 pathways involving NCAM1 
(Supplementary Table 4.9 #17–25) were overrepresented uniquely in LN+ tumors, but 
not in LN− tumours. 
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Figure 4.4: Word Clouds demonstrating differences between overrepresented mutated pathways in lymph node-positive (a) and lymph 
node-negative (b) tumours.   The abstracted pathways (see methods) were plotted if present two or more times. The size of the words as well as 
the corresponding colours of the pathway names indicates the frequency of that abstracted pathway, and can be compared within and between 
the word clouds of each tumour subset. 
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NCAM1, or the neural cell adhesion molecule, is a member of the immunoglobulin super 
family with a role in cell-cell and cell-matrix interactions during development and 
cellular differentiation. Mutations in NCAM1 signaling genes for neurite outgrowth 
(Supplementary Table 4.10 #1) were still overrepresented in tumours with lymph node 
invasiveness, even after genes common to both tumour subsets were masked from the 
analysis, i.e. primarily collagen and ECM genes (Supplementary Tables 4.10 and 4.11). 
These include defects in NCAM1 interactions with FYN and GRB2, a ternary complex 
that participates in the conversion of RAS:GDP to RAS:GTP, which subsequently 
initiates the RAF/MAP kinase cascade. 
We then reanalyzed these data after conservatively limiting the set of mutant genes to 
those containing the most deleterious mutations (Appendix S4.9.4; stop-gain, stop-loss, 
frameshift/indel mutations, and validated splicing mutations). Four of the 8 sub-pathways 
of NCAM1 signaling for neurite outgrowth were overrepresented solely in LN+ tumours. 
Autophosphorylation/dephosphorylation of NCAM1- bound Fyn, as well as NCAM1-
interactions with collagens were overrepresented. The most commonly mutated genes 
within these pathways are SPTA1, CACNA1D, COL6A5, NCAM1, and COL6A6 
(Appendix S4.10). CACNA1D is a voltage-dependent Ca2+ channel (VDCC) that 
associates with NCAM1 in growth cones at the sites of NCAM1 clustering (29,30). In 
addition, 6 other channel genes that are expressed in breast tissue (31) were found to be 
frequently mutated (CACNA1C, CACNA1D, CACNA1G, CACNA1H, CACNB1, 
CACNB3). Mutations interrupting these VDCC interactions may alter the NCAM-
dependent Ca2+ influx. Collagen VI is expressed as supramolecular aggregates of 
composite structures of different chains and is among the most abundant components of 
the ECM (32). Knockdown of NCAM significantly reduces expression of ECM 
components (33), including collagen, weakening the ECM. Mutations in these ECM 
components may also diminish matrix integrity, possibly resulting in more porous 
structures (34). 
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4.3.7 Elevation of NCAM1-related gene pathway mutations in lymph 
node-positive tumours 
NCAM1, collagen, and ECM pathway mutations were assessed in tumours, stratifying by 
lymph node status and tumour stage (Figure 4.5). The percentage of tumours with 
NCAM1-related pathway splicing mutations was increased in N0 (110 localized tumours) 
and N1 (84 tumours with lymph node involvement), as well as Stage I (37) and II 
tumours (140). Advanced lymph node involvement and tumour stage were not associated 
with increased numbers of collagen and ECM pathway splicing mutations, but rather a 
decrease in the percent of tumours with these pathway mutations in advanced stages was 
observed. A multiple factor analysis (MFA; Table 4.3) was performed to assess 
contributions of the number of NCAM1-related pathway mutations per tumour (both 
protein coding and splicing), clinical parameters including stage (AJCC tumour stage, 
lymph node status and metastasis stage), receptor status (HER2, PR, and ER positivity), 
and patient outcome (relapsed, living/deceased). NCAM1-related pathway mutations 
were either absent (n = 213), harbored a single mutation (n = 117), or two or more 
mutations (n = 112) per tumour. The MFA components containing NCAM1-related 
pathway mutations were moderately correlated with both tumour stage and receptor 
status, and accounted for 11% of the variance. 
4.3.8 Analysis of tumour subtypes 
Splicing mutation analysis in different tumour subtypes revealed between 9–15 mutations 
per tumour, which generally accounted for 8–9% of all mutations detected (Appendix 
S4.11.1) and are similar levels to those previously reported (18). Pathway analyses for 
each subtype, stratified by lymph node status, indicated higher enrichment of NCAM1-
related gene mutations in basal-like and HER2/ERBB2-enriched LN+ tumours (Appendix 
S4.11.2 & S4.11.3: see word clouds). LN+ basal-like and HER2-enriched tumours were 
the only tumours found to have significant enrichment in “NCAM signaling for neurite 
out-growth”, identifying those tumour subtypes and pathways that may play a role in 
tumour migration. No single gene was significantly mutated within the NCAM1  
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Figure 4.5: Percent of tumours with mutations by pathway group and clinical factors.  The 
percent of tumours with NCAM1 (red square), collagen (blue diamond), and ECM (green triangle) 
pathway mutations were plotted by lymph node status and tumour stage for all mutations (solid 
lines), and splicing mutations alone (dashed line). 
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Table 4.3: Multiple factor analysis of NCAM1 related pathway mutations and clinical 
parameters per tumour 
 Dim.1 Dim.2 Dim.3 Dim.4 Dim.5 
A. No. Mutations in NCAM 
Pathways* 
0.103 0.892 0.910 0.367 0.321 
Stages 0.804 0.459 0.381 0.833 0.725 
Receptor status 0.379 0.356 0.406 0.471 0.641 
Patient status 0.868 0.159 0.050 0.106 0.159 
% Variance explained 7.618 5.699 5.635 4.944 4.694 
B. No. Mutations Unique to 
NCAM Pathways∧  
0.264 0.899 0.894 0.304 0.300 
Stage 0.791 0.413 0.380 0.877 0.752 
Receptor status 0.389 0.427 0.411 0.429 0.610 
Patient status 0.851 0.083 0.158 0.168 0.221 
% Variance explained 7.716 5.816 5.534 4.941 4.743 
*mutation count for all genes in NCAM pathways. 
∧mutation count for genes unique to NCAM pathways, and not in collagen or ECM pathways. 
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pathways that were overrepresented in LN+ tumours. This suggests that a general defect 
in NCAM1-pathway signaling may be associated with lymph node metastasis in breast 
cancer. 
4.4 Discussion 
Breast carcinoma tumour exomes contain more deleterious mutations than previously 
recognized. Using Shannon information theory, we have predicted an expanded set of 
mutations that affect post-transcriptional mRNA processing that either reside in non-
coding regions, or overlap known codons. We then employed Veridical (24), a high-
throughput, genome-scale method, to statistically validate mRNA splicing consequences 
that result from the predicted variants. This study complements the analyses performed 
by TCGA (5), which comprehensively reported protein-coding mutations, along with 
gene expression, epigenetic, and copy number changes. Together with known deleterious 
coding sequence variants, the identification of such splicing mutations can refine and 
impact our understanding as to which biochemical pathways are dysregulated in these 
tumours. 
Pathway overrepresentation analyses reproduced many of the same pathways identified 
by TCGA. In our analysis, a number of these attained or increased significance when 
genes with previously unrecognized splicing mutations were included. Both splicing 
mutations alone and the complete variant set from all tumours were enriched for genes in 
pathways known to play a role in tumour development and progression including 
signaling by growth factors, cell cycle, ECM organization, and cell-to-cell 
communication. Stratifying the tumours by lymph node status revealed that splicing 
mutations were enriched for genes within NCAM1 pathways in LN+ tumours, 
exclusively. Splicing mutations in these pathways were much rarer and sparsely 
distributed in LN− tumours, with 11 mutations in 92 LN− tumours and 25 mutations in 
118 LN+ tumours. Interestingly, this enrichment was not observed when all protein 
coding substitutions were analyzed, but was significant when assessing all variants that 
were likely to be deleterious (i.e. validated splicing mutations, stop codon gain or losses 
  
146 
and frameshift substitutions). We did not attempt to differentiate loss versus gain of 
function, however splicing mutations and nonsense codons usually result in loss of 
function. The percent of tumours with NCAM1-related pathway mutations increased by 
6% from lymph node stage N0 to N1 and N3 and by 7% from stage I to III. The lower 
fraction of tumours with collagen pathway mutations at higher lymph node stages (N3, 
N4), and with ECM-related mutations in tumour stages III and IV could be related to 
clonal selection of distinct metastatic phenotypes (35), however it is also possible that the 
decreases may not be significant due to the lower numbers of tumours in these categories. 
Our results indicate that NCAM1 pathways are more likely to be dysregulated in tumours 
that have migrated to lymph nodes. We found the enrichment of NCAM1-related 
pathway splicing mutations in LN+ tumours was specifically present in HER2-enriched 
and basal-like tumours. Basal-like, specifically triple-negative, tumours have been 
associated with poor prognosis and survival (36). Early and metastatic HER2 positive 
tumours were associated with poor prognoses (37) until the more recent introduction of 
HER2-targeted therapies (38). In these tumour subtypes, the presence of NCAM1-related 
pathway mutations may indicate a propensity to migrate and/or form distant metastases. 
Dysregulated expression of NCAM1 has been suggested to contribute to tumour 
migration in other cancers: (i) gene silencing and localization studies have suggested that 
“NCAM is both necessary and sufficient to promote a migratory and invasive phenotype 
in EOC cells, with no major effect on cell proliferation” (34), (ii) overexpression of 
NCAM1 has been linked to high ovarian carcinoma tumour grade (34) and greater 
metastatic potential in melanoma cells (39); (iii) preserved NCAM1 expression in 
differentiated thyroid carcinoma has been cited as an indicator for tumours with as 
increased risk of forming distant metastases (40) and (iv) blocking NCAM1 function in 
murine lung tumour cells led to cell vulnerability to apoptosis. More generally, NCAM1 
is known to play a role in apoptotic evasion and matrix degradation, and has potential 
roles in directional cell migration, cell polarity, extravasation and immunological escape 
(41). NCAM1-mediated stimulation of FGFR activity is causally linked to tumour 
malignancy, suggesting that this NCAM1-FGFR interaction may be an effective 
therapeutic target. It is notable that we find mutations in breast tumours that affect the 
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NCAM1-FGFR interaction occur in pathways that are overrepresented in LN+, but not 
LN− tumour genomes. 
NCAM1 homophilic clusters form within lipid rafts on the cell membrane. Spectrin, an 
NCAM1-binding cytoskeletal protein, colocalizes with NCAM1 and is codistributed 
within lipid rafts (42). Frequent mutations in spectrin (SPTA1) may prevent its 
association with RPTPα, thereby impeding its subsequent association with the 
cytoplasmic NCAM1 domain, redistribution of NCAM1 and cluster formation. This 
could abrogate downstream interactions with FYN and GRB2, ultimately affecting 
activation of RAS. These findings merit further investigation into how dysregulation in 
these different partners (i.e. NCAM1, FGFR and the other interacting proteins), acting as 
an ensemble, may promote tumour metastasis. 
The number of aberrant mRNA splicing mutations reported by TCGA (5) is <10% of 
those reported here, and the variants were not functionally validated in the previous 
study. We predict that 8% of all cis-activating point mutations detected in these tumours 
will significantly reduce the strength of the corresponding natural splice sites. The 5,206 
splicing mutations reported here nearly double the number of mutations that lead to stop-
gains or losses (2,587 variants in 1,907 genes), and the number of insertions/deletions 
leading to frameshift substitutions (2,707 variants in 1,848 genes) in this set of tumours. 
It is not surprising that these analyses revealed previously unrecognized pathways that 
may be dysregulated, in addition to those already known in these tumours. 
Our analysis of significantly mutated genes based on the protein coding and splicing 
mutations reproduced many of the genes reported by TCGA, and revealed one additional 
gene, ARID1A. ARID1A has been implicated in breast cancer in a large-scale genomic 
study (4) and has also been mutated in 57% of ovarian clear-cell carcinoma tumours (43). 
Thirteen genes identified as significantly mutated in breast cancer by the TCGA did not 
reach statistical significance within our study (Supplementary Table 4.4). This can be 
explained by a number of different factors: differences in variant callers, variant 
annotation, the number of tumours analyzed and differences in the filtering of variants, 
once the gene set was derived. In addition, TCGA initially analyzed all variants (SNVs 
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and indels) by tumour subtype, unlike our study, which considered mutations in all 
tumours, then reanalyzed overrepresented pathways with mutations by subtype. 
Mutations that lead to a significant level of aberrant splicing can alter or improve 
genomic signatures, which are important when assessing potential biomarkers, diagnosis 
and prognosis, and metastatic or treatment-resistant tumour phenotypes. 
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Chapter 5  
5 Genomic signatures for paclitaxel and gemcitabine 
resistance in breast cancer derived by machine learning 
The work presented in this chapter is reproduced (with permission, Appendix S1) from: 
Dorman, S.N., Baranova, K., Knoll, J.H.M., Urquhart, B.L., Mariani, G., Carcangiu, 
M.L., Rogan, P.K. (2015) Genomic signatures for paclitaxel and gemcitabine resistance 
in breast cancer derived by machine learning. Molecular Oncology. DOI: 
10.1016/j.molonc.2015.07.006.  
5.1 Introduction 
Chemotherapeutic agents, such as paclitaxel and gemcitabine, are recommended to 
patients with developed metastases, basal-like breast cancer, and high-risk indications 
(premenopausal, ER/PR-negative, HER2-status, large tumours, or node-positive) (1,2). 
There is currently no gold standard chemotherapy regimen (1,2). Treatment selection is 
suggested to be individualized and should take into account clinical disease 
characteristics, treatment history, patient-related factors, and patient preference. 
However, resistance is one of the major barriers to successful therapy. In a recent study, 
breast cancer patient response rates to paclitaxel and gemcitabine after 6 cycles of 
chemotherapy were found to be only 50.0% and 78.6% respectively (3). This has 
motivated a number of groups to develop gene signatures aimed at predicting therapeutic 
response to these drugs in breast cancer patients (4-6).  
As in breast cancer patients, breast cancer cell lines show variable responses to growth 
inhibition by paclitaxel and gemcitabine (7,8). Cell lines mirror many of the pathological 
features of breast tumours, such as the intrinsic subtypes of breast cancer (9,10), and can 
be useful for testing anticancer therapy responses (11). Daemen et al. (2013) employed 
random forest machine learning to assess genomic information from 70 breast cancer cell 
lines (including DNA sequence, gene copy number, gene expression, promoter 
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methylation, protein expression, and the corresponding cell line response to 90 anti-
cancer compounds) with the objective of establishing pretreatment signatures that predict 
response. The gene expression profile of the tumor subtype was found to be the most 
effective way to model response to therapy. However, many molecular signatures derived 
using genome-wide approaches are inconsistent between different data sets (12,13). This 
is partly due to the fact that deriving predictive gene models using thousands of genes 
risks overtraining, that is, fitting the noise rather than the actual gene signature in the data 
(12).  
We recently defined a set of genes that are stable in gene expression and copy number in 
the majority (>90%) of breast cancer tumours (14). The stable gene set is composed of 
genes that are unmutated in the majority of tumours. Interestingly, many stable gene 
products were found to be targets of paclitaxel and gemcitabine. We examine the 
possibility that genomic differences in expression, copy number or mutation in these 
genes may be related to GI50. Rather than a genome-wide approach to predict sensitivity 
to paclitaxel and gemcitabine (eg. employed by Daemen et al. (2013)), we analyze stable 
and linked unstable genes in pathways that determine their disposition (Figure 5.1).  
Gene panels were established based on biological and experimental studies of paclitaxel 
and gemcitabine metabolism. Paclitaxel binds to the β subunit of tubulin (TUBB1), 
inhibiting microtubule formation during mitosis (15). It also binds BCL2, which induces 
programmed cell death (16). Paclitaxel is now also recognized to target microtubule-
associated proteins 2 (MAP2), 4 (MAP4) and Tau (MAPT) (17), as well as the xenobiotic 
receptor (NRI12, or PXR) (18). SLCO1B3 transports paclitaxel into cells, and it is 
exported by ABCB1  (P-glycoprotein), multidrug resistance-associated proteins ABCC1 
(19) and ABCC10 (20), and the bile salt export pump ABCB11 (21). Other genes 
previously implicated as contributing to paclitaxel resistance include TMEM243 (22), 
BCAP29 (23), GBP1 (24), TLR6 (25), NFKB2 (26), FGF2 (27), BIRC5 (28), TWIST1 
(29), FN1 (30), OPRK1 (31), CSAG2 (32), and CNGA3 (31). Additionally, genes 
expressed in breast tissue involved in paclitaxel metabolism were included: CYP2C8 and 
CYP3A4 (33), as well as stable genes in pathways of known direct targets (14): BAD, 
BBC3, BCL2L1, BMF, TUBB4A (34), and TUBB4B (34). 
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Gemcitabine, a deoxycytidine analog, is transported into the cell by SLC29A1 (35), 
SLC29A2, SLC28A1 (36), and SLC28A3 (37).The prodrug is then phosphorylated by 
DCK, CMPK1, and NME1 to gemcitabine diphosphate and triphosphate (38). These 
active forms are incorporated into DNA, which halts replication and cell growth (39). 
Gemcitabine di- and triphosphate target ribonucleotide reductase (RRM1, RRM2, and 
RRM2B), and inhibit DNA synthesis (40). An alternative metabolite, 
difluorodeoxyuridine monophosphate, which is derived by cytidine deaminase (CDA) or 
dCMP deaminase (DCTD), inhibits thymidylate synthetase (TYMS), resulting in 
apoptosis (38). 
We examine the hypothesis that genomic differences in genotypes, expression and copy 
number of these genes explain concentration-dependent growth inhibition by gemcitabine 
and paclitaxel. We then use machine learning to stratify the relative contributions of 
different genes to chemoresistance, by identifying corresponding genomic signatures at 
the transcriptional and genomic level in both cell line and patient data. 
5.2 Materials and Methods 
5.2.1 Data Acquisition 
Growth inhibition (GI50), copy number, gene expression, and exome sequencing data 
were obtained from the supplementary data of Daemen et al. (2013). GI50s (-log10M, 
where M is the drug concentration required to inhibit cell line growth by 50%) for 
paclitaxel were available for 49 cell lines and GI50s for gemcitabine were available for 
47 cell lines. Appendix S5.1 indicates the cell lines used and Appendix S5.2 indicates the 
gene, gene product names and their respective drug disposition functions. Appendix S5.3 
& S5.4 describe copy number and variant calling, results of which are shown in 
Supplementary Tables 5.1 and 5.2. Log2 normalized gene expression data were derived 
from Affymetrix Gene Chip Human Exon 1.0 ST arrays. Replication studies performed to 
re-measure and confirm GI50s, verify copy number and mutation data for a subset of the 
cell lines are outlined in Appendix S5.5. Figure 5.1 is an overview of the complete 
workflow used. 
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Figure 5.1 Workflow to derive gene signatures.  Gene sets were derived for paclitaxel and 
gemcitabine based on known drug pathways, metabolism, and genes previously implicated in 
resistance. A multiple factor analysis was completed for each gene to determine which data types 
(gene expression, copy number, and mutation data) were correlated with the growth inhibitory 
values for paclitaxel and gemcitabine. Gene expression values were used to derive the paclitaxel 
SVM classifier, and both gene expression and copy number were used for the gemcitabine SVM. 
Cell lines were then clustered on optimized gene sets to visualize stratification of tumour subtype 
and sensitivity. The SVM classifiers were validated using random gene iterations to determine the 
significance of the classification accuracy, and patient data sets to ensure robustness of the 
models derived. 
  
159 
5.2.2 Cell Lines 
Cell lines were composed of 10 basal, 9 claudin-low, 25 luminal, and 5 normal-like 
subtypes. Cell lines were designated resistant, if their GI50 was <8.0 for paclitaxel and 
<7.0 for gemcitabine, respectively. The threshold values for distinguishing sensitive from 
resistant cell lines were based on median GI50s for each particular drug (7.99 and 7.13, 
for paclitaxel and gemcitabine). Daemen et al. (2013) classified cell lines by comparing 
mean GI50s. We used median GI50, which is not impacted to the same extent by outlier 
cell lines.  
5.2.3 Multiple Factor Analysis (MFA) 
MFA was used to relate each cell line GI50 according to sets of genomic variables (41). 
The 44 (gemcitabine) or 45 (paclitaxel) breast cancer cell lines (Appendix S5.1) were 
treated as separate individuals. MFA was carried out with the R library “FactoMineR” 
(42), with GI50s, gene expression, copy number, mutation status (if the gene contained 1 
or more mutations), and 31 and 18 genes associated with paclitaxel and gemcitabine 
activity, respectively, as input. 
5.2.4 Support Vector Classification  
A binary support vector machine (SVM) was trained with the Statistics Toolbox in 
MATLAB (Natick, MA) using fitcsvm (linear kernel function) and then 
tested with a leave-one-out cross-validation (using ‘crossval’ and ‘leaveout’ 
options). The SVM was trained on the cell lines and explanatory gene variables deemed 
relevant from the MFA: expression data for the paclitaxel SVM, and copy number and 
expression data for the gemcitabine SVM. The input data consisted of measurements 
from all genes used in the MFA. Sequential backward feature selection was performed 
for feature optimization (43) to minimize the percentage of misclassified cell lines 
(classification error) returned from the leave-one-out cross validation (Appendix S5.6). 
Genes that did not reduce or change the classification error were removed from the SVM 
(one at a time). This procedure was iterated until further gene removal lead to a higher 
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classification error (stopping criterion). By contrast with the SVM, a partial-least squares 
regression was not effective in relating genomic findings to paclitaxel response 
(Appendix S5.7).  
The hinge loss was also determined for the subset of genes included in the final SVMs. 
Hinge loss applies a linear penalty for misclassified data according to their distance from 
the hyperplane. The loss function is represented by Equation 1 where yj = {-1,1} and 
f(Xj) is the score, i.e. hyperplane distance, for cell line j: 
𝐿 = max (0,1 − 𝑦𝑗𝑓(𝑋𝑗))    (1) 
5.2.5 Applying the cell line SVM to patient data 
Formalin fixed, paraffin embedded (FFPE) tumour samples were obtained from the 
Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy), from leftover material 
available after diagnostic procedures in consented patients (44). Samples obtained were 
from patients that were first treated with paclitaxel (or in a small number of cases 
docetaxel) and carboplatin, and then subsequently gemcitabine, upon development of 
resistance. Clinical information was available as to whether the patients responded to 
each of the drugs (paclitaxel and gemcitabine). Tumour and control normal tissues were 
analyzed for expression and copy number of SVM genes, respectively, by real-time 
reverse-transcriptase polymerase chain reaction (qRT-PCR) and real time PCR (qPCR, 
methods described in Appendix S5.8). The cell line-based SVM models were used to 
predict patient sample drug responses in a blinded manner. Two SVM models were 
trained for paclitaxel and gemcitabine: one using the normalized gene expression values, 
and the other using expression values binned into 10 categories, using the Matlab 
function: quantile(X,10). Binning was performed because amplifiable RNA template 
concentration in FFPE blocks is not known precisely, because it is subject to long term 
degradation and reactivity (45,46). Expression measurements were obtained for 11 genes 
from the paclitaxel SVM, and 6 genes for the gemcitabine SVM. The SVM was trained 
on the cell line data with these reduced gene sets. Predicted and actual responses were 
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compared, and odds risk ratios (contingency analysis) were calculated (GraphPad Prism, 
San Diego, California). 
Patient data were also obtained from GEO Accession GSE25066, in which expression 
levels of tumours that were treated with taxane and anthracycline chemotherapy were 
reported (5). Expression levels for the paclitaxel SVM genes (except BMF and CSAG2, 
which were not measured) were extracted for those patients treated with paclitaxel (n = 
319). In cases with multiple probe sets per gene, expression levels were averaged. The 
SVM predictions were then related to response to therapy and residual cancer burden 
class for each patient.  
5.2.6 Clustering cell lines and patients using expression values of the 
SVM gene subsets 
The unsupervised, hierarchical clustering function ‘clustergram’ in Matlab was used 
to cluster cell lines and patient data (described in 2.5) according to gene expression 
values included in the optimized SVM. Expression values were normalized by row so the 
mean expression of each gene across individuals was 0, and the standard deviation was 1. 
Clustering was performed by individuals and genes, and dendrograms are displayed for 
each dimension that indicate relatedness based on their lengths and hierarchical 
branching. 
5.3 Results 
5.3.1 Multiple Factor Analysis 
MFAs were performed using GI50s of 49 cell lines, and genomic measurements of 31 
and 18 genes related to paclitaxel and gemcitabine activity from an existing data set (7). 
We re-confirmed measurements for a subset of the cell lines to ensure consistency 
between cell line sources (see Appendix S5.9).  MFAs were assessed by statistics 
generated by the program, FactoMineR (42). Relationships were stratified by the 
correlation between the variable and GI50, the RV coefficient (a multivariate 
generalization of the squared Pearson correlation coefficient), the position of variables on 
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the correlation circle, and the representation quality of each variable group in the first two 
dimensions (cos2 values). These criteria were used to classify each gene as having a 
“strong relationship”, “relationship”, “possible relationship” or “no relationship” to GI50 
(see Appendix S5.10 for the thresholds for each class). Examples of correlation circles 
and individual factor maps for MAPT (paclitaxel) and DCTD (gemcitabine) are illustrated 
in Appendix S5.11. 
MFA revealed “strong relationships” between paclitaxel GI50 and copy number and/or 
gene expression for 11 genes, consisting of both negative relationships (diminished copy 
number and gene expression [-] for CYP2C8, CYP3A4, NR1I2 (previously known as 
PXR), TLR6, and TUBB1) and positive relationships (increased copy number and gene 
expression [+] for BBC3, BCL2L1, BMF, CNGA3, MAPT, and TUBB4B) with increased 
chemoresistance (Appendix S5.12 lists all MFA measurements). The gemcitabine set 
revealed strong associations between resistance and ABCB1 (+), DCTD (-), and SLC28A1 
(+) gene expression as well as strong relationships for ABCC10 (+) and CDA (+) copy 
number (Appendix S5.13). The MFA results for paclitaxel (gene expression results only) 
and gemcitabine treatment (copy number and gene expression), in the respective pathway 
contexts, are summarized in Figure 5.2. 
Point mutation status was based on 74 deleterious coding mutations (Supplementary 
Table 5.2) that were predicted to be damaging (47) or to affect mRNA splicing (48,49). 
Point mutations predicted to be damaging demonstrated strong relationships in ABCB1 (n 
= 4, in 2 cell lines) to paclitaxel resistance and in SLC28A3 (n = 3, in 2 cell lines) to 
increased sensitivity to gemcitabine. The limited number of cell lines with mutations in 
these genes cannot be effectively incorporated into machine learning models, and point 
mutation results were not included in these analyses. 
5.3.2 Support Vector Machine (SVM) Learning 
A binary SVM was employed to develop a predictive multigene classification of genomic 
signatures for resistance to these drugs (50). Based on MFA results, data types orthogonal 
to GI50 were excluded from the SVM (see section 2.5 for details). The classification 
error of the SVM model was minimized by removing genes, i.e. features, which did not  
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Figure 5.2 Genes associated with paclitaxel (A) and gemcitabine (B) mechanism of action 
(direct targets, metabolizing enzymes), genes previously associated with resistance, and 
stable genes in the biological pathways targets.  Genes with an asterisk (*) are stable genes 
(Park et al., 2012). Genes highlighted in red showed a positive correlation (within dimension 1 
and/or dimension 2) between gene expression or copy number, and resistance in the MFA, 
whereas genes highlighted in blue demonstrated a negative correlation. Genes outlined in dark 
grey are those included in the final predictive model that was derived using the SVM. Red T-
shaped bars indicate the genes that paclitaxel directly binds/inhibits. Genes outlined in light grey 
(ie. BAX/BAK) were not included in the analysis because they were not stable genes in the BCL2 
pathway. 
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improve accuracy by leave-one-out cross-validation (see section 2.5 for details). This 
feature selection process is illustrated in Figure 5.3-I. The optimized SVM was then 
trained, respectively, on 15 gene variables for paclitaxel (49 cell lines) and 10 variables 
for gemcitabine (44 cell lines). Gene expression values from ABCC10, BCL2, BCL2L1, 
BIRC5, BMF, FGF2, FN1, MAP4, MAPT, NFKB2, SLCO1B3, TLR6, TMEM243, 
TWIST1, and CSAG2 comprised the final set of features used to train the SVM for 
classification of paclitaxel sensitivity. For gemcitabine, both gene expression values 
(from ABCB1, ABCC10, CMPK1, DCTD, NME1, RRM1, RRM2B) and copy number data 
(from ABCC10, NT5C, TYMS) were used in the final SVM. The distance of each cell line 
value from the SVM hyperplane that distinguishes the degree of sensitivity or resistance 
was plotted against the corresponding GI50 (Appendix S5.14). The trained SVMs 
misclassified 9 of 49 (18%) cell lines for paclitaxel and 7 of 44 (16%) for gemcitabine, 
which is comparable to, or more accurate than other approaches (51). Partitioning by 
histological subtype did not improve the classification accuracy; a single variable SVM 
model based on subtype misclassified 30% of cell lines for paclitaxel and 45% for 
gemcitabine (Appendix S5.15). The feature-optimized SVM outperformed the signature 
derived from the initial set of genes, which misclassified resistance/sensitivity of 36% of 
cell lines for paclitaxel and 64% for gemcitabine treatments. In addition, multi-gene MFA 
analyses of the final SVM gene sets demonstrate that the individual factor maps of the 
resistant and sensitive cell lines segregate to a greater degree than MFAs based on the 
initial gene sets, which were indistinguishable (Appendix S5.16). These differences were 
larger for gemcitabine than paclitaxel.  
To assess the individual impacts of a gene on SVM accuracy, each gene remaining in the 
optimized SVM was removed, and the misclassification rate was redetermined (Figure 
5.3A-II). BCL2L1 and MAPT had the highest predictive value for paclitaxel sensitivity, 
with misclassification rates of 36% and 34%, respectively, when eliminated (compared to 
21-30% for the other genes). It is notable that the MFA also showed strong associations 
with decreasing MAPT or BLC2L1 expression and increasing paclitaxel sensitivity. 
BCL2L1 is a member of the Bcl-2 family and is involved in regulation of apoptosis (16). 
Additional apoptotic regulators, such as BMF and BCL2, also appear in our SVM results,   
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Figure 5.3 Effect of the removal of each gene on the percent of cell lines misclassified 
during the SVM feature selection process to determine the most predictive gene set (left 
panels AI and BI).  The right panels (AII and BII) demonstrate the increase in the percent of cell 
lines misclassified when the expression of genes in the inferred, optimal gene set are 
subsequently eliminated from the SVM. 
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 as paclitaxel is known to trigger apoptosis through these pathways (52). The loss of 
MAPT in breast cancer cells has been shown to sensitize those cells to the action of 
paclitaxel (53), which is supported by our analysis.  
For gemcitabine, removing NT5C copy number, NME1 gene expression, ABCC10 gene 
expression, and RRM2B gene expression had the largest effects, by respectively 
increasing misclassification rates to 34%, 32%, 32%, and 30% (Figure 5.3B-II). NT5C is 
located on 17q25.1 a region associated with cancer (54). Allelic imbalances in TYMS 
have previously been hypothesized to be involved in drug resistance in renal cell 
carcinoma (55) and ABCC10 has been associated with drug resistance (56). NME1 is a 
known metastasis suppressor gene which may have great prognostic value (57). RRM2B 
and RRM1 have been suggested to be associated with gemcitabine resistance (58) and 
have been shown to be overexpressed in a gemcitabine-resistant pancreatic cancer cell 
line (59). 
5.3.3 Applying the cell line-trained SVM to patient data 
Formalin fixed paraffin embedded (FFPE) tissue blocks were obtained from patients that 
were treated with paclitaxel and gemcitabine, and whose responses to both drugs are 
known. Gene expression measurements for 11 genes from the paclitaxel SVM, and gene 
expression (6 genes) and copy number (CN; 3 genes) from the gemcitabine SVM were 
obtained using qRT-PCR and qPCR (Supplementary Tables 5.3 and 5.4). Gene 
expression measurements were not obtained for BMF, CSAG2, SLCO1B3, TWIST1 
(paclitaxel), and ABCB1 (gemcitabine), as no amplification was observed in these 
samples by 40 cycles. The absence of amplification in these genes was related to their 
low levels of expression in breast cancer tissue (Appendix S5.17.1). In cases where qRT-
PCR showed no amplification for a specific sample out of the genes measured, the 
highest cycle run was used as the Ct value for that gene. Older samples, on average, had 
lower numbers of genes with successful measurements (Appendix S5.17.2). 
An SVM was trained using the cell line data with a reduced set of 11 (paclitaxel – 
ABCC10, BCL2, BCL2L1, BIRC5, FGF2, FN1, MAP4, MAPT, NFKB2, TLR6, and 
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TMEM243) and 9 (gemcitabine – ABCC10, CMPK1, DCTD, NME1, RRM1, RRM2B, 
ABCC10-CN, NT5C-CN, and TYSM-CN) gene values, which corresponded to the 
measurements obtained from the FFPE tissue block studies. These SVMs were then 
applied to the FFPE tissue sample data to predict their sensitivity to paclitaxel and 
gemcitabine (see Supplementary Table 5.5 for full FFPE sample predictions). The 
paclitaxel SVM predicted drug sensitivity with 71% accuracy (Table 5.1), which was 
similar to a leave-one-out analysis on the cell line data, which classified cell lines with 
70.2% accuracy (using the reduced 11-gene subset). Patients who were treated with 
docetaxel were excluded from this summary because the trained SVM only predicted cell 
line response to docetaxel with 57% accuracy (misclassified 19/44, based on GI50s). 
Docetaxel and paclitaxel GI50s for all cell lines were correlated only to a limited extent 
(R
2
 = 0.722), consistent with the possibility that there might potentially be differences in 
mechanisms of drug metabolism and resistance between these drugs. The gemcitabine 
SVM did not perform as well on the patient sample data as it did on the cell line leave-
one-out analysis, which was 79.6% accurate (using the reduced 9-gene subset). The 
gemcitabine SVM derived using binned expression values predicted patient response with 
62% accuracy, however, 72% accuracy was achieved for samples with gene expression 
measurements available for at least 4 of the 6 genes.  
Although DNA variants were not incorporated into the SVM models, we sequenced a 
subset of the FFPE samples to determine whether any potentially damaging mutations 
were present in paclitaxel/gemcitabine genes of interest, especially for genes that showed 
relationships between mutations and drug sensitivity in the MFA (Appendix S5.12 & 
S5.13). Native DNA from 8 samples (all tumours) and whole genome amplified (WGA) 
DNA from 16 samples (9 tumour and 7 matched normal tissue) were used for next 
generation sequencing that enriched for the genes of interest. WGA was required for 16 
samples, because the amount of DNA extracted from the samples was not a sufficient 
starting quantity for the sequencing protocols used. Despite the fact that the samples had 
been qualified by PCR amplification from exons of several genes (including BRCA1 and 
BRCA2), attempts to prepare NGS libraries for 2 of the original DNA samples were 
unsuccessful, presumably due to accumulated DNA damage during formaldehyde 
treatment and storage of the sample. Since spectrophotometric measurements indicated  
  
169 
Table 5.1 Using the SVM to predict patient response from archived FFPE tissue 
 
Paclitaxel Gemcitabine 
 
NORM 10 bins NORM 10 bins 
No. of accurate predictions 12 12 9 13 
Total 17* 17 21 21 
Percent accurate 71% 71% 43% 62% 
Odds Ratio 5.83 6.00 3.00 3.33 
P-value^ 0.1534 0.1534 0.5333 0.3615 
*4 patients were treated with docetaxel instead of paclitaxel, and were not included in this 
summary. ^Fisher's exact test. Gene expression values were either normalized (NORM) or 
binned into 10 categories (10 bins), as described in the methods. Please refer to Supplementary 
Table 5.5 for all FFPE clinical response/prediction data and the values used for binning. 
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that DNA was present in nearly all samples, WGA was used to recover the fraction of 
intact DNA present in the isolates that did not yield libraries by conventional procedures.  
The full methods used are described in Appendix S5.5.3, and the RNA sequences used 
for targeted DNA gene capture are listed in Supplementary Table 5.6.  
DNA sequencing coverage was variable beween samples, ranging from 7-31 reads per 
base pair for the original DNA, and between 0-139 for the WGA DNA. DNA variants 
were detected in five of the original DNA samples (each with 6, 32, 46, 8, and 32 
variants) and three of the WGA DNA samples (each with one variant). Of the variants 
residing in paclitaxel and gemcitabine genes of interest, 12 were predicted to be 
damaging (47) (two were novel with average heterozygosity <1% and 10 were known 
SNPs), and the remainder were predicted to be “tolerated” (4 novel, 108 known SNPs, 
see Supplementary Table 5.7 for full mutation list). There were very few (ie. 1 or none) 
variants detected in the WGA samples because these samples did not have uniform 
coverage throughout targeted genes. There was significant bias in the WGA DNA 
sequencing, where there were few regions with very high coverage (ie. as high as 4000 
reads per bp), and the majority of regions with no coverage (Figure 5.4 – B/C). This was 
not the case with the original DNA samples that were sequenced, as coverage was more 
uniformly distributed among the genes of interest. This mirrors what we found in the 
gene expression experiments, where measurements were not obtained for every sample in 
every gene, suggesting that there are regions of the FFPE template DNA that are more 
difficult to amplify than others. In total, 5 (22%) out of 22 samples had acceptable, 
uniform coverage, which is in line with a previous study that found ~18% of FFPE 
samples pass quality control for subsequent next generation sequencing  (81).  
Ultimately, only 4 samples harbored potentially damaging mutations (47), including 
samples from patients 2 (in SLC28A1, two in MAP4, and RRM2B), 6 (in NFKB2), 8 
(ABCC1, SLC28A1, and RRM2B), and 24 (three in MAPT and BAD). Of these genes, 
ABCC1 mutations were associated with increased sensitivity to paclitaxel in the MFA 
(Appendix S5.12), and RRM2B mutations were associated with resistance (Appendix  
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Figure 5.4 Coverage and reads from sequencing of three FFPE tumour samples using 
originally extracted (A) and whole genome amplified (B/C) DNA.  An IGV screen shot 
covering a 25 kb portion of FN1 (gene displayed at the bottom in blue shows exons [thick bars] 
and introns [thin bars]) on chromosome 2 (specific band is indicated by the red bar in the top 
chromosome diagram). Coverage values for A-C are indicted in the top panel by the grey peaks, 
with the scale in square brackets on the right hand side. DNA sequencing reads are individually 
displayed as grey (and other colour) bars in the bottom panels of A-C. 
 
[0-36] 
[0-116] 
[0-4317] 
A) OR. 
B) WGA1 
C) WGA2 
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S5.13). This corresponds with our patient response data: sample 2B was a gemcitabine 
non-responder and sample 8C initially responded to paclitaxel (and then subsequently 
developed resistance), and was resistant to gemcitabine. Although mutation data are a 
sparse data source that is not easily modeled by SVMs, it appears that mutations on an 
individual basis may provide insight into tumour response to paclitaxel or gemcitabine.  
Gene expression measurements and clinical data were also obtained for 319 patient 
samples who were treated with paclitaxel and anthracycline chemotherapy (5). Gene 
expression data were not available for two genes from the paclitaxel SVM (BMF and 
CSAG2), which were two of the 4 genes that could not be measured in the FFPE samples. 
Consequently, the same 11-gene SVM used for the FFPE samples was applied to the data 
from Hatzis et al. (2011).  SVM predictions were compared with the clinical outcome - 
whether the patient had recurrent disease (RD) or complete pathological response (pCR, 
see Table 5.2 for a summary, and Supplementary Table 5.8 for all predictions). The SVM 
predicted sensitivity in 52 of the 63 patients (84%) that showed pCR. All patients that 
showed complete pathological response exhibited no or minimal residual disease 
(residual cancer burden [RCB] class 0/1 (60), although some patients within this subset 
did not respond to therapy. This group of patients (RCB 0/1) may derive the greatest 
benefit from the paclitaxel SVM analysis. The SVM did not perform as well in predicting 
resistance, miscategorizing 135 patients of the 257 with RD (52.5%) as sensitive. 
However, performance of the SVM exceeded that of the 512-gene signature described in 
Hatzis et al. (2011) for both sensitive and resistant patients. The odds ratio of the 11-gene 
SVM was 4.484 (Fisher’s exact test, p<0.0001), compared to the odds ratio of 3.181 of 
the  predictive signature described in that study (Fisher’s exact test, p<0.0001).   
5.3.4 Clustering cell line and patient data based on SVM gene 
subsets 
Two distinct groups emerge from unsupervised clustering using the SVM gene set for 
paclitaxel in the cell line data (Figure 5.5A). The left cluster (highlighted in light grey) 
corresponds with the luminal subtype, and the right corresponds to a mix of basal,  
  
173 
 
Table 5.2 SVM predictions on 319 patients treated with paclitaxel from Hatzis et al. (2011) 
 
Cell Line 11-gene SVM Hatzis "Rx" Prediction 
 
RD pCR RD pCR 
ALL RCB Classes         
Predicted Insensitive 119 10 186 28 
Predicted Sensitive 138 52 71 34 
Odds Ratio 4.484 3.181 
P-value^ <0.0001 <0.0001 
RCB Class 0/1 Only         
Predicted Insensitive 11 10 10 28 
Predicted Sensitive 19 52 20 34 
Odds Ratio 3.011 0.6071 
P-value^ 0.0359 0.3673 
RD = recurrent disease (designated "insensitive" patient response), pCR = pathological complete 
response (designated as "sensitive" patient response), RCB = residual class burden (as 
described in Symmans et al. 2007). ^ p-values were determined using a Fisher's exact test. 
Please refer to Supplementary Table 5.8 for all predictions and patient information. 
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Figure 5.5 Expression heatmap of the paclitaxel and gemcitabine SVM derived genes for 
the tested cell lines.  Each row represents a gene and each column a cell line. Red indicates 
higher expression and blue represents lower expression, as shown by the colour bar on the left. 
‘Resistant’ cell lines are coloured grey and ‘sensitive’ cell lines are coloured white in the row 
labeled ‘response’. Cell lines are labeled by subtype and copy number according to the legends. 
Clustering was done based on the similarity of each cell line’s expression profile in the 1st 
(column) dimension and each gene's expression profile in the 2nd (row) dimension. The 
dendrograms on the top and left indicate the relatedness of each cell line and gene by the length 
and subdivision of the branches, with deeper branches indicating a stronger relationship and 
branches in the same 'tree' being more closely related to each other than data in other 'trees‘. A) 
A section of the dendrogram for paclitaxel is shaded grey to indicate a cluster composed entirely 
of luminal cell lines and a higher proportion of resistant cell lines. The other section is white to 
indicate a cluster with very few luminal cell lines and a higher proportion of sensitive cell lines. B) 
A section of the dendrogram for gemcitabine is shaded grey to indicate a cluster composed of a 
higher proportion of resistant cell lines. The other section is white to indicate a cluster with a 
higher proportion of sensitive cell lines. 
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 claudin-low, and normal-like subtypes. The proportions of resistant (71% of the left 
cluster) vs. sensitive (58% of the right cluster) cell lines are not statistically significant  
(2 = 3.67, 1 degree of freedom, p = 0.056). Cell lines clustered using the gemcitabine 
SVM gene expression values display at least two distinct clusters that do not correspond 
to any subtype(s), but, stratify according to gemcitabine sensitivity (73%; left) or 
resistance (69%; right) (Figure 5.5B, chi-statistic = 10.75, p = 0.001, d.f. =1). Clustering 
of the FFPE derived samples was not as strong as a consequence of limited sample 
numbers and lack of expression measurements for every gene in every sample (Appendix 
S5.18.1). Nevertheless, clustering of expression in these samples mirrored the cell line 
data based on results for MAPT and BCL2 (for paclitaxel) and DCTD (for gemcitabine). 
Unsupervised clustering of expression data from Hatzis et al. (2011), using the paclitaxel 
SVM distinguished patients according to the proportions of those free of distant relapse 
(Figure 5.6 and Appendix S5.18.2). These clusters are partially distinguished by MAPT 
and BCL2 expression (Figure 5.6A, the “low MAPT” cluster is indicated in purple, “high 
MAPT” in green). MAPT and BCL2 are both components of the PAM50 Breast Cancer 
Intrinsic Classifier. Their expression patterns segregate into luminal and basal subtypes to 
a large extent. Low MAPT expressing luminal subtypes were observed to have 
significantly worse prognoses than higher MAPT expressing luminal tumours in the 
patient dataset (p<0.05, Appendix S5.19). The gene signature described by Hatzis et al. 
(2011) predicted treatment “sensitivity” and “insensitivity” accurately within the low 
MAPT cluster, where “sensitive” patients exhibit significantly longer times to distant 
relapse (Figure 5.6C, p = 0.0013, log rank test). However, this was not the case for the 
high MAPT cluster, as the proportion free of distant relapse between two predicted groups 
did not differ significantly (p = 0.10, log-rank test).   
5.3.5  Significance of SVM classification accuracy 
To assess the significance of the derived SVM, we selected 100,000 random sets of 15 
genes from a set of expression values (to compare to the paclitaxel SVM) and 10 genes 
from a set of copy number and expression values (gemcitabine SVM) for 23,030 genes. 
Only 0.14% of paclitaxel and 0.01% of gemcitabine random gene combinations exceeded  
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Figure 5.6 A) Expression heatmap of the paclitaxel SVM derived genes for 319 tumour 
samples (Hatzis et al. 2011).  See Figure 5.5 for heat map labeling and diagram details. A 
section of the dendrogram on the top is shaded purple to indicate a cluster of tumours (83% 
luminal) with a significantly worse outcome assessed by the proportion free of distant relapse 
curves (shown in B). Another section is shaded green (63% basal) with significantly better 
outcomes. The cluster shaded gray (22% basal, 53% luminal) can be clustered independently 
with similar stratification by subtype and outcome (Supplemental Information VI). C) The Hatzis et 
al. (2011) gene signature performs very well in the purple cluster and poorly in the green, based 
on the Kaplan-Meier curves constructed on each subset using their published labels ("insensitive" 
and "sensitive"). 
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Figure 5.7 The proportion of misclassified cell lines (A/C) and hinge loss scores (B/D) were 
measured on SVMs derived using randomly selected gene sets.  15-gene (to compare to the 
paclitaxel SVM, A/B) or 10-gene (to compare to the gemcitabine SVM, C/D) values were 
randomly selected from an initial set of 23,030 genes and used to derive SVMs. The performance 
of 100,000 iterations of the random signatures are plotted in the above histograms. The hinge 
loss scores for the paclitaxel and gemcitabine final SVM gene subsets lie in the lowest 2nd 
(paclitaxel, z-score -2.0, p < 0.05 one-sided) and 1st percentiles (gemcitabine, z = -2.16, p < 
0.05) of the data. Expression alone was used for the 15-gene sets (A/B). Copy number and 
expression were used for the 10-gene sets (C/D). The red arrow-heads indicate where the 
optimized paclitaxel and gemcitabine SVM gene signatures are found in the distribution. 
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the classification accuracy of the derived SVMs. (Figure 5.7 – A/C). The hinge loss, 
which increases based on the misclassified object’s distance to the hyperplane, was 0.64 
for the paclitaxel SVM and 0.66 for the gemcitabine SVM (optimal is close to zero). 
Among the random gene combinations, the likelihood of deriving SVMs with equal or 
lower scores was 1.45% and 0.83% for paclitaxel and gemcitabine, respectively (Figure 
5.7 – B/D). Thus, the accuracy of the SVMs achieved for both drugs were not likely due 
to random chance (p<0.05 in all cases, Table 5.3). 
Nearly all of the high performance random gene set combinations appear to be statistical 
artifacts. Analysis of 10,000 random gene selections found 18 combinations with lower 
paclitaxel misclassification response rates. All 18 signatures were unique (2 transcripts 
occurred twice) and transcript combinations were dominated (24%) by alternative splice 
variants and expressed pseudogenes. None of the random gene combinations were 
significantly associated with known biological pathways. Six of the random signatures 
contained ≥ 10 gene expression values in the patient data. None of these signatures 
predicted paclitaxel sensitivity, except one set containing WWP1, which has previously 
been suggested to be a prognostic indicator in breast cancer (61). This signature (and one 
based on WWP1 expression alone) predicted more patients (5) to be sensitive to 
paclitaxel than our derived SVM.  Similar numbers of patients predicted to be sensitive by 
both SVM models exhibited complete remission (52 vs. 55), however the WWP1-based 
SVM predicted sensitivity in a greater number of non-responders (n = 178) than our 
derived SVM (n= 138) and misclassified 41% of the cell lines. For the gemcitabine 
response, the SVM of a single random gene set had a lower misclassification rate than 
our derived SVM. The genes in this set were unrelated to gemcitabine metabolism, with 9 
of 10 SVM variables exhibiting copy number changes, two of which involved non-coding 
RNA genes.  
5.3.6 Translation of signature to other cancer types 
To mitigate tissue-specific effects, we rederived SVM models specific to lung cancer 
(lung) and hematopoietic and lymphoid tissue cancer (hematopoietic) cell lines using 
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Table 5.3 SVM performance using randomly selected genes based off 100,000 iterations 
 
minimum maximum average 
standard 
deviation 
drug 
SVM 
z-score p-value 
No. random SVMs  
≤ drug SVMs1 
percent misclassification of cell lines in leave-one-out analysis 
15-gene2 12.2% 83.7% 42.7% 8.8% 18.4% -2.78 0.0027 141 
10-gene3 12.2% 90.2% 48.0% 10.5% 15.9% -3.06 0.0011 10 
hinge loss score 
15-gene 0.39 1.66 0.93 0.14 0.64 -2.04 0.0207 1,453 
10-gene 0.30 2.02 1.05 0.18 0.66 -2.16 0.0153 826 
         
Misclassification rates and hinge loss scores were determined from SVMs derived using 100,000 random combinations of gene expression and 
copy number values from 23,0303 genes. The minimum, maximum, average, and standard deviations of each 100,000 iterations were determined, 
and compared to the paclitaxel and gemcitabine SVMs ("drug SVM"). 
1
the number of random gene combinations with equal or lower 
misclassification rates or hinge loss scores compared to the drug SVMs, 
2
random selection of 15 gene expression values were compared to the 
paclitaxel SVM, 
3
random selection of 10 gene expression or copy number values were compared to the gemcitabine SVM. 
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expression data from the broad institute (www.broadinstitute.org/ccle/home; 
“CCLE_Expression_2012-09-29.res” and  
“CCLE_NP24.2009_profiling_2012.02.20.csv”). Lung and hematopoietic tissue types 
were chosen because they contained the highest number of cell lines with expression and 
paclitaxel GI50s. The final lung SVM contained 14 genes, and classified cell lines with 
72% accuracy (Appendix S5.20.1). The final hematopoietic SVM was composed of 8 
genes, and classified cell lines with 75% accuracy (Appendix S5.20.2). Four genes were 
present in all three (breast, lung and hematopoietic) cancer cell line SVMs (BMF, FGF2, 
TMEM243, and TWIST1), and 8 genes were eliminated from all of the SVMs (ABCB11, 
BBC3, CNGA3, CYP2C8, CYP3A4, NR1I2, TUBB4A, and TUBB4B; Appendix S5.20.3). 
MFAs using the Lung and Hematopoietic SVM gene sets do not show the same degree of 
segregation between resistant and sensitive cell lines as the breast SVM (Appendix 
S5.20.4 & S5.20.5). 
5.4 Discussion 
This paper describes the development of genomic signatures using support vector 
machines that can predict breast cancer tumour response to paclitaxel and gemcitabine.  
We used a biologically-driven approach to identify a meaningful group of genes whose 
expression levels and copy number may be useful in guiding selection of specific 
chemotherapy agents during patient treatment. Previous studies have derived associations 
between the genomic status of one or more genes and tumour response to certain 
therapies (5,51,62-65). Correlations between single gene expression and tumour 
resistance (32,62) do not take into account multiple mechanisms of resistance or assess 
interactions between multiple genes. ABC transporter overexpression has long been 
shown to confer resistance, but enzymatic or functional inhibition has not substantially 
improved patient response to chemotherapy (66).  
Multi-gene analytical approaches have previously been successful in deriving prognostic 
gene signatures for metastatic risk stratification (Oncotype DX
TM
, MammaPrint®), 
subtypes (PAM50), and efforts to predict chemotherapy resistance (67). Given the 
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complexity of genomic changes and the fundamental biological differences among the 
intrinsic subtypes of breast cancer (68,69), this approach has advantages over analysis of 
isolated genes. Reasonable gene signatures associated with breast cancer outcome can be 
obtained by chance alone (70), however our results show that such signatures are 
especially rare. Gene signatures derived without reference to the underlying mechanisms 
of chemotherapy response do not capture meaningful biological results (71).  
Our approach started with a focused biologically-relevant initial gene set, rather than 
taking a genome-wide approach. The derived signatures were demonstrated to 
significantly outperform random selected combinations of genes in prediction of 
sensitivity and resistance. The random gene sets may be statistical artifacts, as they were 
not enriched for any biological relevant pathways, and included expressed pseudogenes. 
The compositions of these other gene sets were distinct from the set used to derive the 
SVM and another 20-gene signature for taxane sensitivity (6).  
Our analysis highlights the importance of the expression of genes encoding microtubule-
associated proteins and apoptotic regulators in paclitaxel resistance (17,72,73). MAPT 
expression was significantly correlated with drug resistance, and both MAPT and MAP4 
were components of the optimized paclitaxel SVM gene set. In clustering analysis of both 
cell lines and patients, MAPT was differentially expressed between tumour clusters 
stratified by subtype and outcome (Figures 5.5 and 5.6). Our results confirm that 
apoptosis-related proteins, particularly BCL2L1, but also BCL2, BMF, and BIRC5, 
contribute to paclitaxel sensitivity (74). BCL2L1, BCL2 and BMF were found to be stable 
in breast cancer tumours, reinforcing the notion that alterations in stable genes contribute 
to drug resistance (14). Supplementary Table 5.9 describes genes analyzed in the context 
of their biological pathways and relevant literature. 
The gemcitabine metabolic pathway has been well characterized (75), however the 
critical genes have not been treated as an ensemble in conferring resistance (see 
Supplementary Table 5.10 for interpretation of the MFA results for all genes). The MFA 
analyses indicated gemcitabine genes predominately contribute to drug resistance through 
overexpression. For DCTD, however, underexpression is associated with increased 
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resistance in the MFA analysis. DCTD deficiency causes an imbalance in the dNTP pool 
(76), which affects control of DNA replication. DCTD is inhibited by dFdCTP (a 
gemcitabine metabolite) through a mechanism by which gemcitabine exhibits self-
potentiation (the reduction of competing natural metabolites) (77). Lower DCTD 
expression and as a consequence, activity would reduce gemcitabine self-potentiation by 
altering the dNTP pool. This state is related to drug resistance, which was noticeably 
lower in 4 cell lines with increased resistance (HCC1187, HCC1428, HCC202, and 
MDAMB134VI). Like DCTD, CDA also catalyzes the conversion of gemcitabine 
monophosphate to difluorodeoxyuridine monophosphate (Figure 5.2B), and accounts for 
90% of this conversion in the cell (37). However, drug resistance was associated with 
CDA overexpression. Likewise, the ribonucleotide reductase subunits RRM1 and RRM2B 
make significant contributions to the gemcitabine SVM. The RRM1-RRM2B complex is 
associated with mitochondrial genomic integrity (78) and RRM2B is necessary for 
nucleotide synthesis in DNA repair (79). Changes in RRM2B expression could be 
associated with mitochondrial dysfunction, or may result from loss of p53 expression, 
which usually induces RRM2B expression (80).  
The 11-gene paclitaxel SVM was able to classify FFPE patient samples we obtained and 
measured in our lab with similar accuracy to that of the cell lines. In addition, the same 
SVM model was able to predict complete pathological response on a second patient data 
set, with greater accuracy than the originally reported gene signature (5). The SVM 
performed particularly well for predicting drug-sensitive tumours with low or no minimal 
residual disease (Table 5.2). The SVM gene signature proved to be resilient as a 
diagnostic marker, as the performance was not compromised by the lack of expression 
data for 4 genes.  
Unlike paclitaxel, gemcitabine was not used to treat patients in the study by Hatzis et al. 
(2011) or other publically available data sets.  The SVM analysis on RNA expression and 
DNA copy number from the FFPE-derived tumour punches appeared to predict response 
more accurately when expression values were obtained for most of the genes in the SVM. 
Obtaining high quality gene expression measurements from FFPE samples was especially 
difficult from older tissue blocks (Appendix S5.17.2) as previously noted (81). 
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Consequently, the SVM analysis may be better suited for fresh-frozen tumour tissue or 
more sensitive gene expression analyses (such as mRNA sequencing). Missing data 
appeared to impact the gemcitabine SVM to a greater extent than the paclitaxel SVM, 
which may be due to the smaller number of gene measurements required for this SVM.  
Including gene expression subtype in the SVM did not improve the classification 
accuracy even though subtype is known to contribute to tumour biology (11). However, 
the two paclitaxel PAM50 genes (MAPT and BCL2) partially stratify the cell lines by 
subtype during unsupervised clustering (Figure 5.6). This is not the case in the 
gemcitabine gene set. In patient data, clustering by expression of the SVM genes also 
revealed statistically significant deterioration in outcome for low MAPT expressing 
luminal tumours (Appendix S5.19).  
Machine learning may be a fruitful approach in the selection of other chemotherapy 
agents. Translating our results to the assessment of human tumour samples (4) confirmed 
our gene signature's relevance to predicting chemoresistance by SVM. A limitation of our 
work is that both SVMs were not integrated because cell lines were only treated with 
individual drugs, so predicting whether patient response to these drug interactions will be 
synergistic or antagonistic is not currently possible. In addition, while point mutations are 
well known contributors to chemoresistance of other drugs, this approach – for either 
SVM training or testing - is not conducive for prediction of chemosensitivity given the 
sparse number of observations for these types of mutations.  
In cases without residual disease, the paclitaxel SVM was particularly effective in 
predicting which tumours would show complete pathological response. Docetaxel is 
prescribed somewhat interchangeably (5,82,83) and both paclitaxel and docetaxel act 
through similar biological pathways (84). However the performance of the paclitaxel 
SVM on patients treated with docetaxel was reduced. This SVM contains 8 paclitaxel 
resistance genes. Predictions of docetaxel sensitivity might be improved by rederiving a 
specific SVM using taxane pathway genes (84), and those known to be associated with 
resistance to doclitaxel (such as CYP1B1 (85,56), miR-141 or EIF4E (87), DKK3 (88), 
ABCB1 (89,90), BIRC5 (91), ABCC10 (92), miR-452 (93), and PAWR (94)). The 
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approach that we have introduced could aid in rational selection of other therapeutic 
regimens that evade or at least minimize the effects of chemoresistance.  
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Chapter 6  
6 Contextual Insights of Findings in this Dissertation 
It is estimated that in Canada, almost 24,000 deaths due to female breast cancer have 
been avoided since the mortality rate peaked in 1986 (1). Since then, the age-standardized 
mortality rate has fallen 43%, due to an increase in breast cancer screening and 
advancements in breast cancer treatment (1). The discoveries of the intrinsic subtypes of 
breast cancer and prognostic transcript profiles using gene expression microarrays have 
been instrumental in making breast cancer patient management to be more individualized. 
The ongoing advancements and reduction in cost of genomic technologies now provide 
even further opportunity to personalize breast cancer care. However, there are still gaps 
in genomic experiments, both in experimental design and interpretation of the data. In 
addition, there are currently no personalized genomic indicators for managing 
chemotherapy regimes that take into account drug resistance for breast cancer patients. 
The field has, and will, benefit from methods to improve upon current genomic analyses 
that detect cardinal abnormalities in driver genes, and predict metastatic progression and 
chemotherapy response. This thesis describes improvements for data quality and analysis 
for existing genomic technologies, with the aim of detecting and interpreting genomic 
abnormalities relevant to breast cancer metastasis and chemotherapy resistance. 
6.1 Current limitations of genomic technology 
Genome-wide assays, such as microarrays and next generation sequencing, have greatly 
improved our understanding of both normal and tumour genomes. The large amount of 
data generated from these experiments, however, creates new sets of challenges to ensure 
reproducible measurements, robust analyses, and meaningful interpretations. 
The issue of low reproducibility, both between and within technology platforms, has not 
been fully resolved in genome-wide analyses (2-5) (Section 2.1 describes the variability 
observed in aCGH experiments in further detail). This is not surprising, because FISH, 
microarrays, and next generation sequencing all rely on the same stochastic events: 
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nucleic acid extraction, fragmentation, labeling, and hybridization. A recent study 
assessing replicate next generation sequencing experiments demonstrated concordant 
rates in single nucleotide variant calling ranged between 54-76% (4). In addition, batch 
effects occurring from laboratory-specific conditions can create major problems if the 
batch effect results in incorrect conclusions (6). Improving the reproducibility of these 
technologies has usually involved increasing the number of measurements obtained in a 
given experiment, whether through expanding the number of probes on a single 
microarray slide, or increasing the number of reads obtained from a sequencing 
experiment. However, genomic experiments are subject to both technical (i.e. 
experimental procedure) and biological (i.e. genetic) variation (7). Tumour heterogeneity 
makes the analysis of breast cancer particularly complicated (8). For this reason, single-
cell genomic analyses (9) have been applied to cancer research (10,11). This thesis did 
not address biological variation to the same extent as technical variation, although it is 
nevertheless an extremely important aspect of tumour biology research. 
With the abundance of different technology platforms, generated data, and computer 
software programs available, establishing robust genomic analysis pipelines remains 
challenging. This is true for both microarray and next generation sequencing analyses of 
DNA or RNA. For clinical applications, working groups, such as the American College 
of Medical Genetics (ACMG), have developed thorough guidelines for such analyses 
(12-14). For example, recommendations involving next generation sequencing for 
primary (production of sequence reads and assignment of base quality scores (12,15)), 
and secondary/tertiary (variant calling and interpretation (14,16)) analyses have been well 
documented. However, the main objective for clinical analysis (and the guidelines 
created) is to accurately report genomic variants that are likely relevant to a patient’s 
diagnosis or health. This differs from research groups, who can tolerate greater difficulty 
interpreting the data and variants of unknown significance in exchange for more 
comprehensive results. There are numerous programs that can be used to discover and 
interpret data (Table 1.3), and this list is steadily increasing. Regardless, there is still an 
underrepresentation of non-coding variants in published genomic studies, such as in-
depth splicing mutation analyses outlined in this thesis (Chapters 3 and 4). The 
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emergence of new software to predict or interpret non-coding variants (17-19) indicates 
the field is still working towards filling these gaps in current genomic analyses. 
Interpreting DNA variants, how they affect cellular functions, and whether they are 
causing a certain phenoytype is still extremely difficult. Recent evidence presented in this 
thesis (Chapter 4) and others (20-24) show there is no single cause or set of abnormalities 
that account for these phenotypes. It is well thought that the interpretation of sequencing 
data from a full genome is now a much larger task than generating the data itself (25). 
Large data repositories, such as the International HapMap Project (26) and dbSNP (27), 
begin to allow us to understand which DNA variants are common among the population, 
and which variants are rare and potentially pathogenic. However, given the size of the 
human genome, the majority of variants observed in a given sample will be novel. 
Programs like SIFT (28) and PolyPhen (29) are able to provide some indication as to 
whether a mutation will be damaging to the protein’s function, but have extremely low 
specificity (30). The genomic field will still greatly benefit from new programs to 
validate the predicted effects of a mutation on a genome-wide scale.  
6.2 Advances in genomic technology described in this 
thesis 
6.2.1 Fluorescence in-situ hybridization 
FISH probes typically span a large genomic region along the chromosome, well beyond 
the length of a single gene. They have been very useful in delineating large pathogenic 
chromosomal aberrations, and have played an instrumental role in early gene and disease 
discovery. With the introduction of chromosomal microarrays, however, our ability to 
detect much smaller rearrangements has improved. In many cases, clinically significant 
findings from these high-resolution microarrays will require assays to confirm the 
suspected copy number change. Using ab initio-derived single copy intervals from the 
human genome sequence, high-resolution FISH probes were designed and validated for 
probes of small cancer genes. These FISH probes are small, usually less than 4 kb, and 
the exact genomic location of the probes is known. Further, we have automated the 
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design process, and have developed >450,000 primer pairs covering regions overlapping 
genes that could be developed into single copy probes. The advantages of this technology 
are that it can assess parts of genes and at small single copy regions that are embedded in 
highly repetitive regions. As with most methods involving nucleic acid hybridization, 
developing scFISH probes directly in highly conserved repetitive regions is not possible. 
However, scFISH probes have been used to delineate breakpoints within segmental 
duplicons (31) and telomeric regions (32). Although the scFISH probes are reproducible, 
the fluorescent signal is not as intense as traditional BAC probes, which recognize a 
much larger target on the chromosome. Developing probes with increased signal 
intensities could allow for easier analysis of interphase cells, as the ab initio probes 
developed in this thesis were only validated on metaphase chromosomes. 
Although there are cases where genome-wide analysis is more suitable, FISH is a reliable 
and inexpensive method to assess specific genomic regions. Future work could include 
validating probes for specific actionable or clinically significant genomic alterations in 
oncology (Table 6.1), which would require the development of scFISH on solid tumour 
FFPE samples. scFISH probes are especially useful for cancer types in which 
chromosomal microarrays are not routinely used or effective (i.e. balanced translocations 
(32)). For example, it is now evident that tumours with HER2 amplification, in addition 
to breast cancer for which it was originally developed, benefit from HER2 targeted 
therapies (such as trastuzumab) (33). The ERBB2/HER2 scFISH probe could be used as 
an inexpensive method to determine whether amplification is present in a tumour. 
6.2.2 Chromosomal Microarrays 
Chromosomal microarrays have been instrumental in advancing the evaluation of patients 
with constitutional abnormalities, and are now accepted as a first tier diagnostic test for 
patients with developmental delay, intellectual disability, congenital anomalies, and 
autism (34). However, using genome-wide approaches to detect copy number changes 
raises new limitations and regulatory challenges for clinical testing. There are still 
difficulties associated with accurately measuring copy number gains or losses, and the  
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Table 6.1 Examples of clinically significant genomic alterations in cancer testable by FISH. 
Gene Cancer type Aberration Clinical significance 
APC gastric  Decreased copy 
number/deletion 
Significantly associated with lymph node 
invasion and metastasis
35
 
HER2 breast, gastric  Gene amplification Higher chance of success for treatment 
with HER2 monoclonal antibody (ie. 
trastuzumab)
33,36
 
EGFR colorectal Increased copy number Higher chance of success for treatment 
with antiEGFR monocolonal antibody (ie. 
cetuximab and panitumumab)
37
 
EGFR non-small-cell 
lung 
Increased copy number Higher chance of success for treatment 
with gefitinib
38
 
MET squamous cell 
carcinoma 
(lung) 
Increased copy number Poor prognosis (shorter survival)
39
 
E2F3 Urothelial 
carcinoma 
Increased copy number Higher frequency in metastasis
40
 
ROS1 
or ALK 
non-small-cell 
lung 
rearrangement/gene 
fusion 
Treatment with crizotinib
41,42
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subsequent interpretation of the pathogenicity of any findings. The ACMG has approved 
a set of Standards and Guidelines for genomic copy number testing using microarrays 
(13,43,44). Microarray probes are suggested to be placed throughout the genome at 
regular intervals, to enable the detection of copy number changes of 400 kb or larger with 
99% sensitivity. It is also recommended that there be an emphasis on probes targeting 
haploinsufficient genes with known phenotypic abnormalities (43), or regions known to 
be associated with unbalanced genomic alterations in cancer (44). In addition, it is 
desirable to be able to detect small rearrangements with high confidence and low false 
positive rates, to improve diagnosis of small clinically significant copy number variants 
(45). 
Ab initio single copy intervals were used to design a genomic oligonucleotide microarray 
that demonstrated reduced noise in signal intensities compared to a common commercial 
platform. We suggest that genomic placement of oligonucleotides relative to repetitive 
elements can alter their susceptibility to cross hybridization, which increases variability 
in probe signal intensity. Historically, improved accuracy and resolution of commercial 
microarray platforms has been achieved by increasing the density of probes on the array 
(46). This thesis describes an alternative solution to overcoming noise: including a 
reduced set of oligonucleotides that demonstrate high reproducibility in signal intensity. 
This may offer a cost-effective solution for high throughput microarray testing by 
increasing the number of samples that can be processed per slide (through increased 
multiplexing with the same number of total probes). 
These findings are not limited to microarray analysis, but rather apply to any nucleic acid 
hybridization experiment using genomic DNA. In next generation sequencing analysis, 
solution hybrid selection is becoming a useful method to enrich for targeted genomic 
sequences (47). This approach uses biotinylated RNA ‘bait’ that is hybridized to a 
sheared DNA sample, and then purified using streptavidin-coated beads to enrich for the 
target sequence. This thesis describes the application of ab initio sequences to design the 
RNA sequences (bait) used for DNA capture and subsequent sequencing (Appendix 
S5.5.3). Where possible, sequences were selected to be distant from conserved repetitive 
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sequences to minimize cross-hybridization and wasted coverage on unintended 
sequences. In addition, capture probes were designed in divergent repetitive elements to 
allow for greater coverage in some regions that would be excluded using repeat-masking 
(48). Capture probes resulted in enrichment of the targeted 45 gene sequences, with 
sufficient coverage to allow for multiplexing of 48 samples per sequencing experiment. 
Clinics or research groups with specific gene panels of interest could use this method as a 
cost-effective alternative to whole exome sequencing. 
6.2.3 Next Generation Sequencing 
With decreasing costs and the development of more user-friendly analysis software, next 
generation sequencing is becoming mainstream in both research and clinical settings. 
During mutation analyses, and especially when clinical decisions rely on the results of a 
study, it is important that we leverage the data to the best of our ability to obtain the most 
complete and accurate results. In this thesis, the Shannon Human Splicing Pipeline (49) 
was used to improve splicing mutation detection in 445 breast cancer tumours. Further, a 
software program was developed and described, named Veridical (50), to employ RNA 
sequencing data for validation of the predicted mutations’ affect on mRNA splicing. 
Veridical was the first published genome-wide tool that is able to directly link DNA 
mutations to aberrant mRNA splicing. Before the development of Veridical, validating 
splicing mutation could be fairly laborious. RT-PCR is the most common method used to 
confirm that a splicing mutation will cause abnormal splicing, either through measuring 
patient mRNA or a transfected cell line that expresses the mutation. Although this 
method is reliable for individual mutations, it would be difficult and time consuming to 
apply this technique to all predicted splicing mutations in a genome. For example, 5,206 
splicing mutations were detected in 442 tumours (Chapter 4). Assuming patient mRNA is 
attainable, a very conservative estimate of 4-6 hours of hands-on time would be required 
to validate each mutation (to develop primers, set up and run the RT-PCR reaction, and 
analyze the results). This would amount to at least 2,600 8-hour workdays, or ~6 days per 
tumour to validate these results using a traditional approach. 
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In addition to its genome-wide capabilities, Veridical can compare the mutated sample to 
normal exome sequences or other controls to determine the corresponding frequency of 
the aberrant splicing pattern in samples that do not contain the variant of interest. 
Veridical is able to achieve high statistical power through comparing hundreds of 
controls, the extent of which would not be reasonable for a single-variant wet lab 
experiment. One additional benefit is that the RNA-Seq controls do not need to be 
generated by the group performing the study, due to the availability of data from online 
resources such as TCGA (https://tcga-data.nci.nih.gov/tcga/) and the International Cancer 
Genome Consortium (https://icgc.org). 
Other software programs with similar objectives to Veridical have also been recently 
developed, including PVAAS (51) and SNPlice (52). PVAAS uses “spliced reads” (reads 
spanning two exons) from RNA sequencing data, and identifies non-canonical splicing, 
defined as splicing where the 5’ and/or 3’ splice site(s) are not known. It works in the 
reverse order of Veridical, identifying variants that are associated with the aberrant 
splicing after the non-canonical splicing reads are discovered. SNPlice finds RNA 
sequencing reads that contain a single nucleotide variant, and span into the intronic 
sequence. It highlights variants that preferentially occur in intron-containing molecules 
versus reads that are properly spliced, to implicate the variant in abnormal splicing. 
The recent development of both PVAAS and SNPlice highlight the importance of 
identifying splicing mutations that cause aberrant splicing. They are potentially powerful 
tools that are especially useful in the absence of DNA sequencing data. However, they 
fail to address some key considerations that were incorporated into Veridical. Both 
approaches rely on associations between a variant and a splice form to potentially 
implicate the variant in abnormal splicing. There are two major flaws to this approach. 
First, the authors did not work with complete gene or genome data, and therefore all 
possible splicing variants (especially those deep in an intron) would not be present in the 
analysis. Because the true causal variant may not be detected or known, some atypical 
splicing transcripts may be miscalled as natural alternative splicing events. Second, a 
truly causal variant may be in linkage disequilibrium with the inferred variant, and 
therefore the cause of abnormal splicing is not explained correctly. Further, if two 
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variants reside in the same region, the programs may have difficulty determining which 
variant is affecting splicing. While both of these are serious drawbacks and the first is 
more likely a result of the authors’ lack of complete genome or gene data, which means 
that their inferences were based on a minor fraction of genome variation (53). 
Veridical differs in that it is hypothesis-driven, looking for aberrant splicing at the 
specific location of predicted splicing mutations rather than making post-hoc associations 
of variants to abnormal splicing, as in PVAAS and SNPlice. In addition, Veridical is able 
to perform robust statistical analyses against large sets of controls. This is important 
because it avoids mis-identifying naturally occurring abnormal splicing (i.e. the GATA3 
cryptic splicing found in all controls in Appendix S2.2.3) or intron retention (i.e. the 
abundance of intron-spanning reads in both breast cancer samples and normal controls 
demonstrated in Appendix S2.2.4) as abnormal. 
Veridical confirmed 19% of all splicing mutation predictions in a large subset of breast 
cancer tumours. That leaves the question, however, of why the other 81% of variants 
were not confirmed. The parameters outputted from the Shannon Pipeline (i.e. initial, 
final, or change in the splice site strength, distance to or strength of the nearest natural 
site) showed no obvious indications of whether the variant would be validated by RNA-
Seq. This implies that it is not due to some variable of the algorithm underlying the 
Shannon Pipeline (which uses information theory), but rather related to the methods of 
validation. 
The first of these issues is the fact that genes were not filtered based on breast tissue 
expression, so many of the genes harboring splicing mutations may be in genes not that 
are not expressed (and show minimal read coverage in the RNA-Seq data). For example, 
a donor mutation at a natural site in ACSBG1 with a ΔRi of -18.64 bits (inactivating the 
site) was not validated even though there was a dramatic decrease in the strength of the 
site. The GTEx (54) expression value, however, suggests this gene has very low 
expression in breast (mammary) tissue (Figure 6.1). Second, variants were only called 
and grouped within the tumour samples, so there was no information as to whether the 
normal breast samples contained the variant. If enough of the normal samples contained  
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Figure 6.1 Screenshot from GTEx Portal – ACSBG1 Gene View. Measured gene expression 
values of ACSBG1 for different tissue types are listed along the x-axis. The vertical red bar 
indicates the location of the breast (mammary) tissue, which is filled in light blue. The horizontal 
red bar indicates the log(expression) value measured from 66 samples. Data Source: GTEx 
Analysis Release V4 (dbGaP Accession phs000424.v4.p1). 
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the variant, the abnormal splicing would not have enough statistical power to be observed 
as significant based on the p-value cutoffs applied. This situation is less likely, because 
common variants (in dbSNP present in more than 1% of the population) were filtered out 
of the analysis. Third, although from the same tumour, the DNA- and RNA-Seq data may 
represent genotypically-different cell populations due to tumour heterogeneity. Finally, 
some of the splicing variants may have been false positives (i.e. an artifact of the 
sequencing) or there was simply no evidence of aberrant splicing. Standard quality filters 
were used during variant calling, although this only reduces and does not fully eliminate 
false positives. In addition, predicting splicing mutations using information theory has 
been shown to have a sensitivity of 85% (18), so a minority of the predicted variants may 
not affect mRNA splicing. 
In this thesis, the Shannon Pipeline and Veridical were applied to breast cancer tumours. 
Future studies could apply similar analyses (from Chapters 3 and 4) to other types of 
cancer using newly generated or previously published data (from groups like the Cancer 
Genome Atlas or International Cancer Genome Consortium). This would be particularly 
valuable in both heritable and somatic cancers where there has been either a lack of 
causal variants identified in a large portion of cases or where mutations in specific genes 
lead to clinical decisions. For example, our laboratory is applying splicing (among other 
non-coding) mutation detection to families with a strong history of breast and/or ovarian 
cancer that have tested negative for BRCA1/2 actionable mutations. BRCA testing 
primarily involves Sanger sequencing (55) of exons to assess mutations in coding 
regions, and so there are likely protein-damaging splicing mutations that are missed with 
standard techniques used in the clinic. 
Efforts are currently underway in our laboratory to expand Veridical to incorporate 
additional types of analyses. For example, it could be used to detect whether any type of 
mutation (splicing or coding) is increasing nonsense-mediated decay (NMD). Transcript 
levels of both alleles could be detected, and the proportion of the transcript with versus 
without the mutation could indicate whether the mutated mRNA is susceptible to NMD. 
A similar type of analysis with different objectives (i.e. not assessing NMD) 
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comprehensively mapped genotype relationships with expression of specific transcripts 
using expression quantitative trait loci (eQTLs) in over 40 different tissue types (54,56). 
In addition to allele-specific expression, the RNA-Seq read coverage in the 5’ end of the 
transcript (low) versus the 3’ end of a transcript (high) may also indicate that NMD is 
occurring. Exon-exon junction protein complexes (EJC) are thought to be removed by the 
ribosome during the first round of protein translation. When there is a premature stop 
codon (and the ribosome is released), the 3’ EJCs are not removed, and their presence on 
the transcript triggers the NMD process. Consequently, mutations in the last exon are 
often missed by NMD because they do not have any remaining EJCs. Veridical could 
also be applied to any other read-counting based analysis, such as detecting or 
quantifying non-coding or micro-RNAs in a disease sample or tissue type compared to 
controls.  
6.3 Implications for breast cancer treatment 
6.3.1 DNA mutations in metastasis 
This thesis demonstrates that there are elevated numbers of NCAM pathway mutations in 
lymph node positive tumours. Lymph node involvement compared to tumour size can be 
a marker of the metastatic potential of a tumour independent of the tumour subtype (57). 
Therefore, NCAM pathway mutations may be an indicator for tumours most likely to 
metastasize. 
Cancer has long been proposed as a multistage process, both in tumour development 
(58,59) and advancement of the disease (60). Interestingly, the percent of tumours with 
NCAM pathway mutations drops off in later (stage IV) tumours. It is possible that 
NCAM pathway mutations increase metastatic potential in early tumour development, 
but are not clonally selected for once the tumour has spread. This would explain why 
these mutations are not present at high levels in advanced disease. If the NCAM pathway 
mutations were simply passenger mutations in breast cancer, it has been proposed that 
these genes would be low expressing (61) and late replicating (62-64), which have been 
associated with higher background mutation rates (65). The stage of replication and 
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expression levels were compared between NCAM pathway genes and genes significantly 
mutated in breast cancer, which were cited to be likely driver genes (20-24). We do not 
find any differences in both replication stage and expression levels between NCAM 
pathway and other significantly mutated genes (Figure 6.2), which supports excluding the 
possibility that NCAM pathway mutations are the result of bystander effects. The 
contributions of these defects to tumour metastasis would have to be demonstrated by 
functional studies (see below). 
A high proportion of the breast cancer tumours assessed harbored extracellular matrix 
(ECM) and collagen mutations, although these mutations were found at similar levels in 
all tumours, regardless of their lymph node status. Clonal frequency was previously 
evaluated in a large set of breast tumours to segregate mutations as either early or later 
events, which delineated that mutations appear to be acquired later in tumour 
development in genes that play a role in cytoskeletal pathways, such as myosins, 
laminins, collagens, and integrins (21). In addition, the differential expression of ECM 
components has been used to classify breast cancer tumours into groups related to patient 
prognosis and tumour metastatic potential (66,67). These and other stromal signatures 
can have higher predictive power when combined with current pathogenic features 
(receptor status, tumour grade) (68). The ECM of tumours has been cited as a potential 
target for anti-cancer therapy, although it is challenging to identify which specific ECM 
component may serve as an effective therapeutic target (69). 
Alternative ways to identify tumours that are likely to migrate to other tissues, beyond 
prognostic gene expression profiling, would be beneficial for many patients. Further 
work could be completed to confirm the hypothesis that NCAM pathway mutations are 
indicators for tumour migration. There are now effective, inexpensive ways to test a cell 
line’s metastatic potential. For example, chick chorioallantonic membrane (CAM) assays 
in conjunction with multiple fluorescent imaging is a useful model to study angiogenesis, 
invasion, and metastasis (70-72). The assay involves measuring the level of intravasation 
and growth achieved by inoculated xenogenic tumour cells within the CAM of a chick 
embryo. Splicing mutations in NCAM pathway genes that were observed in this thesis 
(Section 4.3.7) could be introduced into breast cancer cell lines, and the cell line’s ability  
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A) 
B) 
 
Figure 6.2 Replicating stage and expression of NCAM pathway and significantly mutated 
genes. A) Replicating stage was determined using the MCF7 cell line data from the UCSC 
Genome Browser track “Replication Timing by Repli-seq from ENCODE/University of 
Washington” (73,74). In cases where a gene was replicated during two stages equally, the 
earliest stage was used. Gene sets used can be found in Appendix S4.3.3 (significantly mutated 
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genes), and Appendix S4.3.8 (NCAM pathway genes). B) RPKM gene expression values were 
obtained for each gene (average of 66 normal breast mammary tissue samples) from the GTEx 
portal (http://www.gtexportal.org/home/). The log(RPKM) was plotted against replication stage for 
each gene, as in described in A. 
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to migrate through the CAM could indicate the affect of that mutation on a tumour 
metastatic potential. This type of study could also potentially identify specific genes 
within NCAM pathways that contribute the greatest to lymph node invasiveness. Other 
cell migration and metastatic potential in vitro assays that could be applied to study 
NCAM pathway mutations include scratch-wound assays (75) and Boyden chamber 
assays (76). 
Our laboratory has recently proposed to carry out a prospective trial with basal-like and 
HER2-enriched breast cancer patients (Section 4.3.8 and Appendix S2.2.5) that would 
involve sequencing NCAM pathway genes at the point of diagnosis, surgery and/or 
relapse. Patients could be followed to determine whether those tumours with NCAM 
pathway mutations were more invasive than those that lacked mutations. A prospective 
trial would be required due to the fact that some patients with early stage tumours that 
contain NCAM mutations at initial diagnosis may have longer latency periods to 
metastasis. In addition, tumour dormancy (77,78) may significantly increase the time to 
distant metastasis, but the cell migration could still be due to NCAM pathway mutations 
in the primary tumour. Sequencing tumours that have already metastasized and have 
undergone further clonal selection will not necessarily harbor the same set of mutations 
as the primary tumour (21). This study would likely require several years, however would 
be non-invasive because it would not change the course of treatment for current breast 
cancer patients, meaning there would be limited downsides for patients enrolling in the 
study. 
6.3.2 Predicting tumour sensitivity to paclitaxel and gemcitabine 
Chemotherapy is widely used in breast cancer treatment, although selection of which 
specific agent to use is qualitative and variable due to patient-related factors. Developing 
robust genomic signatures to guide selection of chemotherapy agents would be 
particularly useful for triple negative (TNBC) and advanced breast cancer. In the case of 
TNBC, there are limited options for therapeutic treatment beyond conventional 
chemotherapy (79). TNBC (most commonly basal-like and Claudin-low subtypes) are 
usually aggressive and are more likely to become metastatic, however, women with 
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TNBC who have a complete pathological response to treatment have excellent outcomes 
(79). In advanced breast cancer, chemotherapy is used for palliative care and to improve 
quality of life given that the chance of survival and cure are low (80). Usually, a specific 
chemotherapy drug, or class of drugs, is only effective until the tumour develops 
resistance to the treatment. Therefore, it is advantageous to be able to identify those 
patients who would benefit from immediate treatment with cytotoxic therapies, and those 
for which surgery and radiation may be sufficient at the time of initial diagnosis. In 
addition, selecting the chemotherapy agent that is most likely to be effective early on may 
avoid periods of ineffective treatment and the corresponding unnecessary toxicity and 
side effects. 
This thesis describes a novel approach that used machine learning to generate models that 
can predict breast cancer tumour sensitivity to paclitaxel and gemcitabine. Gene selection 
was driven by the biological understanding of these drugs, rather than employing a 
genome-wide approach that risks identifying un-meaningful signatures correlating to 
tumour response by chance (81,82). A reduced 11-gene signature for paclitaxel was able 
to predict tumour response in a set of formalin-fixed paraffin-embedded breast cancer 
tissue samples with similar accuracy to the cell line data. A reduced 9-gene signature was 
able to predict tumour response to gemcitabine in samples where at least 4 of the 6 gene 
expression measurements were obtained, however, it performed poorly on those with 
limited data. This result highlights the difficulties in working with FFPE tissue samples, 
where there can be variable and low preservation of nucleic acids (83,84). Measuring the 
FFPE samples using qRT-PCR was unsuccessful for some genes due to low expression 
and/or the differences in amplifiable template between samples. 
The reduced 11-gene expression signature for paclitaxel was particularly effective in 
predicting patients with low residual cancer burden that will be have a complete 
pathological response to paclitaxel. It was not as effective at predicting tumours likely to 
show resistance, especially in advanced disease. This is not necessarily surprising, as 
primary and metastatic breast cancer tumours, both within and between lesions, are made 
up of multiple genetically diverse subpopulations of cancer cells (85). Recent data 
highlight that differences, in the case of both genomic aberrations and mutation 
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frequencies, have been observed between primary tumours and subsequent metastatic 
lesions (86,87). In multifocal breast cancer, it was found that the genetic differences of 
the lesions in each patient were significantly correlated with the physical differences 
between the tumours (88). Therefore, the gene signatures developed may only be relevant 
to a limited subset of the tumour populations related to primary breast cancer tumours, 
but not those of aggressive clonal isolates. In addition, it is likely that the SVM may only 
predict response to the specific lesion measured, and not to genetically differentiated 
lesions or metastases.  
Recently, a 20-gene signature (“TAXSig”) was developed that predicts chemoresistance 
to taxane-based therapies in breast cancer patients (89). This study included, but was not 
limited to, paclitaxel. There was no direct overlap in genes included in the TAXSig 
signature and the genes included in our SVM model, or randomly generated gene sets 
that had low misclassification rates from Figure 5.7. However, a pathway analysis using 
Reactome (90) revealed slight overlap in biological pathways between FGFR1 from 
TAXSig, and a subset of the paclitaxel SVM genes. The 35 genes from both signatures 
are enriched for the innate immune system (p=0.034), as 7 genes (FGF2, BCL2, BCL2L1, 
TLR6, NFKB2, FN1 from the SVM and FGFR1 from TAXSig) are part of the 1,031 
genes in this pathway. In addition, FGFR1 (from TAXSig) interacts with FGF2 and FN1 
in at least 53 and 31 additional specific signaling pathways, respectively. Although there 
is some overlap in biological pathways of the TAXSig and paclitaxel SVM gene sets, the 
majority of genes are unrelated. The taxane (TAXSig) resistance signature may be 
capturing a different mechanism (or mechanisms) of resistance, which may at least 
partially explain why chemosensitivity is not predicted with greater accuracy. The 
paclitaxel SVM was not predictive of docetaxel GI50s, further supporting the notion that 
they are unrelated processes. The paclitaxel SVM derived in this thesis was reliable in 
predicting tumours that will respond to the treatment, but nevertheless the phenotypes of 
patients or cell lines could not all be accurately predicted. One possible explanation might 
be that some of the features sensitizing a tumour to paclitaxel are independent from those 
leading to resistance. While we are not aware of any evidence that this occurs, such a 
hypothesis could explain why we are unable to predict the phenotypes of all cell lines and 
patients accurately. 
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Although previous studies have developed gene signatures to predict paclitaxel (or 
taxane) sensitivity, there has been limited work in using gene expression signatures to 
predict breast cancer sensitivity to gemcitabine. One study found that polymorphisms in 
SLC28A3, SLC29A1, and RRM1 can predict metastatic breast cancer sensitivity to 
combination therapy with paclitaxel and gemcitabine (91). RRM1 was included in the 
paclitaxel SVM, and SLC28A3 mutations and GI50s were strongly related in the set of 44 
cell lines assessed using a multiple factor analysis. A study assessing copy number 
changes in RRM1 and RRM2B found that copy number aberrations of these genes were 
present in breast cancer tumours, but were not related to clinical outcome of patients 
treated with gemcitabine (92). During feature selection (used to generate the SVM), we 
found that copy number of both RRM1 and RRM2B had no impact on the model’s ability 
to predict gemcitabine sensitivity (Figure 5.3). Given that there is a need for models to 
predict gemcitabine, further work on large patient sets could be completed to validate or 
improve upon the gemcitabine SVM derived in this thesis. Although the SVM did not 
perform as well on a small number of FFPE tumour samples as it did in the cell lines, 
obtaining reliable gene expression measurements from these tumour blocks was 
challenging. Attempting a similar analysis on fresh-frozen tumours may provide further 
insight into the utility of the gemcitabine SVM in patient care. 
Similar methods may be effective in generating models for other chemotherapy agents for 
which the biological mechanism of action is known. For example, pathways involved in 
the thiopurine class of drugs (including azathioprine, mercaptopurine, and 6-thioguanine) 
mechanisms of action and metabolism are well documented (93). As with gemcitabine, 
multiple enzymes (for example, HPRT1, IMPDH1, GMPs, and TPMT) are required to 
convert the drugs into their active metabolites before they are incorporated into RNA and 
DNA to exert cytotoxicity. Similarly, genes involved in the pathway (i.e. NQO1, NOS3, 
XDH, TOP2A, NFKB1) and transport (i.e. ABCC1, ABCB1, RALBP1, SLC22A16) of 
doxorubicin have also been previously described (94). These gene sets are strong 
candidates for use in the development of SVMs to predict chemosensitivity to the 
respective drugs (using their gene expression and/or copy number values), as the genes 
playing a role in drug disposition within the tumour itself. Therefore, it is reasonable to 
expect that changes in expression or copy number of the genes identified may predict the 
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effectiveness of thiopurine, doxorubicin, or other drugs with similar information. 
Conversely, tamoxifen metabolism largely takes place in the liver by multiple genes from 
the cytochrome P450 (CYP) and the UDP glucuronosyltransferases (UGT) families (95), 
and the exact downstream mechanism of action is not well documented. Measuring breast 
tumour expression or copy number of the CYP and UGT genes would not be informative, 
because this is not where the metabolism occurs for these drugs. We did not find the 
cytochrome P450 (CYP) genes to be informative for paclitaxel or gemcitabine, as they 
were not included in the final SVMs. Therefore, the approach described in this thesis may 
not be suitable for tamoxifen or other drugs with limited knowledge beyond the fact that 
their metabolism takes place in the liver. Eight genes were included in the final paclitaxel 
SVM that were not implicated in paclitaxel’s disposition, but were previously implicated 
in resistance (FGF2, TMEM243, BIRC5, CSAG2, FN1, NFKB2, TLR6, TWIST1). These 
genes improved the accuracy of the SVM, indicating ancillary data would be useful in 
generating chemosensitivity models for other drugs (Figure 6.3). However, there were no 
additional genes in the gemcitabine analysis other than those directly in the drug 
pathway, indicating that they are not necessary for developing a successful model. 
6.4 Thesis impact on personalized medicine in breast 
cancer  
There are still a number of challenges that researchers and healthcare providers face 
regarding data analysis, management, and interpretation. This thesis describes 
improvements upon the techniques that are increasingly used for clinical care. Although 
this thesis focuses on leveraging genomic technologies to advance our knowledge in 
breast cancer, all of the techniques and methods described could be applied to other 
disease types. 
There are many cases where point mutations in specific genes are relevant for cancer 
patient management in regard to predicting outcome or response to treatment. For 
example, Afatinib was found to be active in non-small-cell lung cancer in patients 
harboring uncommon EGFR mutations (96). The application of the Shannon Pipeline and 
Veridical for splicing mutation prediction and validation in the analysis of any tumour 
  
217 
type can expand current efforts to detect potentially damaging and relevant mutations. In 
breast cancer, this thesis found that a large subset of synonymous mutations identified by 
the TCGA to actually affect mRNA splicing. Synonymous mutations are usually not 
considered in downstream analyses (beyond variant detection), which would leave some 
potentially relevant or crucial mutations unreported due to a misidentification of their true 
effect on the protein product. 
Machine learning is proving to be a robust tool in interpreting features and making 
predictions using large biological datasets (97,98). The biologically-driven machine 
learning approach described in this thesis could be employed for additional cancer types 
that are treated with generic chemotherapy agents. While there is no single recipe that 
will assure successful prediction of chemotherapy response, there are a number of key 
considerations that need to be accounted for in applying this approach. Specifically: 
1) The quality of the tissues analyzed or data obtained should be verified before their 
application to this type of study. The availability of large genomic data sets with drug 
response information for a specific type of cancer are crucial for training and testing the 
predictive SVMs. Resources such as the Gene Expression Omnibus have greatly 
improved access to this type of data, which are usually made available from previous 
studies. However, this thesis and other studies (84) have described the level of 
degradation of nucleic acids in FFPE samples can be variable between tumours, and 
should be considered when conducting any study; 
2) The training data needs to be representative of the tumour type as a whole, and contain 
roughly equal numbers of sensitive and resistant samples. In this thesis, we demonstrated 
that cell lines are both a practical and minimally invasive tool; one that can be used to 
generate gene signatures. However, SVMs perform the best when trained on equal (or 
close to equal) numbers of data sets in each of the binary classes (i.e. resistant or 
sensitive). We found that using 44-49 cell lines was sufficient, but when reducing this set 
by half, it was not adequate for the creation of robust models (data not shown). In 
addition, the dynamic ranges of GI50 observations did not appear to greatly affect SVM 
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performance, as paclitaxel GI50s were between 6.5-8.5, and gemcitabine GI50s were 
between 2.5-9. 
3) Any SVM model generated (including the ones described in this thesis) would need to 
be validated on multiple independent patient data sets before they could be applied to 
patient treatment, where the outcome of the SVM may alter the course of therapy. For 
any biomarker, the FDA (or Health Canada) requires extensive analytical validation, 
clinical validation, and clinical qualification before it is approved to be used in the clinic 
(99). This level of validation was beyond the scope of this thesis, although we apply the 
paclitaxel derived SVMs to two different patient datasets. Ultimately, how these type of 
signatures perform in other patient groups would need to be determined before clinical 
adoption (as has been done for commercial diagnostic/prognostic assays (100,101). 
4) SVM models would likely need to be derived for each tumour type separately. As 
described in Section 5.3.6, the genes distinguishing tissue specific expression classes 
dominated those associated with chemotherapy resistance in previous studies employing 
machine learning (102), but was not true for regression models (103). For example, tissue 
specific expression patterns were dominant when using genome-wide data with the 
random forest method (unsupervised machine learning) used by Daemen et al (2013). A 
benefit to the biologically-driven approach is that SVMs have a greater likelihood of 
success when using a limited number of attributes (i.e. gene parameters). 
5) The genes selected should be relevant to chemotherapy response, and play a role in 
drug disposition within the tumour itself (as outlined in paragraph 5 of section 6.3.2). 
Pathways and genes that contribute to resistance in other less well-studied drugs may not 
be known, and the lack of these features in the SVM would lower prediction accuracy. 
There may be additional genes or biological functions involved in paclitaxel and/or 
gemcitabine mechanism of action that are not yet known, which may explain why the 
SVM is not able to predict drug sensitivity in 15-20% of cases. Alternatively, the these 
cases may habour point mutations in the present set of genes, or others, that are leading to 
chemosensitivity, which are not included in the current SVM models. 
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6) Unrelated prognostic indicators do not appear to be synergistic with our derived gene 
signatures. In section 5.3.5, this thesis demonstrated that gene signatures using randomly 
selected expression values (from 23,030 genes) that are able to predict cell line response 
to paclitaxel were not accurate in predicting response in a patient data set. Many of the 
genes included in these random signatures were pseudogenes and genes unrelated to the 
biology of a tumour or paclitaxel metabolism, which is an indication that the signatures 
derived from them could be statistical artifacts. 
The only random signature, among the 10,000 that were derived, that was able to predict 
patient sensitivity in an external patient data set contained WWP1, which has been 
previously identified as a prognostic indicator for breast cancer (104). Adding WWP1 to 
the paclitaxel SVM, however, greatly increased the misclassification rate of predicting 
cell line response (18% to 26%), and increased the number of patients predicted to be 
sensitive that were actually non-responsive. WWP1 has not been previously identified as 
having a role in paclitaxel drug disposition, indicating that adding generic patient-
outcome related genes that are not pertinent to biologically meaningful signatures of drug 
response, may not be an effective strategy to improve SVM accuracy. 
7) One strategy worth considering for improving SVM performance is to stratify tumours 
by subtype (and/or receptor status) in concert with chemotherapy response. We showed 
in Chapter 4 of this thesis that different subtypes have diverse splicing mutation profiles, 
specifically that NCAM-related pathway mutations appear to be preferentially enriched in 
basal-like and HER2-enriched lymph node positive tumours (section 4.3.8). In our 
analysis of SVMs derived using random sets of genes, we found that one signature 
containing WWP1 could be related to patient outcome. It has been suggested that WWP1 
plays a role in apoptosis in ER positive breast cancer (105), so although it did not 
improve the paclitaxel SVM for all tumour types, WWP1 incorporation into an ER 
positive-specific SVM may possibly increase the classification accuracy for this subset of 
tumours. However, there were insufficient numbers of ER positive cell lines available for 
SVM training, and too few patients available with known ER phenotype to test its 
accuracy. Incorporating additional subtype-specific genes to the current SVM models 
could be one strategy that might increase the accuracies of these gene signatures. 
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8) In order to successfully incorporate any genomic signature for clinical application 
(whether for breast cancer or other tumour types), the expression and copy number 
studies would need to be performed within the clinically relevant time window either 
preceding or early on in chemotherapy treatment. For solid tumours, the assay would 
need to be completed in the timeframe between surgical removal, or biopsy of the tumour 
tissue, and the onset of treatment. Although this time frame will vary on a case-by-case 
basis, it would be advantageous and more feasible to accurately measure a small set (10-
15) of expression and copy number values compared to performing larger scale (complete 
genome or exome) determination and analyses.  
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Appendix S2:  Supplementary Information for Chapter 2  
Appendix S2.1 Supplementary Methods: Ab Initio single copy (sc) 
sequence algorithm and implementation 
The ab initio method eliminates the requirement to exclude sequences from a catalog of 
consensus-like repetitive elements.  It exploits a state space search strategy in which a 
depth-limited search is run repeatedly, increasing the depth limit with each iteration, until 
it reaches the depth of the shallowest level, in order to determine the copy number of seed 
subsequences of a larger input sequence (e.g. a complete chromosome). In each iteration, 
progressively shorter sequences containing elements present in multiple copies in the 
genome are searched in a sequenced genome, at low stringency using BLAT (BLAST-
like alignment tool), in parallel (using threaded jobs) on a cluster computer. To define the 
boundaries of sc segments, the above steps are recursively run on branched subsequences 
of repeat-containing intervals that occur adjacent to sc segments discovered in the 
previous step. In addition to finding known repeat sequence families, ab initio eliminates 
repeat elements, segmental duplicons, and conserved paralogs that are not filtered out by 
catalogue-based approaches. The algorithm is tuned to exclude highly and moderately 
conserved multicopy and/or repetitive sequences, but not highly divergent repetitive 
elements. The algorithm can be applied to any genome. 
A secondary screen using multiprocessor BLAST analysis  (54) filtered out any residual 
repetitive sequences. Parameters were selected to maximize speed without compromising 
sensitivity. The default parameters were modified to return 2 sequence alignments, using 
a word size set to 28, the number of best hits kept limited to 2, descriptions of 5 
sequences retained, and an expected hit value threshold of 0.1. This threshold produced 
significant alignments ≤50 base pairs in length to genomic targets, when present. The 
parameters provided a reasonable level of genomic resolution and adequate sensitivity to 
detect nearly all conserved or moderately conserved repeat elements, while exhibiting 
performance suitable for genome-scale application. The average run time for the 
recursive BLAT runs, followed by filtering apparent sc results with mpiBLAST, using a 
128 CPU Xeon-based compute cluster was 19 hours 20 minutes for a chromosome length 
of~130 Mb. 
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We then compared the ab initio genomic regions output with a deduced set of annotated, 
non-repetitive intervals to determine the sensitivity and specificity of the algorithm. The 
comparison set comprised the genomic complement of the combined set including 
segmental duplication, self-chained paralogous intervals, and repeat-masked sequences.   
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Appendix S2.2  Coordinates and PCR primers of validated scFISH 
probes 
Gene 
Target 
Genomic 
Coordinates         
Probe 
Length 
(bp) 
Primers                                                                                       
Hybridization 
Efficiency* 
ERBB2 
chr17: 37861155-
37863542 
2388 
L GCATTGGGAGAATTAGTGTGTATTTATGTTG 
96/68 
R GTTAGATGTTAGAAAGGACTTCCTGGTTGAG 
CDKN2A 
(Probe 1) 
chr9: 21991990-
21995076 
3087 
L GTAAATGCACCAAGGTAGAAGTAACAAATCA 
100/79.8 
R GTTTAGTTTAATTTCGCTTGTTTTCCAAATCT 
CDKN2A 
(Probe 2) 
chr9: 21981743-
21985184 
3442 
L TAGTTCTACCACCTACTTTGTTACCCTGAAAA 
97.7/75.9 
R TATATTTCATCAAGAAGTTGATTCCCTTGAGT 
CDKN2A 
(Probe 3) 
chr9: 21984688-
21987911 
3224 
L TTTCACTGATAGGTTTAACACTGGTTTAGGAT 
91.4/75.4 
R AATCTGCATTTTAAATAAACACTTGAAGGAGA 
TP53 
chr17: 7589527-
7592796 
3270 
L CAAAGCTAGATAACAGGTAGATTGTTTTTCC 
95.7/70.3 
R TAGAAGACACAAACTGCTAGATAAAATGTAAGC 
CCND1     
(Probe 1) 
chr11: 69458658-
69461950 
3293 
L ACGATTTCATTGAACACTTCCTCTCCAAAAT 
100/94.1 
R CTGATGTAGCCCAACAATTCCAGTGACTT 
CCND1      
(Probe 2) 
chr11: 69465465-
69469037 
3573 
L ACATGGAGAGGTTAAGTCTGAAAAGGCTGA 
100/77.9 
R CTCTCGATACACACAACATCCAGGACTTG 
NOTCH1 
chr9: 139435414-
139438778 
3365 
L CCCAGCTCTCCTCAAAACAAAGAGAAAAA 
100/73.9 
R TGACTACAGAACTCTGGGCAGAATGTTGA 
scFISH probe primer design: Gene targets, genomic location, probe length and 
primers used for each validated probe. *Hybridization efficiencies are indicated as the 
percent of cells with both homologues clearly hybridized, preceded by the percent of 
cells that had at least one homologue hybridized to the correct chromosome band. 
Genomic coordinates are based on NCBI Build 37/hg19. L = left, R = right. 
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Appendix S3: Supplementary Information for Chapter 3 
Appendix S3.1 Veridical variant input format 
This input format most easily accepts formatted output from the Shannon Pipeline. In 
particular, all variants of interest should be concatenated into a single file. Once a, tab-
delimited, concatenated file has been generated, it can easily be formatted correctly by 
using FilterShannonPipelineResults.pl. All file headers must precisely match their 
outlined schema. One can also manually ensure the following: the header line has no 
quotation marks or special characters, empty columns have been replaced by a period (.) 
and each variant line contains only a single gene (comma-delimited gene lists must be 
split such that there is only one gene per line). If one wishes Veridical to consider 
variants pertaining to more than one experimental sample, a comma-delimited list of 
experimental samples, in the form of BAM file names, must be provided as the key 
column. The key column must always contain at least one file name that is present as the 
base name of one of the files listed in the BAM file list that must be passed to Veridical. 
Alternatively, one can prepare the input format as follows. The header must contain at 
least the following, case-insensitive, values to which the file’s columns must adhere to: 
chromosome, splice&coordinate, strand, type, gene, location, location_type, 
heterozygosity, variant, input, key. The column headers need only contain the given text 
(i.e. a column labeled gene_name would be sufficient to satisfy the above requirement 
for a “gene” column). Column headers with ampersands (&) denote that all words joined 
by this symbol must be present for that column (i.e. Splice_site_coordinate satisfies the 
“splice&coordinate” requirement). The order of the columns is immaterial. The input 
column can contain any identifier for the variant and need not be unique. The location 
column specifies if the site is natural or cryptic. For Veridical, all that matters is that 
cryptic variants contain the word “cryptic” as part of their value in this column and that 
non-cryptic variants do not. The location_type column is only used for cryptic variants 
and specifies if the variant is intronic or exonic. It is not currently used by the program. 
This column must be present but can always be set to null (i.e). 
 
A few rows from a sample variant file is provided below (text wrapped for readability): 
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Chromosome     Splice_site_coordinate      Strand Ri-initial Ri-
final ∆Ri Type  Gene_Name  Location Location_Type Loc._Rel._to_exon 
Dist._from_nearest_nat._site Loc._of_nearest_nat._site        
Ri_of_nearest_nat Cryptic_Ri_rel._nat. rsID  Average_heterozygosity 
Variant_coordinate    Input_variant      Input_ID RNASeqDirectory_ID 
RNA_Seq_BAM_ID_KEY 
chr10 89711874 + 12.09 -2.62 -14.71 ACCEPTOR PTEN NATURALSITE . . . 
. . . . . 89711873 A/G ID1  dir  file 
chr10 89712017 + 5.18   -1.85  -7.03  DONOR  PTEN NATURALSITE . . . 
. . . . . 89712018 T/C ID1  dir file 
chrX   9621719 + -4.78  2.25  7.03   DONOR  TBL1X CRYPTICSITE 
EXONIC . 11  9621730  2.24  GREATER . . 9621720 C/T ID1 dir file 
 
Veridical exome annotation input format 
This input format can be generated via ConvertToExomeAnnotation.pl. The file must 
be tab-delimited, excepting its header, which must be comma-delimited. It must have the 
following, case-insensitive, header columns, to which its data must adhere: transcript, 
chromosome, exon chr start, exon chr end, exon rank, gene. The column headers need 
only contain the given text (i.e. a column labeled gene_name would be sufficient to 
satisfy the above requirement for a “gene” column). The order of the columns is 
immaterial. 
A few rows from a sample exome annotation file is provided below (text wrapped for 
readability): 
 
Transcript ID,ID,ID,Chromosome Name,Strand, Exon Chr Start,Exon Chr 
End, Exon Rank in Transcript,Transcript Start, Transcript End, 
Associated Gene Name 
NM_213590 NM_213590   NM_213590 chr13  +  50571142 50571899 1 
50571142   50592603 TRIM13 
NM_213590 NM_213590   NM_213590 chr13  +  50586070 50592603 2 
50571142   50592603 TRIM13 
NM_198318 NM_198318   NM_198318 chr19  +  50180408 50180573 1 
50180408   50191707 PRMT1 
Appendix S3.2 Veridical output 
If a variant contains any validating reads, Veridical outputs the variant in question, along 
with some summary information and a table specifying the numbers of each validating 
read type detected for both the experimental and control samples. Within the output of 
Veridical, the phrase: “Validated (x) variant n times” means that the variant was validated 
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mainly for splicing consequence x and has n validating reads. The variant will only 
appear within the *.filtered output file if the p-value for either junction-spanning or read-
abundance-based reads for splicing consequence x was statistically significant (defined, 
by default, as: p < 0.05). After the variant being validated is provided, along with its 
primary predicted splicing consequence, the output is divided into two sections with 
identical contents: one for the experimental sample(s) and another for control samples. 
The summary enumerates the number of reads of each splicing consequence, partitioned 
by evidence type (junction-spanning or read-abundance-based), and by sample type 
(tumour or normal for control samples, and only tumour for experimental samples). A 
table describing the number of each read type for every file follows this summary. An 
example of this output, for the variant within RAD54L, as shown by Figure 7 and the last 
portion of Table 2, is provided. While Veridical outputs this as plain text, with the table 
in a tab-delimited format, we provide this output as an Excel document with descriptions 
of the meaning of each table heading, to clarify the presentation of the data. All input and 
output files for the five variants presented are provided. VeridicalOutExample.xls 
contains the output for the variant within RAD54L, along with descriptions of the terms 
used and the output format. all.vin contains the input variant file. 
allTumoursBAMFileList.txt and allNormalsBAMFileList.txt are the BAM file lists 
for tumour and normal samples, respectively. all.vout contains the Veridical output. The 
exome file can be retrieved using ConvertToExomeAnnotation.pl, available with the 
other programs at: www.veridical.org. The BAM file lists contain the TCGA file UUID, 
followed by a slash, followed by the file name. The RNA-Seq data itself can be 
downloaded from TCGA at: https://tcga-data.nci.nih.gov/tcga/. 
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Appendix S3.3 Supplementary Figure 1 
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Histogram and embedded Q-Q plots portraying the difference between untransformed 
and Yeo-Johnson (YJ) transformed data. The plots depict intron inclusion for the 
inactivating mutation (chr12:83359523G>A) within TMTC2, as shown in Figures 3.6(B) 
and 3.6(C). The arrowheads denote the number of reads in the variant-containing file, 
which is, in all cases, more than observed in the control samples (p < 0.01). The figure 
legend for all panels is provided in (G), which shows that blue and red plot elements 
correspond to untransformed data, while yellow and purple correspond to YJ transformed 
elements. Dotted lines in the Q-Q plots are lines passing through the first and third 
quantiles for a normal reference distribution. (A), (C), and (E) show junction-spanning 
based reads, while (B), (D), and (F) show read-abundance-based reads. (A/B) depict 
tumour sample distributions, (B/C) depict normal sample distributions, and (E/F) depict 
combined tumour and normal sample distributions.  
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Appendix S4: Supplementary Information for Chapter 4  
Appendix S4.1 SomaticSniper Supplementary Materials 
Appendix S4.1.1 Supplementary Methods – Variant Calling Methods 
Two independent variant callers, Strelka (1) and SomaticSniper (2), were evaluated. The 
main analysis performed using results from Strelka, which has greater sensitivity and 
ability to detect subclonal mutations, by minimizing reporting of spurious variants and 
germline polymorphisms (3). Additionally, the SomaticSniper methods and results are 
reported below.  
Before running SomaticSniper, all DNA sequencing BAM files were realigned using the 
Genome Analysis Toolkit (GATK) Indel Realigner program (4). In addition to default 
parameters, the knownAlleles parameter was used with the well-documented 
insertions/deletions (indels) files: Mills_and_1000G_gold_standard. 
indels.b37.sites.vcf  (5) and 1000G_phase1.indels.b37.vcf (6), available 
through the bioinformatic resource Galaxy (7, 8). SomaticSniper data was then post-
processed to only include variants with both mapping and somatic qualities of at least 40 
(equivalent to running it with  ‐Q 40  ‐q 40). 
Appendix S4.1.2 Supplementary Results – SomaticSniper Variant 
Calling Results 
SomaticSniper variant predictions are summarized in Appendix S3.1.3. Notably, there 
were 1,208 variants from SomaticSniper that are predicted to affect both protein coding 
and splicing 594 genes. In the SomaticSniper data, mutations classified as both protein 
coding and splicing variants were found in 383 tumours, with 63 of these variants in 
PASD1, 61 in PRSS3, 52 in NF1. The variants in these genes, as well as others that were 
highly mutated, are the exact same genomic location and nucleotide change, suggesting 
that SomaticSniper reported higher numbers of SNPs (3) that were not annotated with 
dbSNP135 in >1% of the population, which was used to filter out common SNPs. There 
were 248 variants in 186 tumours from the SomaticSniper set that were classified as 
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silent amino acid changes from ANNOVAR, but were revealed to affect splicing from the 
Shannon Pipeline predictions. 
There was relatively low concordance between the two variant callers, which reported 
variant lists with less than 50% similarity. There were 21,112 protein coding and 1,811 
splicing variants common to both Strelka and SomaticSniper. The predicted variants were 
compared to the previously reported TCGA Level 2 somatic mutations (Appendix 
S3.1.4). Strelka showed the highest concordance with TCGA mutations, reporting 82.1% 
of protein coding mutations, and 86.5% of the splicing variants. Conversely, 
SomaticSniper predicted 73.4% protein coding and 75.3% splicing variants reported by 
TCGA. 
Both of the somatic variant callers we employed utilize Baysian methods to elucidate 
somatic event probabilities. Strelka and SomaticSniper were found to be the two best 
variant callers in a comparison by Roberts et al 2013. Additionally, these two are a 
valuable combination, in that SomaticSniper is useful to generate “a variety of candidate 
SNV sites without any particular drawbacks”, although with a fair amount of false 
positives, while Strelka is least prone to returning germ-line polymorphisms. The relative 
stringency of Strelka was our main reason for performing most of our analyses with it, 
along with the fact that many of its candidates (at probability 0.2) were also returned by 
other callers. It is worth mentioning that different callers have been found to have poor 
correlations at the same sites; in particular, Strelka and SomaticSniper were found to have 
a 0.21 Pearson correlation coefficient in the abovementioned study. Our use of Veridical 
to validate splicing variants with functional evidence of the mutation significantly 
resolves the inconsistency between somatic variant callers (for this type of mutation). 
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Appendix S4.1.3 Variant Summaries by Mutation Type 
 Somatic Sniper 
ANNOVAR protein coding variants  
Synonymous 23,458 
Nonsynonymous 52,634 
Stop gain or loss 2,127 
Total protein coding variants 78,219 
Shannon Pipeline splicing variants  
Cryptic 6,441 
Inactivating  2,685 
Leaky 10,648 
Total splicing variants 19,774 
Synonymous 248 
Nonsynonymous 905 
Stop gain or loss 55 
Total 1,208 
% Synonymous also splicing 1.0572% 
% Nonsynonymous also splicing 1.7194% 
% Stop gain or loss also splicing 2.5858% 
 
Appendix S4.1.4 SomaticSniper Variants Compared to TCGA 
Findings 
 
Total TCGA 
TCGA predicted by 
SomaticSniper 
TCGA Protein Coding Variants   
SNVs Validated 5,557 4,365 (77.3%) 
SNVs Not Validated 18,197 13,380 (72.2%) 
Indels Validated 125 N/A 
Indels Not Validated 1,758 N/A 
Total 25,637 17,745 (73.4%) 
TCGA Splicing Variants   
SNVs Validated 87 70 (80.5%) 
SNVs Not Validated 342 253 (74.0%) 
Total 429 323 (75.3%) 
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Appendix S4.2 Filtering criteria for splicing mutations 
Supplementary Figure S6. Flowchart 
indicating procedure for filtering splicing 
mutation variants. Shannon pipeline splicing 
variants output was filtered using the steps 
shown in this flowchart to identify those 
variants that are likely to cause aberrant 
splicing. Upon identifying variants with 
Strelka (or Somatic Sniper), the VCF files 
were submitted to the Shannon splicing 
mutation pipeline, then categorized as either 
mutations affecting natural splice sites (3’ 
acceptor, or 5’ donor) or cryptic splice site 
strengths. In a small number of cases, both 
natural and cryptic splice sites were 
simultaneously altered. Natural sites that 
were predicted to be abolished were further 
considered. Predicted leaky splicing 
mutations were excluded from the present 
analysis, since the validation methods for 
such mutations has not yet been assessed. 
Aside from standard information theory- 
based mutation criteria, cryptic splicing 
mutation candidates were also filtered for 
proximity to the nearest neighboring natural 
splice site and population frequency. The 
filtered variant subset (n = 5,206) was used 
for all subsequent analyses. 
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Appendix S4.3 Supplementary Figure 1 
RNA-Seq Coverage Heat Map by Subtype. Heatmap depicting coverage per exonic base 
of TCGA RNA-Seq tumour and normal data. Expression based on RNA-Seq datasets is 
shown along the x-axis, with tumours first, ordered by subtype, followed by matched 
normal breast tissues. These categories are demarcated within the heatmap by black 
vertical lines, which correspond to the sample types: (A) basal-like; (B) HER2-enriched; 
(C) luminal A; (D) luminal B; (E) tumour, subtype not available; (F) normal-like tumor; 
and (G) normal control samples. The y-axis consists of all RefSeq genes (with major and 
minor tick marks every 5,000 and 1,000 genes, respectively), clustered to form a 
dendrogram, which is visible on the left side of the graph. Genes with low nominal 
expression levels were below minimum threshold read counts for analysis by Veridical. 
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Appendix S4.4 Variants compared to those previously published by 
TCGA 
 
Total TCGA No. TCGA mutations 
predicted  
TCGA Protein Coding Variants   
SNVs Validated 5557 5085 (91.5%) 
SNVs Not Validated 18197 15742 (86.5%) 
Indels Validated 125 44 (35.2%) 
Indels Not Validated 1758 170 (9.7%) 
Total 25637 21041 (82.1%) 
TCGA Splicing Variants 
  
SNVs Validated 87 80 (92.0%)* 
SNVs Not Validated 342 291 (85.1%)^ 
Total 429 371 (86.5%) 
*contains two variants that were filtered out based on our filtering criteria 
^contains eight variants filtered out 
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Appendix S4.5  Overrepresentation analysis of TCGA mutations 
missed by Strelka 
A pathway analysis using G:Profiler (Reimand et al. 2011) on the 4,654 TCGA variants, 
missed by Strelka, revealed 116 overrepresented pathways including development (20), 
morphogenesis (11), cellular processes (16), regulation (10), ion binding (6) and adhesion 
(5). Details below. 
PATHWAY NAME 
Pathway 
Group 
Pathway 
Depth in 
Group 
P-VALUE 
# Genes 
mutated 
in 
pathway 
Total # 
Genes in 
Pathway 
cell adhesion 2 3 4.52E-15 200 1059 
biological adhesion 2 2 5.61E-15 200 1061 
multicellular organismal 
development 
2 4 1.35E-14 626 4561 
homophilic cell adhesion 2 5 4.26E-14 52 140 
system development 2 5 5.93E-14 552 3942 
single-organism cellular process 2 3 3.90E-13 1325 11241 
developmental process 2 2 7.50E-13 685 5169 
single-multicellular organism 
process 
2 3 2.51E-12 813 6363 
anatomical structure development 2 3 3.59E-12 614 4568 
single-organism process 2 2 7.29E-12 1438 12461 
multicellular organismal process 2 2 2.59E-11 833 6605 
cellular process 2 2 6.19E-11 1668 14918 
nervous system development 2 6 4.51E-10 296 1939 
single-organism developmental 
process 
2 3 6.29E-10 541 4033 
cell-cell adhesion 2 4 8.99E-10 99 459 
calcium ion binding 7 5 1.10E-09 139 737 
organ development 2 6 7.55E-09 396 2824 
anatomical structure morphogenesis 2 3 5.76E-08 337 2362 
cellular component movement 2 4 1.07E-07 240 1570 
neurogenesis 2 7 1.41E-07 204 1286 
cell differentiation 2 4 2.72E-07 428 3176 
cellular developmental process 2 3 3.58E-07 450 3375 
cell development 2 4 3.66E-07 254 1704 
generation of neurons 2 8 7.55E-07 192 1215 
circulatory system development 2 6 2.25E-06 144 856 
cardiovascular system development 2 6 2.25E-06 144 856 
ion binding 7 2 5.39E-06 813 6765 
cation binding 7 3 9.74E-06 565 4489 
BioGRID interaction data 6 1 1.07E-05 933 7657 
neuron differentiation 2 9 1.15E-05 176 1128 
metal ion binding 7 4 1.74E-05 556 4424 
cell communication 2 4 2.62E-05 693 5695 
cell projection organization 2 2 2.68E-05 167 1069 
organ morphogenesis 2 7 2.72E-05 145 896 
cellular component morphogenesis 2 2 4.53E-05 175 1141 
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heart development 2 7 4.84E-05 83 438 
signaling 2 2 5.57E-05 677 5571 
single organism signaling 2 3 5.57E-05 677 5571 
neuron development 2 10 6.08E-05 146 915 
Factor: LRF; motif: 
VNNRMCCCC; match class: 3 
3 2 6.81E-05 1542 12643 
regulation of cellular process 2 3 1.02E-04 1040 9037 
cell morphogenesis 2 3 1.12E-04 165 1075 
biological regulation 2 2 1.15E-04 1157 10182 
locomotion 2 2 1.87E-04 205 1410 
calcium-dependent cell-cell 
adhesion 
2 5 1.92E-04 15 31 
biological_process 2 1 2.11E-04 1812 16892 
binding 7 1 2.97E-04 1488 13523 
cell-cell junction 25 1 5.93E-04 62 313 
regulation of biological process 2 2 6.62E-04 1088 9577 
cell morphogenesis involved in 
differentiation 
2 4 7.48E-04 124 778 
cytoskeleton 15 1 7.98E-04 273 2015 
basement membrane 11 2 8.52E-04 27 93 
Small cell lung cancer 14 1 9.47E-04 25 98 
neuron projection development 2 3 9.98E-04 125 790 
localization 2 2 1.24E-03 596 4926 
tissue development 2 4 1.62E-03 226 1629 
chordate embryonic development 4 2 1.62E-03 101 610 
Factor: LRF; motif: 
VNNRMCCCC; match class: 2 
3 3 1.63E-03 1374 11197 
cytoskeletal part 15 1 2.10E-03 205 1457 
system process 2 4 2.34E-03 258 1911 
cytoskeleton organization 16 1 2.38E-03 141 931 
embryo development ending in 
birth or egg hatching 
4 1 2.77E-03 101 617 
anatomical structure formation 
involved in morphogenesis 
2 3 2.98E-03 144 959 
MI:hsa-miR-940 22 1 3.63E-03 105 625 
Factor: Sp1; motif: 
CCCCGCCCCN; match class: 3 
5 2 4.64E-03 779 6025 
cell morphogenesis involved in 
neuron differentiation 
2 5 6.22E-03 101 628 
cell projection morphogenesis 2 3 6.26E-03 119 770 
cell projection 20 1 6.88E-03 194 1389 
muscle structure development 2 4 7.08E-03 89 537 
Factor: LRF; motif: 
VNNRMCCCC; match class: 4 
3 1 7.75E-03 1600 13333 
cellular response to growth factor 
stimulus 
8 1 7.80E-03 102 639 
plasma membrane part 9 1 8.10E-03 297 2282 
negative regulation of biological 
process 
2 3 9.91E-03 453 3686 
axonogenesis 2 5 1.11E-02 92 566 
Muscle contraction 13 1 1.11E-02 12 33 
Striated Muscle Contraction 13 2 1.11E-02 12 33 
Calcium Binds Troponin-C 13 3 1.11E-02 12 33 
Myosin Binds ATP 13 3 1.11E-02 12 33 
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ATP Hydrolysis By Myosin 13 3 1.11E-02 12 33 
Release Of ADP From Myosin 13 3 1.11E-02 12 33 
response to growth factor stimulus 8 1 1.20E-02 103 653 
neuron projection guidance 2 1 1.30E-02 68 386 
axon guidance 2 2 1.30E-02 68 386 
MI:hsa-miR-939 18 1 1.36E-02 104 637 
Factor: Sp1; motif: 
CCCCGCCCCN; match class: 4 
5 1 1.41E-02 881 6940 
regulation of metabolic process 2 3 1.51E-02 660 5616 
proteinaceous extracellular matrix 11 1 1.51E-02 71 410 
Factor: LRF; motif: 
VNNRMCCCC; match class: 1 
3 4 1.56E-02 925 7323 
localization of cell 2 3 1.68E-02 150 1039 
cell motility 2 4 1.68E-02 150 1039 
cell part morphogenesis 2 3 1.70E-02 119 786 
MI:hsa-miR-615-5p 10 1 1.72E-02 125 799 
Pathways in cancer 21 1 1.80E-02 56 343 
Factor: VDR; motif: 
GGGKNARNRRGGWSA; match 
class: 3 
12 2 1.86E-02 1140 9204 
neuron projection morphogenesis 2 4 2.15E-02 100 638 
signal transduction 2 2 2.36E-02 596 5036 
regulation of nucleobase-containing 
compound metabolic process 
2 1 2.42E-02 473 3900 
Factor: AP-2; motif: 
SNNNCCNCAGGCN; match class: 
3 
26 1 2.44E-02 753 5869 
cell surface receptor signaling 
pathway 
2 3 2.64E-02 361 2886 
MI:hsa-miR-423-5p 23 1 2.68E-02 114 723 
muscle organ development 2 7 2.76E-02 69 402 
negative regulation of cytoskeleton 
organization 
16 2 2.80E-02 23 86 
in utero embryonic development 4 3 2.87E-02 66 380 
positive regulation of cellular 
process 
2 1 3.32E-02 451 3710 
regulation of nitrogen compound 
metabolic process 
2 4 3.36E-02 484 4013 
cytoskeletal protein binding 24 1 3.41E-02 111 733 
Factor: VDR; motif: 
GGGKNARNRRGGWSA; match 
class: 4 
12 1 3.45E-02 1415 11684 
Chronic myeloid leukemia 17 1 3.78E-02 18 75 
transmission of nerve impulse 2 1 3.87E-02 120 808 
blood vessel morphogenesis 2 4 3.89E-02 77 467 
cellular component organization 2 1 4.33E-02 585 4958 
cellular response to stimulus 2 1 4.44E-02 705 6085 
negative regulation of cellular 
process 
2 4 4.76E-02 411 3358 
cellular response to epidermal 
growth factor stimulus 
8 1 4.77E-02 8 14 
MI:hsa-miR-675 1 1 4.95E-02 101 635 
Phosphatidylinositol signaling 
system 
19 1 4.99E-02 19 83 
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Appendix S4.6 MuSiC Results Compared to Significantly Mutated Genes 
Gene Name 
# 
Studies  
Total 
Mutations 
#Stop 
Gain/ 
Loss 
# 
Missense 
# 
Silent 
# 
Splicing 
# 
Validated 
Splicing 
% Splicing 
Mutations 
Validated 
MuSiC 
P-Value 
LRT 
MuSiC 
P-Value 
CT 
MuSiC 
FDR - 
LRT  
MuSiC 
FDR - 
CT 
PIK3CA* 5 181 0 3 177 1 0 0% 0.0226 0.0493 0.4088 1 
TP53* 5 153 19 2 107 25 18 56% 0 0 0 0 
GATA3* 4 10 0 2 7 1 1 100% 0.0075 0.0232 0.1926 0.7132 
RB1* 4 19 5 1 12 1 0 0% 0.0610 0.0471 0.7410 1 
AKT1* 3 6 0 1 5 0 0 NA 1 1 1 1 
CBFB* 3 12 2 1 7 2 2 100% 0.0011 0.0001 0.0414 0.0122 
CDH1* 3 20 5 1 5 9 4 22% 0 0 0 0 
MAP3K1* 3 40 13 5 17 5 4 80% 0 0 0 0 
KMT2C 
(MLL3)* 3 
72 7 16 30 19 7 37% 0 0 0 0 
PTEN* 3 11 4 0 5 2 2 100% 0.0116 0.0023 0.2677 0.1240 
RUNX1* 3 8 1 1 6 0 0 NA 1 1 1 1 
SF3B1* 3 19 1 6 11 1 0 0% 0 0.0006 0.0009 0.0418 
CDKN1B* 2 1 0 0 1 0 0 NA 1 1 1 1 
NF1* 2 27 3 3 17 4 2 50% 1 1 1 1 
STMN2 2 1 0 0 1 0 0 NA 1 1 1 1 
TBX3* 2 5 0 0 5 0 0 NA 1 1 1 1 
AFF2* 1 20 3 5 11 1 0 0% 0.0006 0.0003 0.0257 0.0263 
AGTR2 1 0 0 0 0 0 0 NA 1 1 1 1 
APC 1 7 0 2 5 0 0 NA 1 1 1 1 
ARID1A 1 32 6 5 19 2 1 50% 0 0 0 0.0005 
ARID2 1 11 2 3 5 1 0 0% 0.4970 0.2598 1 1 
ASXL1 1 8 1 3 4 0 0 NA 0.0025 0.0089 0.0806 0.3561 
ATR 1 11 0 3 6 2 0 0% 1 1 1 1 
BAP1 1 6 1 3 2 0 0 NA 0.1206 0.1182 1 1 
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BRAF 1 7 1 0 6 0 0 NA 1 1 1 1 
BRCA1 1 15 2 2 7 4 2 50% 0.1109 0.0531 0.9945 1 
BRCA2 1 15 2 3 9 1 1 100% 0.2360 0.2227 1 1 
CCND3* 1 2 0 0 2 0 0 NA 1 1 1 1 
COL6A3 1 15 1 3 11 0 0 NA 1 1 1 1 
ERBB2 1 16 0 2 13 1 0 0% 0.1453 0.3469 1 1 
ERBB3 1 16 1 2 11 2 0 0% 0.0355 0.3206 0.5458 1 
GH1 1 1 0 1 0 0 0 NA 0.0893 0.4113 0.8910 1 
KRAS 1 3 0 0 3 0 0 NA 1 1 1 1 
LDLRAP1 1 0 0 0 0 0 0 NA 1 1 1 1 
MAP2K4 1 16 2 0 10 4 4 100% 0.0536 0.0120 0.6904 0.4405 
MLL2 1 24 1 10 13 0 0 NA 0.01427 0.02027 0.3081 0.6498 
MYH9 1 15 0 2 13 0 0 NA 1 1 1 1 
MYO3A 1 11 0 6 3 2 0 0% 0.0050 0.0009 0.1390 0.0571 
NRAS 1 0 0 0 0 0 0 NA 1 1 1 1 
PIK3R1* 1 7 0 1 5 1 0 0% 1 1 1 1 
PTPN22* 1 5 0 0 5 0 0 NA 1 1 1 1 
PTPRD* 1 25 3 4 18 0 0 NA 0.0335 0.0410 0.5258 1 
SETD2 1 16 1 3 9 3 1 0% 0.0408 0.1420 0.5975 1 
SMAD4 1 1 0 0 1 0 0 NA 1 1 1 1 
STK11 1 1 0 0 1 0 0 NA 1 1 1 1 
SYNE1 1 65 4 14 41 6 0 0% 1 1 1 1 
SYNE2 1 57 0 10 44 3 0 0% 1 1 1 1 
UBR5 1 29 0 10 18 1 1 100% 0.1179 0.0142 1 0.4993 
USH2A 1 65 0 12 52 1 0 0% 1 1 1 1 
* Identified by TCGA to be significantly mutated
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Appendix S4.7 Validated Cryptic Splicing Mutations 
Appendix S4.7.1 Cryptic Splicing Mutation Details 
Information theory based analysis and corresponding evidence demonstrating abnormal 
mRNA splicing in predicted mRNA splicing mutations. (A) Table indicates the TCGA 
sample identifier, variant, information analysis and statistical support for the mutation. 
(B) Screenshots from the Integrative Genomics Viewer (IGV) displaying junction-
spanning reads that demonstrate cryptic splicing for mutations predicted by the Shannon 
Pipeline in the genes CBFB, GATA3, PALB2, and ABL1. The normal exonic structure is 
indicated by blue, with the thick bars representing exons, and the thin lines introns. RNA-
Seq reads are shown in grey with the vertical dotted black lines demarcate the location of 
the cryptic splice site. 
(A) 
Patient Gene 
Splice Site 
Coordinate 
Variant 
Coordinate 
Ref/ 
Var 
Ri-
initial 
Ri-
final 
Δ 
Ri 
Cryptic 
Site 
Use P-
Value 
Exon 
Skipping 
P-Value 
TCGA-
A8-
A08S CBFB 
chr16: 
67070591 
chr16: 
67070577 G/T 5.6 7.5 1.9 < 0.005 0.12 
TCGA-
B6-
A0I5 GATA3 
chr10: 
8115709 
chr10: 
8115702 A/C 4.2 5.9 1.7 < 0.005 NA 
TCGA-
B6-
A0RT PALB2 
chr16: 
23637694 
chr16: 
23637710 T/A 5.3 7.0 1.7 < 0.005 0.05 
TCGA-
B6-
A0RV ABL1 
chr9: 
133750256 
chr9: 
133750254 G/C 0.8 9.6 8.8 < 0.005 NA 
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(B) CBFB 
 
(C) GATA3 
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(D) PALB2
 
(E) ABL1
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Appendix S4.7.2 The rate of GATA3 abnormal splicing in variant 
containing tumour and tumour/normal controls 
Junction-spanning, cryptic splicing read counts for GATA3 mutation (chr10: 
g.8115702A>C). The number of RNA-Seq reads per exonic base were plotted against the 
number of reads demonstrating GATA3 cryptic splicing in the variant-containing 
tumours and controls. The variant containing tumour is indicated by the number of 
cryptic splicing reads (n = 791), tumours that do not contain this variant are in red, and 
normal controls are in blue. Cryptic splicing in the control samples likely occurs because 
the cryptic splice site (Ri = 4.2 bits) exceeds the strength of the natural splice site (Ri = 
0.9 bits). However, the mutation further weakens the natural splice site (final Ri = 0.0 
bits), while simultaneously strengthening the cryptic splice site (final Ri = 5.8 bits), which 
are consistent with the RNA-Seq analysis. 
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Appendix S4.8 Supplementary Figure 4 
Intron inclusion in tumour and normal breast genomes, based on RNA-Seq evidence. 
Histogram of the density of intronic sequence reads for normal (blue) and tumour (red) 
RNA-Seq samples. Purple shading represents overlapping components of the two density 
distributions. Intron inclusion was calculated with RSeQC's ReadDist script and RefSeq’s 
gene annotation. High levels of unspliced isoforms with intron inclusion were the most 
frequent outcome of mutations with significant effects on mRNA splicing. Nevertheless, 
when considering non-specific aberrant splicing across the transcriptome, the numbers of 
junction-spanning, intron inclusion reads present in normal and tumour samples did not 
significantly differ (p > 0.1). In fact, non-junction-spanning, intronic read-abundance 
reads of normal controls exceeded those of the tumour samples (p < 0.01). This suggests 
that validation events in these tumour samples are not due solely to intron inclusion and 
aberrant mRNA splicing known to be present in breast tumours (9). It is notable, 
however, that the levels of intronic inclusion for validated mutations significantly 
exceeded the read counts for all controls that did not contain these variants. 
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Appendix S4.9 Pathway Analyses 
Appendix S4.9.1 Pathways Overrepresented by Protein Coding and 
Splicing Mutations 
Pathway 
#  
Pathways common to both Strelka splicing 
and protein coding mutations 
Present in Pathway 
Analysis with both 
Protein Coding and 
Splicing Mutations? 
 
1 Anchoring fibril formation YES Col/ECM 
2 
Assembly of collagen fibrils and other 
multimeric structures YES Col/ECM 
3 Association of procollagen chains YES Col/ECM 
4 Collagen biosynthesis and modifying enzymes YES Col/ECM 
5 Collagen formation YES Col/ECM 
6 
Collagen prolyl 3-hydroxylase converts proline 
to 3-hydroxyproline YES Col/ECM 
7 
Collagen prolyl 4-hydroxylase converts proline 
to 4-hydroxyproline YES Col/ECM 
8 
Collagen type VII binds laminin-322 and 
collagen IV YES Col/ECM 
9 DDR1 binds collagens YES Col/ECM 
10 ECM proteoglycans YES Col/ECM 
11 Extracellular matrix organization YES Col/ECM 
12 
Galactosylation of collagen propeptide 
hydroxylysines by PLOD3 YES Col/ECM 
13 
Glucosylation of collagen propeptide 
hydroxylysines YES Col/ECM 
14 Interaction of NCAM1 with collagens YES Col/ECM 
15 Non-integrin membrane-ECM interactions YES Col/ECM 
16 PDI is a chaperone for collagen peptides YES Col/ECM 
17 
Procollagen lysyl hydrolases convert lysine to 5-
hydroxylysine YES Col/ECM 
18 Procollagen triple helix formation YES Col/ECM 
19 Removal of fibrillar collagen C-propeptides YES Col/ECM 
20 Removal of fibrillar collagen N-propeptides YES Col/ECM 
21 Secretion of collagens YES Col/ECM 
22 Formation of collagen fibres NO Col/ECM 
23 Formation of collagen fibrils NO Col/ECM 
24 
Galactosylation of collagen propeptide 
hydroxylysines by procollagen 
galactosyltransferases 1, 2. NO Col/ECM 
25 PDGF binds to extracellular matrix proteins NO Col/ECM 
26 Cell Cycle, Mitotic NO Cancer 
27 Cell-Cell communication YES Cancer 
28 
CBL, GRB2, FYN and PI3K p85 subunit are 
constitutively associated NO ? 
29 Signaling by FGFR1 fusion mutants YES Cancer 
30 
Indirect recruitment of PI3K to KIT via p(Y)-
GAB2 YES Cancer 
31 Loss of Nlp from mitotic centrosomes YES ? 
32 Base Excision Repair YES Cancer 
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33 Mitotic Prometaphase YES Cancer 
34 Signaling by FGFR in disease YES Cancer 
35 PLCG1 events in ERBB2 signaling YES Cancer 
36 Downstream signaling of activated FGFR NO Cancer 
37 Signaling by FGFR1 mutants NO Cancer 
38 Separation of sister chromatids YES ? 
39 Kinetochore assembly YES ? 
40 
Recruitment of mitotic centrosome proteins and 
complexes YES ? 
41 Centrosome maturation YES ? 
42 Mitotic G2-G2/M phases YES Cancer 
43 Signaling by ERBB2 NO Cancer 
44 
Resolution of AP sites via the single-nucleotide 
replacement pathway YES Cancer 
45 G2/M Transition YES Cancer 
46 Transmembrane transport of small molecules YES Other 
47 Ion channel transport YES Other 
48 Axon guidance YES Other 
49 Integrin cell surface interactions YES Other 
50 Ion transport by P-type ATPases YES Other 
51 Developmental Biology YES Other 
52 
NICD1 displaces co-repressor complex from 
RBPJ (CSL) NO Other 
53 
NICD1 PEST domain mutants displace co-
repressor complex from RBPJ (CSL) NO Other 
54 L1CAM interactions YES ? 
55 
Transport of inorganic cations/anions and amino 
acids/oligopeptides YES Other 
56 SLC-mediated transmembrane transport YES Other 
57 cAMP degradation by Phosphodiesterases YES Other 
58 CBL is tyrosine phosphorylated YES Other 
59 Dystroglycan binds Laminins and Dystrophin YES Other 
60 Signalling by NGF YES Other 
61 
P-type ATPases type IV transport external-facing 
APLs to internal side of the plasma membrane YES Other 
62 
P-type ATPases type IV transport internal-facing 
APLs to external side of the plasma membrane YES Other 
63 NCAM signaling for neurite out-growth YES Other 
64 NRAGE signals death through JNK YES ? 
65 
p75NTR indirectly activates RAC and Cdc42 via 
a guanyl-nucleotide exchange factor YES Other 
66 Signaling by Rho GTPases YES Other 
67 Rho GTPase cycle YES Other 
68 Stimuli-sensing channels YES Other 
69 ABC-family proteins mediated transport YES Other 
70 GEFs activate RhoA,B,C NO Other 
71 Other semaphorin interactions YES Other 
72 Signaling by PDGF YES Other 
73 Semaphorin interactions YES Other 
74 Signaling by Interleukins YES Other 
75 Interaction between L1 and Ankyrins YES Other 
76 Transmission across Chemical Synapses YES Other 
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77 Plk1-mediated phosphorylation of Nlp YES Other 
78 
Loss of proteins required for interphase 
microtubule organizationÃƒâ€šÃ‚ from the 
centrosome NO ? 
79 Loss of C-Nap-1 from centrosomes YES ? 
80 
Dissociation of Phospho-Nlp from the 
centrosome YES ? 
81 Recruitment of Plk1 to centrosomes YES ? 
82 Resolution of Abasic Sites (AP sites) YES ? 
83 Platelet calcium homeostasis YES Other 
84 
Recruitment of additional gamma tubulin/ 
gamma TuRC to the centrosome YES ? 
85 Recruitment of CDK11p58 to the centrosomes YES ? 
86 
Ankyrins link voltage-gated sodium and 
potassium channels to spectrin and L1 YES Other 
87 
Translocation of Influenza A virus nonstructural 
protein 1 (NS1A) into the nucleus YES Other 
88 
Synthesis of PIPs at the early endosome 
membrane YES Other 
89 
The ABCC family mediates organic anion 
transport NO Other 
90 PLC beta mediated events YES Other 
91 Downstream signal transduction YES ? 
92 
Phosphorylation of cohesin by PLK1 at 
centromeres YES ? 
93 
PP2A-B56 dephosphorylates centromeric 
cohesin YES ? 
94 DAG and IP3 signaling YES Other 
95 G-protein mediated events YES Other 
96 Kinetochore capture of astral microtubules YES ? 
97 ESPL1 (Separase) cleaves centromeric cohesin YES Other 
98 Recruitment of Grb2 to pFAK:NCAM1 YES Other 
99 
2GABRA:2GABRB:GABRG:GABA transports 
extracellular Cl- to cytosol YES Other 
100 GABA A receptor activation YES Other 
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Appendix S4.9.2  Pathways Overrepresented by Every Splicing 
Mutation Type (inactivating, leaky, cryptic) 
   
Overrepresented by protein 
coding mutation set? 
1 Association of procollagen chains 
Collagen 
YES 
2 
Collagen biosynthesis and modifying 
enzymes YES 
3 Collagen formation YES 
4 
Collagen prolyl 3-hydroxylase converts 
proline to 3-hydroxyproline YES 
5 
Collagen prolyl 4-hydroxylase converts 
proline to 4-hydroxyproline YES 
6 DDR1 binds collagens YES 
7 
Galactosylation of collagen propeptide 
hydroxylysines by PLOD3 YES 
8 
Galactosylation of collagen propeptide 
hydroxylysines by procollagen 
galactosyltransferases 1, 2. YES 
9 
Glucosylation of collagen propeptide 
hydroxylysines YES 
10 PDI is a chaperone for collagen peptides YES 
11 
Procollagen lysyl hydrolases convert lysine 
to 5-hydroxylysine YES 
12 Procollagen triple helix formation YES 
13 Secretion of collagens YES 
14 Degradation of collagen NO 
15 ECM proteoglycans 
ECM 
YES 
16 Extracellular matrix organization YES 
17 Non-integrin membrane-ECM interactions YES 
18 Anchoring fibril formation YES 
19 Axon guidance 
Other 
YES 
20 Cell Cycle, Mitotic YES 
21 Developmental Biology YES 
22 Integrin cell surface interactions YES 
23 L1CAM interactions YES 
24 
Transmembrane transport of small 
molecules YES 
25 
Activation of Chaperone Genes by 
XBP1(S) NO 
26 Activation of Chaperones by IRE1alpha NO 
27 Cell Cycle NO 
28 Hemostasis NO 
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Appendix S4.9.3 Comparing Grouped Pathways Overrepresented between LN- and LN+ Tumour 
Mutations 
RED = collagen, BLUE = extracellular matrix, GREEN = NCAM1 pathways, No. = number of pathways in group 
Lymph Node Negative Tumours No. Lymph Node Positive Tumours No. 
Pathways in Both Lymph Node Positive and 
Negative Tumours 
No. 
LN- 
No. 
LN+ 
Signaling by FGFR1 fusion mutants 10 Neurotransmitter Release Cycle 10 Collagen biosynthesis and modifying enzymes 12 12 
Cytosolic tRNA aminoacylation 9 Complement cascade 8 Semaphorin interactions 9 10 
Striated Muscle Contraction 7 
NCAM signaling for neurite out-
growth 
8 L1CAM interactions 8 8 
PI3K events in ERBB2 signaling 6 SHC1 events in ERBB2 signaling 4 Signaling by Interleukins 12 1 
COPI Mediated Transport 6 SHC1 events in ERBB4 signaling 4 Extracellular matrix organization 4 6 
Glucose metabolism 4 Downregulation of ERBB4 signaling 3 GPCR downstream signaling 4 4 
Synthesis of PIPs at the late endosome membrane 3 Generic Transcription Pathway 3 
Regulation of Cholesterol Biosynthesis by 
SREBP (SREBF) 
2 6 
STAT6-mediated induction of chemokines 3 Nuclear signaling by ERBB4 3 Hemostasis 4 3 
Signaling by SCF-KIT 3 
Regulation of Hypoxia-inducible 
Factor (HIF) by Oxygen 
3 
Transport of inorganic cations/anions and amino 
acids/oligopeptides 
5 1 
Regulation of signaling by CBL 3 Signaling by ERBB4 3 Transmembrane transport of small molecules 3 3 
Regulation of AMPK activity via LKB1 3 Xenobiotics 3 Condensation of Prometaphase Chromosomes 3 3 
Transport of vitamins, nucleosides, and related 
molecules 
2 
Apoptosis induced DNA 
fragmentation 
2 Signal Transduction 2 4 
Synthesis of PIPs at the Golgi membrane 2 
Assembly of the pre-replicative 
complex 
2 Fc epsilon receptor (FCERI) signaling 1 5 
Signaling by constitutively active EGFR 2 
Binding and Uptake of Ligands by 
Scavenger Receptors 
2 
Recruitment of mitotic centrosome proteins and 
complexes 
3 2 
PIP3 activates AKT signaling 2 Conjugation of carboxylic acids 2 
Factors involved in megakaryocyte development 
and platelet production 
3 2 
PI3K events in ERBB4 signaling 2 DAG and IP3 signaling 2 Synthesis of PIPs at the plasma membrane 2 3 
PI3K Cascade 2 
Metabolism of amino acids and 
derivatives 
2 Non-integrin membrane-ECM interactions 2 3 
Nuclear import of Rev protein 2 Mitotic G1-G1/S phases 2 Ion channel transport 2 3 
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Metabolism of steroid hormones and vitamin D 2 
Nitric oxide stimulates guanylate 
cyclase 
2 
COPII (Coat Protein 2) Mediated Vesicle 
Transport 
2 3 
Intrinsic Pathway 2 Opioid Signalling 2 Cell Cycle 2 3 
GPVI-mediated activation cascade 2 PI Metabolism 2 
Assembly of collagen fibrils and other 
multimeric structures 
1 4 
Downstream signal transduction 2 Phospholipid metabolism 2 Muscle contraction 3 1 
Cross-presentation of particulate exogenous 
antigens (phagosomes) 
2 Scavenging of Heme from Plasma 2 Membrane Trafficking 3 1 
Costimulation by the CD28 family 2 Signaling by ERBB2 2 Integrin cell surface interactions 3 1 
Cell Cycle, Mitotic 2 
Synthesis of IP2, IP, and Ins in the 
cytosol 
2 
Inactivation, recovery and regulation of the 
phototransduction cascade 
3 1 
CD28 dependent PI3K/Akt signaling 2 
Synthesis of very long-chain fatty 
acyl-CoAs 
2 Regulation of the Fanconi anemia pathway 2 2 
Vitamin C (ascorbate) metabolism 1 
Activated NOTCH1 Transmits Signal 
to the Nucleus 
1 Nephrin interactions 2 2 
VEGF ligand-receptor interactions 1 Amino Acid conjugation 1 
Loss of proteins required for interphase 
microtubule organization√Ç¬†from the 
centrosome 
2 2 
tRNA Aminoacylation 1 
Antiviral mechanism by IFN-
stimulated genes 
1 Loss of Nlp from mitotic centrosomes 2 2 
Transport of glucose and other sugars, bile salts and 
organic acids, metal ions and amine compounds 
1 Asparagine N-linked glycosylation 1 
Fatty acid, triacylglycerol, and ketone body 
metabolism 
2 2 
Translocation of GLUT4 to the Plasma Membrane 1 
CDC6 association with the 
ORC:origin complex 
1 Developmental Biology 2 2 
Tie2 Signaling 1 CDO in myogenesis 1 Collagen formation 2 2 
TCR signaling 1 
CDT1 association with the 
CDC6:ORC:origin complex 
1 Stimuli-sensing channels 1 3 
STING mediated induction of host immune 
responses 
1 
CREB phosphorylation through the 
activation of Adenylate Cyclase 
1 Ion transport by P-type ATPases 1 3 
Smooth Muscle Contraction 1 Calnexin/calreticulin cycle 1 ECM proteoglycans 1 3 
Signaling by Rho GTPases 1 Chromosome Maintenance 1 DAP12 interactions 1 3 
Signaling by FGFR mutants 1 Circadian Clock 1 Unfolded Protein Response 2 1 
S6K1-mediated signalling 1 Conjugation of benzoate with glycine 1 
Synthesis of PIPs at the early endosome 
membrane 
2 1 
S6K1 signalling 1 
Conjugation of phenylacetate with 
glutamine 
1 Platelet activation, signaling and aggregation 2 1 
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RIG-I/MDA5 mediated induction of IFN-alpha/beta 
pathways 
1 DNA Repair 1 
NGF signalling via TRKA from the plasma 
membrane 
2 1 
Rho GTPase cycle 1 Disease 1 Cell-Cell communication 2 1 
Response to elevated platelet cytosolic Ca2+ 1 
E2F-enabled inhibition of pre-
replication complex formation 
1 Signalling by NGF 1 2 
Regulation of mRNA Stability by Proteins that Bind 
AU-rich Elements 
1 
EGFR interacts with phospholipase C-
gamma 
1 Regulation of Insulin Secretion 1 2 
Rap1 signalling 1 
ER Quality Control Compartment 
(ERQC) 
1 p75 NTR receptor-mediated signalling 1 2 
Polo-like kinase mediated events 1 Fanconi Anemia pathway 1 G2/M Checkpoints 1 2 
Platelet Adhesion to exposed collagen 1 G-protein mediated events 1 Effects of PIP2 hydrolysis 1 2 
PKB-mediated events 1 Interferon Signaling 1 Axon guidance 1 2 
Phase 1 - Functionalization of compounds 1 Interleukin-2 signaling 1 Transmission across Chemical Synapses 1 1 
Organic cation/anion/zwitterion transport 1 Lipoprotein metabolism 1 Stabilization of p53 1 1 
NRAGE signals death through JNK 1 Lysine catabolism 1 SLC-mediated transmembrane transport 1 1 
mTORC1-mediated signalling 1 
MyD88 cascade initiated on plasma 
membrane 
1 
Signaling by NOTCH1 PEST Domain Mutants 
in Cancer 
1 1 
mTOR signalling 1 
N-glycan trimming in the ER and 
Calnexin/Calreticulin cycle 
1 Signaling by FGFR1 mutants 1 1 
Metabolism of water-soluble vitamins and cofactors 1 NGF processing 1 Peroxisomal lipid metabolism 1 1 
Metabolism of nucleotides 1 Neuronal System 1 
NOTCH1 Intracellular Domain Regulates 
Transcription 
1 1 
Metabolism 1 PKA activation 1 Metabolism of proteins 1 1 
Ligand-gated ion channel transport 1 Phase II conjugation 1 Meiosis 1 1 
ISG15 antiviral mechanism 1 Platelet calcium homeostasis 1 M Phase 1 1 
Integration of energy metabolism 1 Platelet homeostasis 1 Interleukin receptor SHC signaling 1 1 
Inhibition of replication initiation of damaged DNA 
by RB1/E2F1 
1 Platelet sensitization by LDL 1 Inositol phosphate metabolism 1 1 
Homologous recombination repair of replication-
independent double-strand breaks 
1 
Pyruvate metabolism and Citric Acid 
(TCA) cycle 
1 ER to Golgi Transport 1 1 
Golgi to ER Retrograde Transport 1 Signaling by EGFR 1 
Depolarization of the Presynaptic Terminal 
Triggers the Opening of Calcium Channels 
1 1 
Gene Expression 1 Signaling by FGFR 1 
Conversion from APC/C:Cdc20 to APC/C:Cdh1 
in late anaphase 
1 1 
Gamma-carboxylation of protein precursors 1 Signaling by NOTCH2 1 Collagen degradation 1 1 
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E2F mediated regulation of DNA replication 1 Signaling by PDGF 1 
ATM mediated phosphorylation of repair 
proteins 
1 1 
Cytokine Signaling in Immune system 1 Signaling by Robo receptor 1 Activation of Chaperones by IRE1alpha 1 1 
Cyclin E associated events during G1/S transition  1 
Signaling by the B Cell Receptor 
(BCR) 
1 
   
Constitutive PI3K/AKT Signaling in Cancer 1 Syndecan interactions 1 
   
ChREBP activates metabolic gene expression 1 
Synthesis and interconversion of 
nucleotide di- and triphosphates 
1 
   
Cell surface interactions at the vascular wall 1 Synthesis of IP3 and IP4 in the cytosol 1 
   
Cell death signalling via NRAGE, NRIF and NADE 1 
Transcriptional Regulation of White 
Adipocyte Differentiation 
1 
   
CD28 co-stimulation 1 
     
Biological oxidations 1 
     
Antigen processing-Cross presentation 1 
     
AMPK inhibits chREBP transcriptional activation 
activity 
1 
     
Activation of the AP-1 family of transcription 
factors 
1 
     
Activation of Chaperones by ATF6-alpha 1 
     
Abacavir transmembrane transport 1 
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Appendix S4.9.4 Pathway Analysis of Deleterious Mutations in LN- and LN+ Tumours 
RED = collagen, BLUE = extracellular matrix, GREEN = NCAM1 pathways 
Lymph Node Positive Tumour Mutations Lymph Node Negative Tumour Mutations 
Over Represented by Both Lymph Node 
Positive and Negative Tumour Mutations 
Autophosphorylation of NCAM1 bound Fyn Activation of Chaperones by ATF6-alpha 
Assembly of collagen fibrils and other multimeric 
structures 
Dephosphorylation of NCAM1 bound pFyn Cargo, Sec31p:Sec13p, and v-SNARE recruitment Association of procollagen chains 
Interaction of NCAM1 with collagens Cell-Cell communication Collagen biosynthesis and modifying enzymes 
NCAM signaling for neurite out-growth Cleavage of ATF6-alpha by S1P Collagen formation 
NCAM1 interactions COPII (Coat Protein 2) Mediated Vesicle Transport 
Collagen prolyl 3-hydroxylase converts proline to 
3-hydroxyproline 
Formation of collagen fibres ER to Golgi Transport 
Collagen prolyl 4-hydroxylase converts proline to 
4-hydroxyproline 
Formation of collagen fibrils 
factor VIII + von Willebrand factor multimer -> 
factor VIII:von Willibrand factor multimer 
Galactosylation of collagen propeptide 
hydroxylysines by PLOD3 
Removal of fibrillar collagen N-propeptides 
factor VIII:von Willibrand factor multimer -> 
factor VIIIa + factor VIIIa B A3 acidic polypeptide 
+ von Willibrand factor multimer 
Galactosylation of collagen propeptide 
hydroxylysines by procollagen 
galactosyltransferases 1, 2. 
Syndecan-1 binds collagen types I, III, V FGFR1 fusions bind PLCgamma 
Glucosylation of collagen propeptide 
hydroxylysines 
Syndecan-1 binds collagen types I, III, V Hemostasis PDI is a chaperone for collagen peptides 
Degradation of the extracellular matrix 
Inhibition of integrin activation by sequestering 
PIP5KIgamma 
Procollagen lysyl hydrolases convert lysine to 5-
hydroxylysine 
ECM proteoglycans Interaction of integrin alphaEbeta7 with Cadherin-1 Procollagen triple helix formation 
Non-integrin membrane-ECM interactions Interleukin-1 receptor type 1 binds Interleukin 1 Removal of fibrillar collagen C-propeptides 
PDGF binds to extracellular matrix proteins Interleukin-2 signaling Secretion of collagens 
Activation of Adenylate Cyclase Interleukin-7 signaling Extracellular matrix organization 
Activation of Chaperones by IRE1alpha Na+-coupled HCO3- cotransport Axon guidance 
Activation of PPARA by Fatty Acid Ligands NrCAM interactions Cell Cycle 
AGRN binds Laminins with gamma-1 subunit p-PLCgamma dissociates from FGFR1 fusions Developmental Biology 
Ankyrins link voltage-gated sodium and potassium 
channels to spectrin and L1 
Phosphorylation of STAT5 by FGFR1 fusions Dissociation of Phospho-Nlp from the centrosome 
Antiviral mechanism by IFN-stimulated genes 
PI is phosphorylated to PI5P by PIKFYVE at the 
late endosome membrane 
DOCKs bind to RhoGEFs 
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Association of MCM8 with ORC:origin complex 
PI is phosphorylated to PI5P by PIKFYVE at the 
late endosome membrane 
Integrin cell surface interactions 
Binding of Beta-TrCP1 to phosphorylated PER 
proteins 
PI(3,5)P2 is dephosphorylated to PI3P by FIG4 at 
the early endosome membrane 
Interaction between L1 and Ankyrins 
Binding of IP3 to IP3 receptor 
PI(3,5)P2 is dephosphorylated to PI3P by FIG4 at 
the Golgi membrane 
Loss of C-Nap-1 from centrosomes 
Ca2+ influx through voltage gated Ca2+ channels 
PI(3,5)P2 is dephosphorylated to PI3P by FIG4 at 
the late endosome membrane 
Loss of Nlp from mitotic centrosomes 
Calcium Influx through Voltage-gated Calcium 
Channels 
PI3P is phosphorylated to PI(3,5)P2 by Pikfyve at 
the early endosome membrane 
Loss of proteins required for interphase 
microtubule organizationÃ‚Â from the centrosome 
Calnexin/calreticulin cycle 
PI3P is phosphorylated to PI(3,5)P2 by Pikfyve at 
the early endosome membrane 
Meiosis 
Cell Cycle, Mitotic 
PI3P is phosphorylated to PI(3,5)P2 by PIKFYVE 
at the Golgi membrane 
Phosphorylation of MEK4 by MEKK1 
Cell death signalling via NRAGE, NRIF and 
NADE 
PI3P is phosphorylated to PI(3,5)P2 by PIKFYVE 
at the Golgi membrane 
Phosphorylation of p53 at ser-15 by ATM kinase 
cGMP effects 
PI3P is phosphorylated to PI(3,5)P2 by PIKFYVE 
at the late endosome membrane 
Plk1-mediated phosphorylation of Nlp 
Dephosphorylation of CK2-modified condensin I 
PI3P is phosphorylated to PI(3,5)P2 by PIKFYVE 
at the late endosome membrane 
Recruitment of CDK11p58 to the centrosomes 
Depolarization of the Presynaptic Terminal 
Triggers the Opening of Calcium Channels 
PLCgamma is phosphorylated by FGFR1-fusions Recruitment of Plk1 to centrosomes 
Dystroglycan binds Laminins and Dystrophin Plexin-A1-4 binds NRP1 
Transport of inorganic cations/anions and amino 
acids/oligopeptides 
ER Quality Control Compartment (ERQC) 
Recruitment of additional gamma tubulin/ gamma 
TuRC to the centrosome  
ERBB4:TAB2:NCOR1 complex translocates to the 
nucleus 
Release of platelet cytosolic components 
 
ERBB4:TAB2:NCOR1 complex translocates to the 
nucleus 
Replication initiation regulation by Rb1/E2F1 
 
ERBB4s80 binds Tab2:Ncor1 complex Semaphorin interactions 
 
ERBB4s80 binds Tab2:Ncor1 complex Signaling by FGFR1 fusion mutants 
 
Fanconi Anemia pathway SLC-mediated transmembrane transport 
 
Formation of the BRCA1-PALB2-BRCA2 
complex 
Stabilization of mRNA by HuR 
 
Interaction of L1 with Laminin-1 Synthesis of IP3 and IP4 in the cytosol 
 
Interaction of nephrin with adherens junction- Transcriptional activation of Acetyl-CoA 
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associated proteins carboxylase by ChREBP:MLX 
IP3 binds to the IP3 receptor, opening the 
endoplasmic reticulum Ca2+ channel 
Transmembrane transport of small molecules 
 
ISG15 antiviral mechanism Vesicle Budding 
 
L1CAM interactions Vesicle Uncoating 
 
Mitotic Prometaphase Vesicular glutamate transport 
 
N-glycan trimming in the ER and 
Calnexin/Calreticulin cycle   
NDP + reduced thioredoxin => dNDP + oxidized 
thioredoxin + H2O   
Neurofascin binds contactin-1:CASPR complex 
  
NICD1 displaces co-repressor complex from RBPJ 
(CSL)   
NICD1 displaces NCOR co-repressor complex 
from CSL   
NICD1 PEST domain mutants displace co-
repressor complex from RBPJ (CSL)   
Nitric oxide stimulates guanylate cyclase 
  
NTN4 binds laminins with gamma-1, gamma-3 
  
Opening of ER calcium channels by activated PKA 
  
p75 NTR receptor-mediated signalling 
  
Phosphorylation of FANCD2 by ATR/ATM 
  
Phosphorylation of FANCI by ATM/ATR 
  
Release of calcium from intracellular stores by IP3 
receptor activation   
Signaling by ERBB4 
  
Signaling by PDGF 
  
Signalling by NGF 
  
Syndecan interactions 
  
Transport of Ca++ from platelet dense tubular 
system to cytoplasm   
Unfolded Protein Response 
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Appendix S4.10 Frequency of Mutations in NCAM1 Pathway Genes 
Gene Name All Mutations Splicing Mutations 
Indel Frameshift & 
Stop Gain/Loss 
Mutations 
Total: 425 37 35 
SPTA1 30 2 3 
CACNA1D 22 3 7 
COL6A5 19 1 0 
NCAM1 17 2 1 
COL6A6 16 1 1 
COL6A3 15 0 3 
CACNA1G 13 2 0 
CACNA1I 13 1 0 
COL4A1 13 4 0 
CACNA1C 12 0 1 
SPTBN1 12 2 1 
COL3A1 11 0 2 
SPTBN4 11 0 0 
CACNB2 10 1 1 
COL4A4 10 0 0 
COL4A5 10 1 1 
SPTB 10 0 2 
CACNA1S 9 0 0 
COL4A3 9 2 0 
COL5A2 9 2 1 
CNTN2 8 1 1 
COL5A3 8 1 2 
COL9A2 8 4 0 
NCAN 8 1 1 
SPTAN1 8 0 0 
AGRN 6 0 0 
COL5A1 6 0 2 
COL6A2 6 0 0 
PTPRA 6 0 0 
CACNA1H 5 0 0 
CACNB1 5 1 0 
COL9A3 5 1 0 
FGFR1 5 0 0 
PRNP 5 0 0 
SOS1 5 0 1 
SPTBN5 5 0 0 
COL9A1 4 0 0 
CREB1 4 0 0 
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PTK2 4 0 0 
CACNB3 3 0 0 
COL4A2 3 0 0 
KRAS 3 0 0 
MAPK3 3 0 1 
RAF1 3 1 0 
RPS6KA5 3 0 0 
CDK1 2 0 0 
COL2A1 2 0 1 
FYN 2 1 0 
GDNF 2 0 0 
GFRA1 2 0 0 
GFRA2 2 0 0 
GRB2 2 1 0 
MAPK1 2 1 0 
SPTBN2 2 0 0 
SRC 2 0 0 
ST8SIA2 2 0 1 
HRAS 1 0 0 
MAP2K2 1 0 0 
YWHAB 1 0 1 
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Appendix S4.11 Breast Cancer Mutations by Subtype 
Appendix S4.11.1 Number of Mutations by Subtype 
Subtype* 
No. 
Tumours 
All Coding 
Deleterious 
Coding^ 
Splicing 
  
No.  Av. No. Av. No. Av. 
Basal Like 81 15,383 190 1,350 16.7 1,288 15.9 
HER2-
enriched 
51 8,633 169 708 13.9 729 14.3 
Luminal A 192 22,634 118 1,889 9.8 1,786 9.3 
Luminal B 104 14,501 139 1,166 11.2 1,209 11.6 
"Normal 
Like" 
6 1,105 184 105 17.5 78 13 
*subtype not available for 8 tumours, ^ Frameshift indels, stop codon gain or loss, No. = 
total number of mutations, Av. = average number of mutations per tumour 
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Appendix S4.11.2 Pathway Analysis of Mutations by Subtype 
and Lymph Node Status 
 
Basal Her2 Luminal A Luminal B 
Normal-
Like 
 
- + - + - + - + - + 
# Tumours 50 31 18 32 89 96 43 59 1 5 
# Enriched 
Pathways Total 
115 115 132 120 122 142 185 147 8 7 
# NCAM Pathways 0 9 2 7 0 2 1 2 0 0 
# Collagen 
Pathways 
0 26 16 3 11 36 21 15 0 0 
# ECM Pathways 0 4 3 0 1 5 4 4 0 0 
# Mutations Total 844 444 300 414 1013 698 548 639 29 49 
# NCAM Pathway 
Mutations 
3 6 3 4 3 7 4 5 0 0 
# Collagen Pathway 
Mutations 
9 11 4 5 13 11 7 8 1 0 
The “NCAM1 Interactions” and “Interaction of NCAM1 with collagens” pathways, were 
overrepresented in luminal B and HER2-enriched LN+ tumours. The NCAM1 interaction 
pathways contain a large number (n = 153) of different proteins where NCAM1 acts as a 
signal transducing receptor molecule. These functions are tangential to NCAM1’s role in 
neurite outgrowth and may explain why they are overrepresented in tumours that have 
not invaded the lymph nodes. 
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Appendix S4.11.3 Word clouds of overrepresented pathways by 
subtype. 
Word clouds of generalized overrepresented Reactome pathways for mutations stratified 
by lymph node status (positive or negative) and breast cancer subtype (basal-like (A), 
HER2-enriched (B), Luminal A (C), or Luminal B (D)). The size of each word is 
proportional to its frequency in the abstracted list of overrepresented pathways. 
(A)  Basal Like Lymph Node Positive 
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Basal Like Lymph Node Negative
 
  
277 
 (B)  HER2-enriched lymph node positive 
 
 HER2-enriched lymph node negative 
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(C) Luminal A lymph node positive 
 
 Luminal A lymph node negative 
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(D)  Luminal B lymph node positive 
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Luminal B lymph node negative 
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Appendix S4.11.4   
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Appendix S5: Supplementary Information for Chapter 5 
Appendix S5.1 Cell Lines Used 
Cell Line 
Transcriptional 
subtype 
Pac 
GI50 
Gem 
GI50 
Mut CN Exp 
Pac 
SVM 
Gem 
SVM 
Pac 
MFA 
Gem 
MFA 
Total Count   49 47 48 46 49 49 44 45 44 
184A1 Normal-like 7.35 6.16 1 1 1 1 1 1 1 
184B5 Normal-like 7.74 6.14 1 1 1 1 1 1 1 
600MPE Luminal 7.51 7.64 1 1 1 1 1 1 1 
AU565 Luminal (Her2+) 8.14 7.81 1 1 1 1 1 1 1 
BT474 Luminal (Her2+) 7.99 4.88 1 1 1 1 1 1 1 
BT483 Luminal 7.00 8.05 1 1 1 1 1 1 1 
BT549 Claudin-low 8.16 8.08 1 1 1 1 1 1 1 
CAMA1 Luminal 7.95 6.79 1 1 1 1 1 1 1 
HCC1143 Basal 7.80 7.92 1 1 1 1 1 1 1 
HCC1187 Basal 8.05 5.07 1 1 1 1 1 1 1 
HCC1395 Claudin-low 7.71 6.47 1 1 1 1 1 1 1 
HCC1419 Luminal (Her2+) 7.04 4.81 0 1 1 1 0 0 0 
HCC1428 Luminal 7.58 3.58 1 1 1 1 1 1 1 
HCC1569 Basal (Her2+) 7.95 6.76 1 1 1 1 1 1 1 
HCC1806 Basal 8.11 8.72 1 1 1 1 1 1 1 
HCC1937 Basal 7.81 5.97 1 1 1 1 1 1 1 
HCC1954 Basal (Her2+) 8.15 4.51 1 1 1 1 1 1 1 
HCC202 Luminal (Her2+) 8.10 4.82 1 1 1 1 1 1 1 
HCC2185 Luminal 8.22 7.61 1 1 1 1 1 1 1 
HCC3153 Basal 7.70 7.19 1 1 1 1 1 1 1 
HCC38 Claudin-low 8.13 8.17 1 1 1 1 1 1 1 
HCC70 Basal 8.03 4.58 1 1 1 1 1 1 1 
HS578T Claudin-low 8.38 5.66 1 1 1 1 1 1 1 
LY2 Luminal 7.97 7.62 1 1 1 1 1 1 1 
MCF10A Normal-like 8.03 7.70 1 1 1 1 1 1 1 
MCF10F Normal-like 8.08 7.08 1 1 1 1 1 1 1 
MCF12A Normal-like 7.97 7.17 1 1 1 1 1 1 1 
MCF7 Luminal 7.79 4.77 1 1 1 1 1 1 1 
MDAMB134VI Luminal 7.99 2.85 1 1 1 1 1 1 1 
MDAMB157 Claudin-low 8.27 NA 1 1 1 1 0 1 0 
MDAMB175VII Luminal 7.74 8.12 1 1 1 1 1 1 1 
MDAMB231 Claudin-low 8.37 5.93 1 1 1 1 1 1 1 
MDAMB361 Luminal (Her2+) 7.79 8.23 1 1 1 1 1 1 1 
MDAMB415 Luminal 8.18 6.05 1 1 1 1 1 1 1 
MDAMB436 Claudin-low 7.65 7.49 1 1 1 1 1 1 1 
MDAMB453 Luminal 7.99 7.85 1 1 1 1 1 1 1 
MDAMB468 Basal 8.06 7.01 1 1 1 1 1 1 1 
SKBR3 Luminal (Her2+) 7.94 7.97 1 1 1 1 1 1 1 
SUM1315MO2 Claudin-low 8.29 6.91 1 1 1 1 1 1 1 
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SUM149PT Basal 8.03 7.84 1 0 1 1 0 0 0 
SUM159PT Claudin-low 8.24 7.99 1 1 1 1 1 1 1 
SUM185PE Luminal 6.64 6.44 1 1 1 1 1 1 1 
SUM52PE Luminal 8.20 8.15 1 1 1 1 1 1 1 
T47D Luminal 8.02 6.02 1 1 1 1 1 1 1 
UACC812 Luminal (Her2+) 8.08 7.75 1 1 1 1 1 1 1 
UACC893 Luminal (Her2+) 7.93 3.54 1 0 1 1 0 0 0 
ZR751 Luminal 7.76 7.45 1 1 1 1 1 1 1 
ZR7530 Luminal (Her2+) 7.66 NA 1 0 1 1 0 0 0 
ZR75B Luminal 7.38 7.34 1 1 1 1 1 1 1 
Pac = paclitaxel, Gem = gemcitabine, GI50 = -log(M), where M is the concentration of 
drug to inhibit cell growth by 50%, Mut = mutation data (exome sequencing), CN = copy 
number data (microarray), Exp = expression data (microarray), SVM = support vector 
machine, MFA = multiple factor analysis. For Mut, CN, and Exp, 1 indicates the data 
type was available for analysis, 0 indicates the data type was unavailable (from Daemen 
et al. 2013). For the SVM and MFA columns, 1 indicated that the cell line was included 
in the analysis, and 0 indicates that the cell line was not included (based on data 
availability). 
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Appendix S5.2 Genes Included in the study relevant to paclitaxel and gemcitabine drug disposition 
Paclitaxel 
Genes 
Full Gene/Protein Name Drug Disposition 
In Capture 
Array? 
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 transporter (out of cell) YES 
ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 transporter (out of cell) YES 
ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 transporter (out of cell) YES 
ABCC10 ATP-binding cassette, sub-family C (CFTR/MRP), member 10 transporter (out of cell) YES 
BAD BCL2-associated agonist of cell death in target pathway (BCL2) YES 
BBC3 BCL2 binding component 3 in target pathway YES 
BCAP29 B-cell receptor-associated protein 29 associated with resistance YES 
BCL2 B-cell CLL/lymphoma 2 direct target YES 
BCL2L1 BCL2-like 1 in target pathway (BCL2) YES 
BIRC5 baculoviral IAP repeat containing 5 associated with resistance YES 
BMF Bcl2 modifying factor in target pathway YES 
CNGA3 cyclic nucleotide gated channel alpha 3 associated with resistance YES 
CSAG2 CSAG family, member 2 associated with resistance NO 
CYP2C8 cytochrome P450, family 2, subfamily C, polypeptide 8 metabolizing enzyme YES 
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4 metabolizing enzyme YES 
FGF2 fibroblast growth factor 2  associated with resistance YES 
FN1 fibronectin 1 associated with resistance YES 
GBP1 guanylate binding protein 1, interferon-inducible associated with resistance YES 
MAP2 microtubule-associated protein 2 direct target YES 
MAP4 microtubule-associated protein 4 direct target YES 
MAPT microtubule-associated protein tau direct target YES 
NFKB2 
nuclear factor of kappa light polypeptide gene enhancer in B-
cells 2 (p49/p100) 
associated with resistance 
YES 
NR1I2 nuclear receptor subfamily 1, group I, member 2 direct target YES 
OPRK1 opioid receptor, kappa 1 associated with resistance YES 
SLCO1B3 solute carrier organic anion transporter family, member 1B3 transporter (into cell) YES 
TLR6 toll-like receptor 6 associated with resistance YES 
TMEM243 transmembrane protein 243, mitochondrial associated with resistance YES 
TUBB1 tubulin, beta 1 class VI direct target YES 
TUBB4A tubulin, beta 4A class IVa in target pathway (TUBB1) YES 
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TUBB4B tubulin, beta 4B class IVb in target pathway (TUBB1) YES 
TWIST1 twist family bHLH transcription factor 1 associated with resistance YES 
    Gemcitabine Genes 
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 transporter (out of cell) YES 
ABCC10 ATP-binding cassette, sub-family C (CFTR/MRP), member 10 transporter (out of cell) YES 
AK1 adenylate kinase 1 nucleotide metabolism YES 
CDA cytidine deaminase metabolizing enzyme YES 
CMPK1 cytidine monophosphate (UMP-CMP) kinase 1, cytosolic direct target YES 
CTPS1 CTP synthase 1 direct target NO 
DCK deoxycytidine kinase metabolizing enzyme YES 
DCTD dCMP deaminase metabolizing enzyme NO 
NME1 NME/NM23 nucleoside diphosphate kinase 1 metabolizing enzyme NO 
NT5C 5', 3'-nucleotidase, cytosolic metabolizing enzyme NO 
RRM1 ribonucleotide reductase M1 direct target YES 
RRM2 ribonucleotide reductase M2 in target pathway (RRM1) YES 
RRM2B ribonucleotide reductase M2 B (TP53 inducible) in target pathway (RRM1) YES 
SLC28A1 
solute carrier family 28 (concentrative nucleoside transporter), 
member 1 transporter (into cell) YES 
SLC28A3 
solute carrier family 28 (concentrative nucleoside transporter), 
member 3 transporter (into cell) YES 
SLC29A1 
solute carrier family 29 (equilibrative nucleoside transporter), 
member 1 transporter (into cell) YES 
SLC29A2 
solute carrier family 29 (equilibrative nucleoside transporter), 
member 2 transporter (into cell) YES 
TYMS thymidylate synthetase direct target YES 
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Appendix S5.3 Copy Number Calling Methods 
Copy number data were available as CEL files from Affymetrix Genome-Wide Human 
SNP Array 6.0. CNV calls were generated with the PennCNV software
1
 (2011 June 16 
version) using the software pipeline and commands found at 
http://www.openbioinformatics.org/penncnv/penncnv_tutorial_affy_gw6.html. 
PennCNV output with copy number changes for all cell lines and genes can be found in 
Supplementary Table 5.1. 
Appendix S5.4 DNA Sequencing Analysis Pipeline– Variant Calling 
and Interpretation Methods 
Whole exome aligned sequencing data were available in the form of .bam files from 
Illumina Genome Analyzer IIx runs aligned to an hg19 genome build 
(“NCI60_WES_BAM_files:,” n.d.). Variants were detected using the software workflow 
below (A-D). The Genome Analysis Toolkit (GATK)
2
was used for variant calling and 
filtering with default parameters (exceptions): Realigner Target Creator, IndelRealigner, 
Haplotype Caller, Variant Recalibrator (for indels, --minNumBadVariants was set to 
5000 for LY2 and SUM159PT), and Apply Recalibration (ts_filter_level for indels was 
set at 99.0 and for SNPs at 99.9). VariantSelect was called to exclude non-variant loci 
and filtered loci with the default parameters for this purpose provided by GATK.  
Annovar
3
 was used to annotate the variants (both single nucleotide changes and 
insertions/deletions) and filter variants present in dbSNP 135. SIFT
4
 was used to predict 
which mutations (SNPs and indels) are likely damaging to the protein product, which 
were used in further analyses. Two software programs were used for splicing mutation 
analysis: Shannon Pipeline
5
 was used to predict splicing mutations, and Veridical
6
 was 
used to confirm aberrant splicing patterns in cell line-matched RNA-Seq data. In the 
Multiple Factor Analysis (MFA), mutation status was depicted with a binary variable in 
which the gene was assigned to be mutated or not. MFAs were also completed with total 
counts of likely deleterious mutation per cell line, which affected 10 genes, but did not 
alter the interpretation of the analysis. 
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A) Bam File Processing B) Bam File Realignment C) Variant Discovery 
 
D) Variant Analysis 
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Appendix S5.5 Reproducibility of Cell Line Data 
Appendix S5.5.1 GI50 Studies 
Growth inhibition (GI50) values represent the concentration of the chemical required to 
inhibit cell growth by 50% in comparison with untreated controls, and the study was 
carried out as previously described
7
. GI50 values were calculated using a sulforhodamine 
B (SRB) assay, which provides a sensitive method to measure cellular protein content. 
Cells were grown in 96 well plates for 24 hours, and then exposed to either paclitaxel or 
gemcitabine for 48 hours. We repeated triplicate GI50 measurements for 5 NCI-60 breast 
cancer cell lines: SKBR3, HS578T, BT549, MDAMB231, and T47D. Additionally, we 
quantified cell densities, and determined growth inhibition in order to resolve drug-
induced cytotoxicity. Percent of cytotoxicity was calculated as 100 x (Cell Control – 
Experimental) ÷ (Cell Control). GI50 was then derived using Graph Pad Prism. Data were 
transformed using X = Log(X) and then a non-linear regression was performed using 
options: “dose-response inhibition” and “Log [inhibitor] vs. response (variable slope).” 
Appendix S5.5.2 CytoScan HD Array 
The re-measured microarray analyses for 5 cell lines in our laboratory (MDAMB231, 
HS578T, MCF7, T47D, and SKBR3) were completed using the CytoScan HD Array Kit 
and Reagent Kit Bundle (catalog #901835) following the recommended manufacturer’s 
protocol  (Affymetrix, Santa Clara, CA). The AffymetrixGeneChip Command Console 
Software was used with default options to analyze the .CEL files for copy number change 
calls, which were visualized and manually confirmed using the Chromosome Analysis 
Suite (version 2.1.0.16). 
Appendix S5.5.3 Gene Capture and DNA Sequencing 
Capture probes were designed (genomic coordinates of probes listed in Supplementary 
Table 5.6, and then produced on a cleavable microarray using Custom Array Microarray 
Synthesizer (Bothell, WA). Exons and 300 bp into the introns, for 44 of the 49 genes, 
were targeted. Genomic DNA was sheared to ~300bp fragments using the Covaris S220 
Focused-ultrasonicator. Library preparation was carried out using the KAPA Biosystems 
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Standard High Throughput Library Preparation Kit and RNA bait from the capture array 
probes was used to enrich for the genes of interest
8
. DNA samples were quantified using 
qPCR (KAPA Library Quantification Kit for Illumina Platform) and then paired end 
reads (70 bp each side) were obtained using the standard Illumina Genome Analyzer IIX 
paired-end sequencing protocol.  
 Sequences of all exons (and 300 bp into each intron) for the 45 genes were 
selected using an ab initio approach
9
. Probe sequences were selected using PICKY 2.2 
software
10
 using the default settings with few exceptions (65ºC Tm, 30-70% GC content, 
5 probes per sequence, 20 nt maximum overlap). MPI-BLAT was used to ensure the 
probes align only to the targeted sequence.  
Generation, Cleavage and Purification Microarray Oligos 
 The selected sequences, with primer binding sites added to each end (5’ 
ATCGCACCAGCGTGTN36-70CACTGCGGCTCCTCA), were then synthesized onto 
two cleavable 12K microarray chips using a CustomArray Microarray Synthesizer 
(Bothell, WA). Probes were cleaved from the microarrays with concentrated (14.5N) 
ammonium hydroxide at 65ºC for 4 hours. Purified oligos were then amplified by 25 
cycles of conventional PCR using KapaHiFi DNA Polymerase (KapaBiosystems). 
Biotin-labelled RNA bait was generated from this product with nested PCR on the 
amplified oligosusgin a MAXIscript SP6 in vitro transcription kit (Ambion) with a UTP 
to biotin-16-UTP (Roche) ratio of 4 to 1. 
Sample Preparation 
Genomic DNA (gDNA) from the MDAMB231 cell line was diluted to 100 ng/μL in a 
volume of 51 μL for S220 Focused-ultrasonicator (Covaris) shearing (150-300nt 
fragments generated with the following settings: Time 120 sec, Duty cycle 10%, Intensity 
5, and Cycles per burst 200).  
Library Preparation and Capture 
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 The sheared samples were prepared using a KAPA Biosystems Standard 
(KK8200) and High Throughput (KK8234) Library Preparation kits, following the 
manufacturer’s protocol (KapaBiosystems). Genes of interest were captured using the 
Tiled RNA bait, using the hybridization selection protocol from Gnirke et al (2009) with 
1 to 2 ug of sample prep, 1.5 ug of RNA bait, and 75 uL of M-280 streptavidin 
Dynabeads (Invitrogen). DNA samples were quantified using qPCR following the 
protocol outlined by KAPA Library Quantification Kit for Illumina Platform (KAPA 
Biosystems, catalog# KK4824). Samples were then treated to standard Illumina paired-
end sequencing on a Genome Analyzer IIx, with 70 bp, then a 7 bp index (used during 
multiplexing), and then 70 bp. 
Bioinformatic Analysis 
When sequencing was completed, data was demultiplexed (when necessary) and aligned 
to the human reference genome (hg19) using CASAVA v1.8.2 and CRAC (v1.3.0). BAM 
files were prepared for variant calling using Picard, and variant calling was performed on 
both sets of aligned sequences using the UnifiedGenotyper tool in the Genome Analysis 
Toolkit (GATK). Variants called outside of target regions were ignored. Variant analysis 
was completed as outlined in Supplementary Methods IID. 
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Appendix S5.6 Support vector machine feature selection 
 
 
Adapted from Dash and Liu (1997)1
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Appendix S5.7 Partial-Least Squares Regression 
A partial-least squares regression (PLSR) was also performed to attempt to relate 
genomic findings to paclitaxel response, based on the fact that GI50 is a continuous 
variable. The predictive error of the model was measured by taking the absolute sum of 
the residuals (the actual GI50 minus the predicted GI50) of a leave-one-out cross-
validation. One cell line at a time was left out of the analysis and its paclitaxel GI50 value 
was predicted using the beta values given by the regression line and then compared with 
its measured GI50 value. 
Using the absolute sum of error as a measurement of predictive accuracy, we randomly 
selected subsets of genes ranging in number from 1 gene to 30 genes (out of a total of 31 
genes) for 1,000 iterations each to attempt to find the most optimal number of genes. Of 
the 9 paclitaxel genes with the lowest error, two million model iterations were performed 
to find the best predictive subsets with the lowest error values. However, the lowest 
absolute sum of residual errors was ~10. The high residual means imply a lack of 
confidence that the genomic signature will reliably predict GI50. For this reason, we 
discontinued attempts to use PLSR to predict gemcitabine (or paclitaxel) 
chemosensitivity.  
Appendix S5.8 Gene expression and Copy Number analyses on 
FFPE tumour blocks 
Nucleic acids were extracted from the FFPE tissue samples using Qiagen’sAllPrep 
DNA/RNA FFPE Kit (Cat. No. 80234, Venlo, Limburg, Netherlands). The recommended 
protocol was used with the following exceptions: 1) Tissue used for the nucleic acid 
extraction was obtained using 1 mm Miltex Sterile Disposable Biopsy Punches (Cat. No. 
33-31AA-P/25, Plainsboro, New Jersey), as opposed to using thin slices of the full block. 
Hematoxylin and eosin stained slides of each tissue block were marked by a pathologist 
to identify cancerous lesions and direct specific regions to punch. Using a biopsy punch 
allowed for targeted extractions, and minimized the amount of normal surrounding tissue 
used in the analysis. 2) 75 μl of mineral oil was used for tissue deparaffinization at 90°C 
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for 20 minutes, as previously described
12
. 3) The first proteinase K incubation was 
performed at 56°C for 2 hours.  
cDNA was produced from tumour RNA using SuperScript II Reverse Transcriptase (Cat. 
No. 18064-014, Invitrogen, Carlsbad, CA, USA) and 250ng IDT ReadyMade random 
hexamer per reaction. (Cat. No. 51-01-18-25, San Jose, CA, USA). cDNA synthesis was 
carried out following the manufacturer’s protocol, and purified using ethanol 
precipitation with 0.1X sodium acetate and 2.5X 100% anhydrous ethanol. Every cDNA 
sample used for gene expression measurement was then re-suspended in RNAse-free 
water, and diluted to 20 ng/μl for gene expression measurement. Purified DNA from the 
QiagenAllPrep columns were diluted to 9 ng/μl for copy number analysis. 
qPCR (gemcitabine copy number genes only) and qRT-PCR (all expression genes) were 
performed with the SensiFast SYBR No-ROX kit (Cat. No. BIO-98020, Bioline, London, 
UK) using the recommended protocol. Primer pairs were designed using PrimerQuest 
(Integrated DNA Technologies, Coralville, Iowa), spanning exons when possible (qRT-
PCR only). Each primer pair was optimized using duplicate 10 μl reactions for forward 
and reverse primer concentrations, and in some cases annealing temperatures. Primer 
sequences, annealing temperatures, and final concentrations used are listed in Table 
S5.6.1. NT5C qPCR was performed with a 10-second denaturation and 20-second 
extension in every cycle. All real-time PCR experiments used an Eppendorf Mastercycler 
realplex machine and followed the program: 95°C for 2 min, and 40 cycles of 5 s at 95°C, 
10 s at 60°C (copy number and some gene expression primers) or 64.5°C (only gene 
expression primers), and 15 s at 72°C. A melting curve was measured for all reactions, 
and any measurements with abnormal melting curve (ie. at a lower temperature due to 
primer diming) were removed from any further analysis. Two 10 μl reactions were 
performed per primer pair, per sample. 
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Table S5.6.1 
Gene Name 
Amplicon 
Size 
F/R Sequence 
Anneal. 
Temp. 
Opt. Conc. 
(nM) 
PACLITAXEL - qRT-PCR 
ABCC10 109 
F TGGGAAGACATTTGATGCAC  
64.5 
400 
R CTTCTCCCCCACCTCTGTCT  900 
BCL2 90 
F CCTGTGGATGACTGAGTACCTGAA 
64.5 
400 
R GGGCCGTACAGTTCCACAAAG 900 
BCL2L1 94 
F CTTGGATGGCCACTTACCTGAATG 
64.5 
900 
R GCATTGTTCCCATAGAGTTCCACAA 400 
BIRC5 113 
F GCAGTTTGAAGAATTAACCCTTGGTG 
64.5 
900 
R CCGCAGTTTCCTCAAATTCTTTCTTC 900 
FGF2 86 
F AGAAGAGCGACCCTCACATCAA 
64.5 
900 
R GTAACGGTTAGCACACACTCCTTTG 900 
FN1 120 
F TTGGAGATTCATGGGAGAAGTATGTG 
64.5 
900 
R CAGGACCACTTGAGCTTGGATAG 900 
MAP4 91 
F TCCTCTCCTGGATGTTGATGAGAA 
64.5 
900 
R AGATGGAGTATCTTCAATCTGGCTAGT 900 
MAPT 93 
F GGCTCATTAGGCAACATCCATCATAA 
64.5 
900 
R CTTCGACTGGACTCTGTCCTTGA 900 
NFKB2 101 
F AGATGACATTGAGGTTCGGTTCTATG 
64.5 
400 
R ACACAATGGCATACTGTTTATGCAC 400 
TLR6 115 
F CCGACGGAAATGAATTTGCAGTAGAC 
64.5 
900 
R AGCTCAGCGATGTAGTTCTGAGAC 900 
TMEM243 104 
F AGGACTTTGCTACCAGGACCTAC 
64.5 
900 
R GCTGCCAACAACTAAATTGATGATTCG 100 
GEMCITABINE - qRT-PCR 
ABCC10 109 
F TGGGAAGACATTTGATGCAC  
64.5 
400 
R CTTCTCCCCCACCTCTGTCT  900 
CMPK1 84 
F GGGAAAGAGTAGTGGTAGGAGTGATG 
64.5 
900 
R ATTGGCTTTGTTGACTGAAGGTAGG 400 
DCTD 96 
F TACCATGATAGTGACGAGGCAACTG 
64.5 
400 
R GACAATCTTGCTGCACTTCGGTATG 900 
NME1 120 
F CCTTCATTGCGATCAAACCAGATG 
64.5 
400 
R GATCTTCGGAAGCTTGCATGAATTT 400 
RRM1 103 
F ACTATTTATTATGGTGCTCTGGAAGCC 
64.5 
400 
R ACTGAAGAATTCCTTTGCTAACTGGAG 900 
RRM2B 80 
F TCTGGCTAAAGAAGAGAGGTCTTATGC 
64.5 
400 
R ACAGTGAAGTCCTTCATCTCTGCTG 400 
GEMCITABINE - qPCR 
ABCC10 93 
F GAGAATAGTAGTAGCTTACCTTGTAG 
60 
400 
R CATGTATTCAGAGCTTACTTTGTG 400 
NT5C 126 
F CCTTGTCAGGATAATTCGTTCTAC 
57.2 
400 
R CCAAGTCCCTATCCCTGAAT 400 
TYMS 107 
F  GTATGTCAGCCTTTCCCTTC 
60 
400 
R  CAGTGAACACGAGAAACAAATC 400 
STANDARDS - qRT-PCR 
ACTB 101 
F TTGTTACAGGAAGTCCCTTGCC 
64.5 
400 
R ATGCTATCACCTCCCCTGTGTG  400 
B2M 86 
F TGCTGTCTCCATGTTTGATGTATCT 
60 
400 
R TCTCTGCTCCCCACCTCTAAGT 400 
GAPDH 87 
F TGCACCACCAACTGCTTAGC 
60 
400 
R GGCATGGACTGTGGTCATGAG 900 
STANDARDS - qPCR 
ACTB 101 
F TTGTTACAGGAAGTCCCTTGCC 
64.5 
400 
R ATGCTATCACCTCCCCTGTGTG  400 
RMND5A 99 
F GCCAGCTTCTGAATTATGGTCTTC 
60 
400 
R GAAACTCAATGGAACCTTCTGTTTC 400 
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Expression values were normalized per sample based off of three genes: ACTB, B2M, and 
GAPDH using the equation (as previously described
13
): 
𝒆𝒙𝒑𝒓𝒆𝒔𝒔𝒊𝒐𝒏𝒗𝒂𝒍𝒖𝒆 =  𝟐−∆𝑪𝒕 = 𝟐−(𝑪𝒕  𝒐𝒇 𝑮𝑶𝑰 – 𝑪𝒕 𝒐𝒇 𝑨𝒗𝒆𝒓𝒂𝒈𝒆 𝑺𝒕𝒂𝒏𝒅𝒂𝒓𝒅𝒔) 
Gene expression values for the FFPE samples were clustered as described in main 
Methods.  
For copy number, 5 or 6 dilutions from hgDNA (9, 3, 1, 0.33, 0.11, and in some cases 
0.037 ng/µl) were used to construct a standard curve for each primer pair (Figure S5.6.1). 
Two reference genes (ACTB and RNMD5A) were used to normalize for sample variation. 
ACTB is a single copy gene (1 haploid gene), and RMND5A is a multicopy gene (3 
haploid copies
14
). DNA from 9 lymph-node negative samples were used as normal 
controls to adjust for differences in primer efficiencies. Copy number calling was 
determined as previously described
15
: 
Ct Values were measured using two 10 μl reactions for each sample and gene. 
Raw copy values were derived from the equation of the standard curves for each gene 
(Figure S5.6.1), where y = Ct and x = log(Q). 
Copy number calibration was performed per gene for each sample (both tumour and 
normal) by dividing the raw copy value call by the average of the copy value call of 
ACTB and RMND5A for that sample. This adjusted for differences in Ct values between 
samples. 
𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑒𝑑 𝑐𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟 =
𝑟𝑎𝑤 𝑐𝑜𝑝𝑦 𝑣𝑎𝑙𝑢𝑒
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 (𝐴𝐶𝑇𝐵 𝑎𝑛𝑑 𝑅𝑀𝑁𝐷5𝐴 𝑟𝑎𝑤 𝑐𝑜𝑝𝑦 𝑣𝑎𝑙𝑢𝑒𝑠)
 
Final copy number values were determined by adjusting for the average calibrated copy 
numbers of the normal (lymph node negative) samples to adjust for differences in 
primers/gene measurements. 
𝑓𝑖𝑛𝑎𝑙 𝑐𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟 =
𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑒𝑑 𝑐𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟 𝑝𝑒𝑟 𝑠𝑎𝑚𝑝𝑙𝑒
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑒𝑑 𝑐𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 9 𝑛𝑜𝑟𝑚𝑎𝑙𝑠
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Copy number gains and losses were determined if the copy number call was at least 3 
standard deviations (of ACTB and RMND5A) from the mean copy number for that gene 
(see Figure S5.6.2 for copy number changes highlighted in yellow, and Supplementary 
Table 5.3 for copy number calls). Because no copy number changes were expected for 
ACTB and RMND5A, the average standard deviation between the two, when calibrated 
against each other, was used (standard deviation = 0.06269). Any copy number gains 
were assumed to be a copy of 3, whereas losses were assumed to be 1.  
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Figure S5.6.1 – Copy number standard curves 
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Figure S5.6.2 – Copy number gains and losses per gene 
 
Note: For illustrative purporses only. Each gene lists samples (x-axis) in a different order, and not all samples are labeled. See 
Supplementary Table 5.3 for exact copy number calls per sample and gene. 
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Appendix S5.9 Reproducibility of Data 
To assess reproducibility of the data used to derive the genomic signatures for paclitaxel 
and gemcitabine, we sought to determine the degree to which a sample of the cell line 
data was consistent between cell line sources.  We obtained a subset of the cell lines used 
in the prior study by Daemon et al. from the Coriell Institute, and, redetermined their GI50 
and copy number values as well as the variants present in the candidate gene sequences in 
one of the lines. Growth inhibition studies were carried out for 5 breast cancer cell lines 
(BT549, MDAMB231, HS578T, T47D, SKBR3) to determine the reproducibility of cell 
line sensitivity to paclitaxel and gemcitabine (Figures 5.7.1 and 5.7.2). Re-measured GI50 
values were compared to GI50s from Daemen et al. and those previously reported from 
Ring et al., 2008. The standard deviations of the GI50 values between studies were low for 
all measurements, except for the SKBR3 treated with gemcitabine (GI50 for SKBR3 was 
not determined by Ring et al., 2008). Although the differences in cell line growth 
inhibition were minimal (< 1 log10), our results were more similar to those reported by 
Daemen et al., 2013. The standard deviations between replicates from the Ring et al. 
study were more than twice our measurements for the same cell lines, except for BT549 
paclitaxel and MDAMB231 gemcitabine GI50 values. In some instances, substitution of 
our GI50 values (or those obtained by Ring et al., 2008) for those determined by Daemen 
et al., 2013, could affect the subsequent classification of the cell line. For paclitaxel, 
triplicate assays of 4 of 5 lines (all but HS578T) exhibit GI50 values close to the median 
GI50 threshold for distinguishing sensitivity from resistance (-log10M = 8). For 
gemcitabine, a single cell line (SKBR3, -log10M = 7) was close to this threshold. This 
highlights the importance of conducting genomic analyses and GI50 studies on the same 
source line, given that clonal variation and genetic evolution can occur in cancer cell 
lines
16
.  
Copy number data of 5 cell lines (MDAMB231, T47D, MCF7, HS578T, and SKBR3) 
were measured using an AffymetrixCytoScan HD array and analyzed using the 
Affymetrix Chromosome Analysis Suite (ChAS; CytoScan HD data). The 
AffymetrixCytoScan HD array contains approximately 2.6 million copy probes and 
750,000 SNP probes, whereas the Affymetrix SNP 6.0 array contains approximately 
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946,000 copy number probes and 906,600 SNP probes. DNA from MDAMB231 was 
extracted in May 2010 and again in February 2013 to compare different time 
points/passages of the cell line from the same batch.  The copy number calls of the SNP 
6.0 DNA data from the Daemen et al., 2013 study analyzed by PennCNV, and re-
analyzed by ChAS, were compared with our CytoScan HD data (Supplementary Table 
5.11). Copy number changes between the two time points of MDAMB231 were the same 
for all 49 genes. Copy number calls between the Daemen et al. and CytoScan HD data 
were largely concordant. Of the 49 genes and 5 cell lines (total of 245 copy number 
calls), 151 were the same (62%), and an additional 6 (2%) were concordant between our 
CytoScan HD data and PennCNV, but not the Daemen et al. data analyzed by ChAS. 33 
(15%) of the copy number calls were different between our CytoScanHD data and 
Daemen data, but these appear to be real differences between the cell line karyotypes, 
because PennCNV and ChAS were consistent for the Daemen et al. data. Conversely, 33 
(15%) copy number changes were inconsistently called between the PennCNV analyses, 
and the ChAS analyses of both data sets. In these cases, it is likely that PennCNV 
miscalled the copy number state. None of these copy number changes occurred in NT5C, 
ABCC10, and TYMS, which were present in the final SVM model for gemcitabine 
resistance. Another 22 (9%) copy number calls were inconsistent between our CytoScan 
HD data and PennCNV. Upon further analysis of the Daemen data set with ChAS, these 
differences appear to be due to noise in the SNP 6.0 data.  One possible explanation is 
that SNP 6.0 probes neighboring conserved repetitive elements exhibit higher variation in 
signal intensities than probes in the Cytoscan HD, which are located further away from 
these sequences
9
.  Inconsistencies may be also due to heterogeneous populations of 
mixtures of tumour cells each with different copy numbers within these populations. 
Concordant calls, the different noise levels in the data, and ambiguous copy number calls 
(ie. between a copy number of 1 and 2), and actual copy number differences are indicated 
in Figure 5.7.3.  
The relevant gene sequences from MDAMB231 were derived using next generation 
sequencing with a custom oligonucleotide enrichment reagent that targeted 44 of the 49 
genes (Supplementary Table 5.12; CSAG2, CTPS1, DCTD, NME1, and NT5C are not 
included). Results were compared with MDAMB231 exonic sequences 
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(“NCI60_WES_BAM_files:,” n.d.).  In our analysis, which also includes newly 
determined intronic sequences flanking each exon (300 nt), 59 mutations were detected 
(Supplementary Table 5.12). Five variants were predicted to be damaging by SIFT and 
37 were reproduced in both studies (36 SNPs and 1 insertion), of which 35 were known 
variants present in greater than 1% of the population, and 2 were novel. None of the 
damaging mutations were used in the MFA for MDAMB231, because the only likely 
damaging mutations between the two data sets were known, frequent variants. 
GI50s (GI50 drug concentrations are in –log10M) were re-measured for paclitaxel and 
gemcitabine in cell lines BT549, HS578T, MDAMB231, T47D, and SKBR3, and then 
compared to 2 sets of previously published values
17,18
. The yellow bar indicated the GI50 
threshold for resistant (below the line) and sensitive (above) cell lines.  
Figure 5.7.1 – GI50s for Paclitaxel 
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Figure 5.7.2 – GI50s for Gemcitabine 
 
 
Figure 5.7.3 – MDAMB231 Copy Number Analysis 
MDAMB231: Copy number analysis was performed using an AffymetrixCytoScan HD 
with DNA extracted from MDAMB231 in February of 2013 (dark blue in screen shots), 
and May of 2010 (pink). Both time points were compared to the Affymetrix SNP 6.0 data 
from Daemen et al. (light blue). Screen shots from ChAS are displayed for ABCC10, 
NT5C, OPRK1, and TYMS. Log 2 Ratios (green and red bars), copy number state, smooth 
signal, and genes are displayed for all three analyses (top to bottom). Log2 Ratios are 
displayed using a heat map between -1.5 and 1.5 (below). 
Log2 Ratio Heat Map:  
    
-1.5        0           1.5
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ABCC10 (at dotted line), chr6: 42,943,397 – 43,876,083, PennCNV call for Daemen data set: 2. A small deletion is detected by ChAS because the smooth 
signal drops below 1.5.It isn’t clear whether it is a real copy number change because it is small, and the Log2Ratios are noisy (red and green bars). 
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NT5C (at dotted line), chr17: 72,625,852 – 73,628,356, PennCNV call for Daemen data set: 2. Normal copy number of 2 is seen in all three analyses. There is a 
larger range of log 2 ratios seen in the SNP 6.0 array. 
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OPRK1 (at dotted line), chr8: 53,664,288 – 54,638,171, PennCNV call for Daemen data set: 2. A deletion of 1 copy is evident for the two re-measured sets, and 
may be present in the Daemen et al. data. PennCNV called this region a copy number of 2, although the data is noisy and the smooth signal is between a copy of 
1 and 2. This is an example where the noise in the data, or the cells are mosaic, may explain the discordant results between Daemen et al. and re-measured data. 
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TYMS (at dotted line), chr18: 177,496 – 1,153,659, PennCNV call for Daemen data set: 2. This demonstrates an example where the copy number is different 
between the Daemen data set and the re-measured data set. This appears to be a real change, as PennCNV and ChAS both clearly call a copy number of 2, but 
there is one extra copy detected in the re-measured data. 
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Appendix S5.10 MFA Criteria 
Classification 
Criteria (all are required for any given classification) 
RV 
coefficient 
of Factor* 
cos2 value 
of Factor* 
RV 
Coefficient 
of GI50 
cos2 value 
of GI50 
% variance 
explained 
Strong Relationship 
(Str Rel)^ >0.6 >0.4 >0.6 >0.4 >25% 
Relationship (Rel)~ >0.5 >0.25 >0.5 >0.25 >25% 
Possible 
Relationship (Pos) >0.3 >0.1 >0.5 >0.25 >25% 
*gene expression, copy number or mutation status, ^all dimension 1, ~dimensions 1 and 2 
 
Appendix S5.11 Multiple Factor Analysis 
Appendix S5.11.1 Cell Line Numbers in the Multiple Factor 
Analyses Individual Factor Maps: 
Cell Line 
Pac 
MFA 
# 
Gem 
MFA 
# 
Cell Line 
Pac 
MFA 
# 
Gem 
MFA 
# 
Cell Line 
Pac 
MFA 
# 
Gem 
MFA 
# 
184A1 1 HCC1954 16 MDAMB231 31 30 
184B5 2 HCC202 17 MDAMB361 32 31 
600MPE 3 HCC2185 18 MDAMB415 33 32 
AU565 4 HCC3153 19 MDAMB436 34 33 
BT474 5 HCC38 20 MDAMB453 35 34 
BT483 6 HCC70 21 MDAMB468 36 35 
BT549 7 HS578T 22 SKBR3 37 36 
CAMA1 8 LY2 23 SUM1315MO2 38 37 
HCC1143 9 MCF10A 24 SUM159PT 39 38 
HCC1187 10 MCF10F 25 SUM185PE 40 39 
HCC1395 11 MCF12A 26 SUM52PE 41 40 
HCC1428 12 MCF7 27 T47D 42 41 
HCC1569 13 MDAMB134VI 28 UACC812 43 42 
HCC1806 14 MDAMB157 29 N/A ZR751 44 43 
HCC1937 15 MDAMB175VII 30 29 ZR75B 45 44 
Individual factor maps, correlation circles, and groups representations are all formatted 
the same throughout the document. Factors (copy number, gene expression, mutation 
status and GI50) are labeled in the correlation circle arrows (overlaid on the individual 
factor map) and the groups representation. Cell lines are numbered according to the 
legend in the table of contents. Additional quantitative details of the MFAs can be found 
below.  
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Appendix S5.11.2 Paclitaxel Example - MAPT 
Individual Factor Map – Dimensions 1 and 2 (% variance explained in brackets) 
 
Groups Representation 
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Appendix S5.11.3 Gemcitabine Example - DCTD 
Individual Factor Map – Dimensions 1 and 2 (% variance explained in brackets) 
 
Groups Representation 
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Appendix S5.12 Paclitaxel Multiple Factor Analysis Results by Gene 
 
Negative (-) = Higher predictive variable is associated with lower GI50 value (ie. Increased resistance), Positive = Higher predictive 
variable is associated with higher GI50 value (ie. Decreased resistance), CN = copy number, GE = gene expression, Mut = somatic 
SMV*
Gene Name % VE GI50 CN GE Mut % VE GI50 CN GE Mut GI50 CN GE Mut GI50 CN GE Mut CN GE Mut
ABCB1 31% 0.77 0.08 0.17 0.78 28% 0.17 0.75 0.71 0.06 0.60 0.01 0.03 0.61 0.03 0.56 0.51 0.00 Str Rel (-)
ABCB11 41% 0.54 0.61 0.76 NA 32% 0.75 0.63 0.02 NA 0.29 0.37 0.58 0.57 0.40 0.00 Pos (+) Rel (+)
ABCC1 34% 0.22 0.82 0.80 0.08 27% 0.72 0.02 0.10 0.76 0.05 0.67 0.64 0.01 0.51 0.00 0.01 0.57 Pos (+)
ABCC10 43% 0.28 0.80 0.91 0.39 26% 0.38 0.48 0.04 0.81 0.08 0.65 0.83 0.15 0.15 0.23 0.00 0.65 21.28
BAD 55% 0.23 0.90 0.89 NA 33% 0.97 0.09 0.16 NA 0.05 0.81 0.80 0.95 0.01 0.02
BBC3 39% 0.77 0.00 0.77 NA 35% 0.28 0.94 0.28 NA 0.59 0.00 0.59 0.08 0.88 0.08 Str Rel (-)
BCAP29 34% 0.40 0.16 0.82 0.72 26% 0.31 0.93 0.19 0.24 0.16 0.02 0.66 0.52 0.10 0.86 0.04 0.06
BCL2 39% 0.36 0.63 0.80 NA 35% 0.83 0.58 0.08 NA 0.13 0.39 0.63 0.70 0.33 0.01 Rel (+) 25.53
BCL2L1 38% 0.67 0.70 0.74 0.15 32% 0.38 0.52 0.32 0.88 0.45 0.49 0.55 0.02 0.15 0.27 0.10 0.77 Rel (-) Str Rel (-) 36.17
BIRC5 35% 0.14 0.77 0.80 0.42 28% 0.89 0.00 0.39 0.43 0.02 0.59 0.63 0.18 0.79 0.00 0.15 0.19 27.66
BMF 46% 0.77 0.28 0.83 NA 34% 0.38 0.93 0.04 NA 0.59 0.08 0.70 0.14 0.87 0.00 Str Rel (-) 25.53
CNGA3 43% 0.72 0.75 0.46 NA 31% 0.35 0.21 0.88 NA 0.52 0.56 0.21 0.12 0.04 0.78 Str Rel (-)
CYP2C8 32% 0.74 0.76 0.17 0.33 25% 0.30 0.14 0.95 0.13 0.55 0.57 0.03 0.11 0.09 0.02 0.89 0.02 Str Rel (+)
CYP3A4 29% 0.76 0.11 0.68 0.34 27% 0.17 0.69 0.39 0.63 0.58 0.01 0.46 0.11 0.03 0.48 0.15 0.40 Str Rel (+)
FGF2 36% 0.75 0.29 0.57 0.67 26% 0.18 0.89 0.17 0.44 0.56 0.08 0.33 0.45 0.03 0.79 0.03 0.19 Rel (+) Rel (-) 27.66
FN1 32% 0.75 0.53 0.62 0.25 27% 0.25 0.30 0.39 0.87 0.56 0.28 0.39 0.06 0.06 0.09 0.15 0.76 Rel (+) Rel (+) 29.79
GBP1 52% 0.54 0.75 0.84 NA 30% 0.81 0.49 0.09 NA 0.29 0.56 0.71 0.66 0.24 0.01 Rel Rel (+)
MAP2 31% 0.43 0.32 0.65 0.72 28% 0.55 0.73 0.48 0.22 0.19 0.10 0.43 0.52 0.31 0.54 0.23 0.05 Pos (+)
MAP4 43% 0.38 0.74 0.81 0.60 27% 0.77 0.44 0.29 0.45 0.14 0.55 0.66 0.36 0.59 0.19 0.08 0.20 25.53
MAPT 33% 0.81 0.11 0.82 0.10 27% 0.32 0.45 0.27 0.83 0.65 0.01 0.67 0.01 0.10 0.20 0.07 0.69 Str Rel (-) 34.04
NFKB2 31% 0.68 0.72 0.52 0.06 29% 0.40 0.06 0.54 0.83 0.46 0.52 0.27 0.00 0.16 0.00 0.29 0.69 Rel (+) Pos (+) 23.4
NR1I2 38% 0.74 0.74 0.21 NA 33% 0.12 0.16 0.98 NA 0.55 0.54 0.04 0.01 0.03 0.96 Str Rel (+)
OPRK1 33% 0.57 0.82 0.57 0.16 26% 0.52 0.07 0.60 0.65 0.32 0.67 0.32 0.03 0.27 0.00 0.36 0.42 Pos Pos(-) Rel (+)
SLCO1B3 35% 0.55 0.49 0.74 0.56 30% 0.68 0.70 0.26 0.39 0.30 0.24 0.55 0.31 0.47 0.50 0.07 0.16 Rel (-) Rel (+) 23.4
TLR6 32% 0.69 0.44 0.70 0.35 27% 0.38 0.44 0.47 0.73 0.48 0.19 0.49 0.12 0.14 0.19 0.22 0.53 Pos Str Rel (+) 25.53
TMEM243 50% 0.04 0.87 0.87 NA 33% 1.00 0.06 0.01 NA 0.00 0.75 0.76 1.00 0.00 0.00 21.28
TUBB1 39% 0.66 0.49 0.71 NA 32% 0.45 0.85 0.17 NA 0.43 0.24 0.50 0.20 0.73 0.03 Str Rel (+)
TUBB4A 43% 0.30 0.78 0.76 NA 33% 0.95 0.11 0.27 NA 0.09 0.61 0.58 0.90 0.01 0.07
TUBB4B 36% 0.75 0.33 0.64 NA 34% 0.05 0.87 0.50 NA 0.56 0.11 0.41 0.00 0.75 0.25 Pos Str Rel (-)
TWIST1 38% 0.75 0.53 0.53 NA 33% 0.00 0.71 0.70 NA 0.57 0.28 0.29 0.00 0.50 0.50 Rel (+) Rel (+) 21.28
CSAG2 29.79
Dim 1 Dim 2
Groups Representation - 
Dim 1 
Groups Representation - 
Dim 2 GI50 Relationship ^
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mutations, % VE = % variance explained, Dim = dimension, SVM = support vector machine, * = percent of misclassification if the 
gene is removed from the SVM, Str Rel = strong relationship to GI50, Rel = relationship to GI50, Pos = possibly a relationship to 
GI50. ^ blank boxes indicate no relationship. 
Appendix S5.13 Gemcitabine Multiple Factor Analysis Results by Gene 
 
Abbreviations for table listed in Appendix S5.12
SVM*
Gene Name % VE GI50 CN GE Mut % VE GI50 CN GE Mut GI50 CN GE Mut GI50 CN GE Mut CN GE Mut
ABCB1 0.32 0.76 0.31 0.77 0.15 0.26 0.26 0.59 0.17 0.79 0.58 0.10 0.60 0.02 0.07 0.35 0.03 0.62 Str Rel (-) 20.45 (Exp)
ABCC10 0.34 0.31 0.20 0.83 0.71 0.27 0.77 0.67 0.06 0.22 0.10 0.04 0.70 0.51 0.60 0.45 0.00 0.05 Str Rel (-) 31.82 (Exp), 25 (CN)
AK1 0.36 0.44 0.35 0.85 0.63 0.26 0.45 0.65 0.03 0.65 0.19 0.12 0.72 0.39 0.20 0.43 0.00 0.42 Pos (-) Pos (-)
CDA 0.42 0.77 0.79 0.16 NA 0.33 0.22 0.01 0.98 NA 0.60 0.63 0.03 0.05 0.00 0.95 Str Rel (-)
CMPK1 0.37 0.55 0.63 0.82 0.29 0.26 0.10 0.42 0.07 0.91 0.31 0.40 0.67 0.08 0.01 0.18 0.00 0.83 Rel (-) Rel (-) 18.18 (Exp)
CTPS1 0.35 0.52 0.77 0.70 0.18 0.27 0.51 0.33 0.22 0.83 0.27 0.59 0.49 0.03 0.26 0.11 0.05 0.68 Pos Pos (-)
DCK 0.31 0.83 0.57 0.43 0.15 0.28 0.04 0.31 0.73 0.71 0.69 0.32 0.18 0.02 0.00 0.09 0.53 0.51 Rel (+)
DCTD 0.40 0.81 0.51 0.83 0.11 0.26 0.21 0.18 0.19 0.96 0.66 0.26 0.68 0.01 0.04 0.03 0.03 0.93 Rel (+) Str Rel (+) 25 (Exp)
NME1 0.53 0.43 0.85 0.82 NA 0.31 0.90 0.15 0.31 NA 0.19 0.73 0.68 0.81 0.02 0.10 Pos (-) Pos (-) 31.82 (Exp)
NT5C 0.55 0.46 0.84 0.87 NA 0.30 0.89 0.30 0.17 NA 0.21 0.70 0.75 0.79 0.09 0.03 34.09 (CN)
RRM1 0.45 0.5 0.82 0.9 0.24 0.25 0.19 0.31 0.07 0.92 0.25 0.67 0.81 0.06 0.03 0.1 0.01 0.85 20.45 (Exp)
RRM2 0.35 0.49 0.66 0.78 0.32 0.27 0.51 0.52 0.18 0.73 0.24 0.44 0.62 0.10 0.26 0.27 0.03 0.53 Pos (-) Pos (-)
RRM2B 0.43 0.37 0.86 0.82 0.41 0.25 0.64 0.12 0.19 0.72 0.13 0.74 0.67 0.16 0.41 0.01 0.04 0.52 Rel (-) 29.55 (Exp)
SLC28A1 0.37 0.36 0.73 0.48 0.76 0.27 0.75 0.25 0.63 0.20 0.13 0.53 0.23 0.58 0.56 0.06 0.40 0.04 Str Rel (-)
SLC28A3 0.31 0.76 0.16 0.31 0.73 0.26 0.21 0.75 0.62 0.21 0.58 0.03 0.10 0.54 0.04 0.56 0.39 0.04 Str Rel (+)
SLC29A1 0.54 0.02 0.90 0.90 NA 0.33 1.00 0.05 0.07 NA 0.00 0.81 0.81 1.00 0.00 0.00
SLC29A2 0.46 0.34 0.87 0.76 0.62 0.25 0.84 0.08 0.14 0.53 0.12 0.76 0.57 0.38 0.71 0.01 0.02 0.28 Pos (-)
TYMS 0.50 0.16 0.87 0.85 NA 0.33 0.98 0.00 0.18 NA 0.02 0.75 0.73 0.97 0.00 0.03 25 (CN)
Dim 1 Dim 2
Groups Representation - 
Dim 1 
Groups Representation - 
Dim 2 GI50 Relationship^
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Appendix S5.14 Cell Line GI50 vs. SVM Classification Score 
Appendix S5.14.1 Paclitaxel SVM 
 
Support vector machine classification score plotted against the GI50 of the cell line for 
paclitaxel. The vertical axis crosses the horizontal axis at the median GI50 of all cell lines 
analyzed.  Cell lines with scores >0 were classified as resistant, those with scores <0 are 
classified as sensitive. Cell lines outlined in a blue box are those classified as resistant, 
but are actually sensitive to the drug (false positives); cell lines outlined in purple box 
were misclassified as sensitive (false negatives). 
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Appendix S5.14.2 Gemcitabine SVM 
 
Support vector machine classification score plotted against the GI50 of the cell line for 
gemcitabine. The vertical axis crosses the horizontal axis at the median GI50 of all cell 
lines analyzed.  Cell lines with scores >0 were classified as resistant, those with scores <0 
are classified as sensitive. Cell lines outlined in a blue box are those classified as 
resistant, but are actually sensitive to the drug (false positives); cell lines outlined in 
purple box were misclassified as sensitive (false negatives) 
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Appendix S5.15 Single Gene paclitaxel and gemcitabine SVMs 
using cell line data 
Paclitaxel 
SVM single variable Percent misclassified Hinge loss 
Subtype 30.6% 0.69 
ABCB1 44.9% 0.90 
ABCB11 44.9% 0.90 
ABCC1 44.9% 0.90 
ABCC10 44.9% 0.90 
BAD 46.9% 0.95 
BBC3 34.7% 0.87 
BCAP29 44.9% 0.90 
BCL2 44.9% 0.90 
BCL2L1 44.9% 0.92 
BIRC5 44.9% 0.90 
BMF 42.9% 0.86 
CNGA3 44.9% 0.90 
CSAG2 36.7% 0.80 
CYP2C8 44.9% 0.90 
CYP3A4 44.9% 0.90 
FGF2 42.9% 0.91 
FN1 44.9% 0.85 
GBP1 36.7% 0.77 
MAP2 40.8% 0.86 
MAP4 44.9% 0.90 
MAPT 34.7% 0.81 
NFKB2 32.7% 0.85 
NR1I2 44.9% 0.90 
OPRK1 44.9% 0.90 
SLCO1B3 34.7% 0.78 
TLR6 38.8% 0.81 
TMEM243 44.9% 0.90 
TUBB1 44.9% 0.90 
TUBB4A 46.9% 0.94 
TUBB4B 44.9% 0.90 
TWIST1 44.9% 0.90 
15 Genes: 18% 0.64 
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Gemcitabine 
SVM single variable Percent misclassified Hinge loss 
Subtype 45.5% 0.95 
ABCB1-GE 45.5% 0.94 
ABCC10-CN 47.7% 0.95 
ABCC10-GE 36.4% 0.90 
CMPK1-GE 40.9% 0.87 
DCTD-GE 36.4% 0.90 
NME1-GE 45.5% 0.91 
NT5C-CN 47.7% 1.01 
RRM1-GE 38.6% 0.95 
RRM2B-GE 50.0% 0.98 
TYMS-CN 45.5% 0.91 
All Genes: 15% 0.66 
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Appendix S5.16 Multiple Factor Analysis– Entire and SVM Gene 
Sets 
(for dimensions 1 and 2, % variance explained in brackets) 
Appendix S5.16.1 Paclitaxel – SVM Gene Set 
Individual Factor Map 
 
The individual factor maps generated with a multiple factor analysis using the gene set 
derived from the respective SVMs are displayed for paclitaxel. Purple points are resistant 
cell lines, blue points are sensitive cell lines. Cell lines outlined in a blue box are those 
classified as resistant, but are actually sensitive to the drug (false positives); cell lines 
outlined in purple box were misclassified as sensitive (false negatives). 9 of 49 cell lines 
were misclassified for paclitaxel. 
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Appendix S5.16.2 Paclitaxel – Entire Gene Set 
Individual Factor Map 
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Appendix S5.16.3 Gemcitabine – SVM Gene Set 
Individual Factor Map 
 
The individual factor maps generated with a multiple factor analysis using the gene set 
derived from the SVM are displayed for gemcitabine. Purple points are resistant cell 
lines, blue points are sensitive cell lines. Cell lines outlined in a blue box are those 
classified as resistant, but are actually sensitive to the drug (false positives); cell lines 
outlined in purple box were misclassified as sensitive (false negatives). 7 of 44 cell lines 
were misclassified for gemcitabine. 
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Appendix S5.16.4 Gemcitabine– Entire Gene Set 
Individual Factor Map 
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Appendix S5.17 FFPE Samples – Gene expression measurements summary 
Appendix S5.17.1 Number of measurements by gene compared to GTEx expression levels 
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Appendix S5.17.2 Year of tissue block compared to number of measurements per sample 
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Appendix S5.18 Patient Clustering Supplementary Results. 
Clustering was performed as in main Methods. Each cluster derived from the MD 
Anderson Patient Data was isolated and the tumours in each were summarized by 
subtype, number of distance recurrences ("events"), and mean time to distant recurrence 
(Tables S5.1-S5.3 – see below). 
The 'grey' clusters were isolated and further clustered with similar stratification by gene 
expression and outcome (Supplementary Figure VI. 1).  
Appendix S5.18.1 FFPE Patient Samples 
Figure VI.1 – Paclitaxel FFPE Clustering Results 
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Expression heatmap of the paclitaxel SVM derived genes for our set of 32 FFPE samples, 
as measured by qPCR. Each row represents a gene and each column a tumour. Red 
indicates higher expression and blue represents lower expression, as shown by the colour 
bar on the left. Clustering was done based on the similarity of each tumour's and gene's 
expression profile. The dendrograms on the top and left indicate the relatedness of each 
tumour and gene by the length and subdivision of the branches, with deeper branches 
indicating a stronger relationship and branches in the same 'tree' being more closely 
related to each other than data in other 'trees'. 
Figure VI.2 – Gemcitabine FFPE Clustering Results 
 
Figure legend as above (Figure VI. 3). 
Note: sample 3A had an extremely high expression value for DCTD and distorted the row 
view for that gene. It has been removed in this figure for ease of visualization. 
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Appendix S5.18.2 Hatzis et al. Patient Data 
Supplementary Figure VI.3 - Further Clustering of the 'Grey' Cluster 
  
The 'grey' cluster from the previous clustering analysis was isolated and clustered further. 
The leftmost cluster (shaded a lighter grey) is composed of 70% luminal tumours with a 
mean survival time of 3.14 years. The rightmost cluster is composed of 43% basal 
tumours with a mean survival time of 2.45 years. The leftmost cluster also contains only 
3 distant recurrences, with two of those being classified by the MD Anderson signature as 
"Sensitive". The 'light grey' cluster, meanwhile, is stratified very well on the basis of the 
MD Anderson signature (results not shown). This mirrors the results of the clustering 
analysis on the 'green' and 'purple' tumour clusters. 
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Supplementary Figure VI.4 - Zoom on the 'purple' and 'green' clusters. 
 
The clusters from Figure 11 in the main paper were isolated from the main heatmap for 
easier visualization of the differential gene expression that distinguishes each cluster. 
Figure legend as in the main paper. 
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Table S5.1: Summary of tumours contained in each cluster. 
 
Table S5.2: Summary of tumours contained in each cluster. 
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Table S5.3: Summary of tumours contained in each cluster. 
 
RD: recurrent disease pCR: pathological complete response 
Insensitive/Sensitive as predicted by Hatzis et. al. (2011) 
Events: distant relapse Time: time to distant relapse 
Appendix S5.19 MAPT Expression Affects Prognosis in Luminal 
Tumours. 
 MAPT is part of the PAM50 and clearly segregates the data into luminal and basal 
subtype to a large extent. However, some luminal tumours express MAPT at a lower level 
than the majority. Low MAPT expressing luminal subtypes fall into the low MAPT 
expressing 'purple' cluster (Supplementary Figure VI. 4) and have a significantly worse 
prognosis than higher MAPT expressing luminal tumours in the patient dataset 
(Supplementary Figure VII. 1). 
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Supplementary Figure VII. 1 - Kaplan-Meier curves for low MAPT expressing luminal 
tumours vs. higher MAPT expressing luminal tumours. 
 
'Low' vs. 'high' expression was stratified by median MAPT expression across all tumours, 
regardless of subtype. Luminal tumours with expression values below the overall median 
were classified as 'low MAPT' and those with values above were classified as 'high 
MAPT'. There were 32 low MAPT expressing' luminal tumours in the low MAPT set and 
123 high MAPT expressing luminal tumours.  In the log-rank test, the Kaplan-Meier 
results are significant (p = 0.037). The log-rank hazard ratio is 2.503 (95% CI of ratio: 
1.071 to 9.203). 
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Appendix S5.20 Creating SVM models using lung and hematopoietic 
cell lines. 
We initially investigated the possibility that the paclitaxel breast cancer SVM model 
could predict cell line sensitivity to this drug in 22 other cancer cell line types. The 
respective misclassification rates were higher than with the breast cancer cell lines. We 
attempted to classify resistance with the SVM model in other neoplastic tissues, including 
from autonomic ganglia (10 cell lines), biliary tract (1), bone (10), central nervous system 
(27), endometrium (17), hematopoietic and lymphoid tissue (55), kidney (8), large 
intestine (18), liver (15), lung (76), oesophagus (15), ovary (24), pancreas (25), pleura 
(7), prostate (3), salivary gland (1), skin (35), soft tissue (11), stomach (14), thyroid (3), 
upper aerodigestive tract (6), and urinary tract (12). As Daemon et al., 2013 reported, 
clustering of individual tissue types dominates the analysis of chemosensitivity. The 
tissue-specific gene expression program of the cell lines could explain why the breast 
cancer signature was not transferable.  
Appendix S5.20.1 Feature Selection Process – Lung Cancer Cell 
Lines 
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Appendix S5.20.2 Feature Selection Process – Hematopoietic 
and Lymphoid Tissue Cancer Cell Lines 
 
Appendix S5.20.3 Final SMV Gene Sets for Paclitaxel 
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Appendix S5.20.4 MFA Using Genes in SVM – Lung 
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Appendix S5.20.5 MFA Using Genes in SVM – Hematopoietic 
and Lymphoid Tissue 
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